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ABSTRACT 
 
This research describes the synthesis of nucleoside analogues and peptides, and their 
application to nanopore technology and cell biology. Nanopore technology is a technique 
in which analytes are detected by disturbances in ionic current caused as they traverse a 
pore, at a fixed applied potential. Here potential applications of the technology are 
explored. 
A nanopore-based method to detect enzymatic activity was investigated. The 
technique involved the detection of peptide fragments proteolytically released from a 
solid-support. The released fragments gave rise to distinct electrical signals which 
facilitated their identification and characterisation. The frequency with which they 
traversed the pore was indicative of enzyme activity. The technique was successfully 
applied to the detection of the protease enzyme, renin, in the presence of human serum. 
An approach to count nucleotide repeat sequences, which are the basis of forensic 
DNA fingerprinting, was also investigated. It was hypothesised that chemically modified 
copies of the repeat regions could be generated using primer extension and nucleoside 
analogues. The copying could be performed such that a single analogue was incorporated 
per repeat. Ensuing nanopore analysis would then give rise to electrical signals in which 
the analogues could be identified from unique signals. The number of repeat sequences 
could simply be determined by counting the number of signals. It was envisaged that this 
could be achieved using adamantane-modified nucleosides. However, these did not give 
rise to the expected result. 
Inspired by the adamantane project, analogues of the drug, azacytidine were 
synthesised. Azacytidine is used to treat cancers that arise due to epigenetic modifications 
of DNA. It was hypothesised that its side-effects could be mitigated using photocaged-
derivatives of the nucleoside, as these would enable greater temporal and spatial control 
of drug release. Analogues of azacytidine were successfully synthesised and shown to be 
uncaged back to the parent nucleoside. 
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EEDQ 2-Ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline 
Et3N Triethylamine 
Foo Frequency of occurence 
16 
 
h hours 
HBTU 
O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
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HIV Human immunodeficiency virus 
HMBA 4-Hydroxymethyl benzoic acid  
HOBt 1-Hydroxybenzotriazole  
HPLC High-performance liquid chromatography (reverse phase) 
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LCMS Liquid chromatography–mass spectrometry 
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MeOH Methanol 
MgSO4 Magnesium sulphate 
MOPS 3-(N-morpholino)propanesulfonic acid 
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mV Millivolts 
NaOH Sodium hydroxide 
NB o-Nitrobenzyl  
NBOC Nitrobenzyloxycarbonyl 
NDP Nucleoside diphosphate 
NH4OH Ammonium hydroxide 
Ni2+-NTA Nickel-nitriloacetic  
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NMP Nucleoside monophosphate 
NMR Nuclear magnetic resonance 
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1 INTRODUCTION 
 
1.1. Basics of Nanopore Analysis 
In recent times there has been growing interest in technologies which enable the 
detection and analysis of individual biomolecules without the need for prior labelling. At 
present much of the time and cost involved in analysing biomolecules is expended on 
their purification, amplification and labelling so that they provide sufficient signal-to-noise 
ratios for optics-based techniques, such as fluorescence spectroscopy and high 
performance liquid chromatography (HPLC), or for use in biological assays.1 As a result of 
labelling, these techniques often require costly reagents and sophisticated 
instrumentation. It is believed that by analysing individual biomolecules directly, sample 
preparation would be simplified and the cost of analysis reduced. Additionally, direct 
analysis would be more sensitive as smaller sample sizes would be required to yield 
results, and sub-populations which ordinarily may be undetected by conventional 
ensemble techniques, may be detected.2 Nanopore technology is one single-molecule 
technique which is currently being pursued as a tool to analyse biomolecules of interest. 
 
 
 
 
 
Figure 1: (A) Principle of nanopore analysis. A pore is placed within a membrane that separates two 
electrolyte-filled compartments. Applying a voltage across the membrane results in the flow of ions, this in 
turn generates a detectable ionic current. (B) Typical electrical trace. When the channel is open and 
unobstructed, the current level is termed ‘open channel current’. As an analyte passes the inner constriction 
of the pore, the flow of ions is temporarily interrupted resulting in a reduction in the ionic current. The 
channel is said to be blocked. 
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At the heart of nanopore technology is a pore with nanometer-scale dimensions which is 
placed within an insulating membrane that separates two electrolyte-filled chambers 
(Figure 1A). When a voltage is applied across the membrane, a flow of ions is induced 
which in turn generates a current. The current is readily detected using standard 
electophysiological techniques. When the pore is open and unobstructed, the ions are 
able to flow freely across the membrane resulting in a constant current, termed the open-
channel current. However, when a charged analyte is added to one chamber, the analyte 
is eletrophoretically driven through the pore. As it does so, the flow of ions is temporarily 
blocked resulting in a reduction in the ionic current (Figure 1B). Once the translocating 
analyte clears the pore, the flow of ions is restored and the current returns to the open-
channel level. By monitoring the magnitude (i.e. amplitude), duration and frequency with 
which the blockades occur, it is possible to characterise the translocating molecule with 
respect to size and concentration.  
1.1.1. Nanopores 
1.1.2. Biological Nanopores 
The α-hemolysin (αHL) nanopore is the most widely used pore in research.3,4 It is a protein 
toxin secreted by the Staphylococcus aureus pathogen. The toxin attacks target cells by 
spontaneously inserting itself into the plasma membrane thus disrupting the cell’s ability 
to regulate its osmotic and electrochemical gradient.5,6 The protein is composed of seven 
identical subunits which self-assemble in the lipid-bilayer to give a heptameric mushroom-
shaped pore. The structure and the approximate dimensions of the pore are shown in 
Figure 2. The pore consists of a large cap domain which sits on the extracellular side of the 
membrane (in nanopore experiments, this side is donated cis) and has dimensions of 10 x 
10 nm.6 The opening of the pore measures 2.6 nm in diameter and widens to 4.6 nm at 
the inner vestibule.1 The inner constriction measures 1.4 nm and widens to 2 nm at the 
intracellular side of the membrane (in nanopore experiments, this side is denoted trans). 
The stem domain is composed of a water filled, slightly anion selective β-barrel which is 
approximately 5.2 nm in length and completely spans the bilayer.  
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Several features help explain the popularity of αHL in nanopore experiments. Firstly, the 
electrical properties of the pore have been well characterised. The pore displays Ohmic 
characteristics with conductivity proportional to electrolyte concentration, and current 
directly proportional to voltage.1,6 For instance, in a 1 M KCl solution, a typical αHL pore 
carries a current of approximately 120 pA when 120 mV is applied from the cis to trans 
side. Furthermore, as the pore lacks any moving parts which could potentially obstruct the 
flow of ions, it is open indefinitely.2,7 These factors facilitate the detection of analyte-
induced blockades against and unchanging current level.2 Secondly, the dimensions of the 
inner constriction are comparable to the dimensions of many biomolecules of interest, 
such as single stranded DNA (ssDNA) and peptides.8,9 Consequently, these biomolecules 
are able to effectively occlude the ionic current as they traverse the pore, giving rise to 
distinct reductions in conductivity which facilitates their detection. This feature has fuelled 
the research and development of αHL-based technologies for next-generation 
bioanalytical and diagnostic tools.3,10 Finally, as the protein is able to withstand mutagenic 
changes and harsh purification procedures, it can be readily engineered or ‘tuned’ to 
detect specific analytes.2,11,12 As the crystal structure of the protein has been solved, such 
modifications can be performed with atomic-scale precision.6 This is typically achieved by 
substitution or replacement of amino acids at the inner constriction or β-barrel. For 
instance, introducing a ring of aromatic residues at the inner constriction of the pore, will 
impart specificity for hydrophobic analytes.13,14 Alternatively, the pore can be tuned to 
detect smaller analytes which would not ordinarily perturb the ionic current and hence be 
detected. This can be achieved by lodging circular adapters into the vestibule, thereby 
Figure 2: Cross-section of α-hemolysin protein pore in plasma membrane. Adapted from [2]. 
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reducing the inner diameter of the pore.15 As a result of such modifications, the range of 
molecules that can be detected by nanopores is not limited to biopolymers, but also 
encompasses smaller organic molecules.16,13  
 Although αHL pores are the mainstay of nanopore technology, they are 
associated with some inherent drawbacks which have limited their use.3 The most 
significant is the instability of the experimental setup. The protein itself has been shown 
to be remarkably stable, tolerating temperatures nearing 100 °C.17 The instability arises 
from the lipid bilayer which supports the nanopore. In a typical nanopore experiment, the 
lipid bilayer is formed across a 30-100 μM orifice in a Teflon cassette. Ideally, the formed 
membrane should be stable enough to allow several hours of nanopore analysis to be 
performed. However, in reality, as a result of the non-covalent and fluid nature of the 
lipids, the bilayer often ruptures within 2 hours.2 The stability of the bilayer can be 
improved by employing chemical reagents to change its composition18 or by tethering it to 
a support.19 Nonetheless, destabilisation by diffusion of the lipid molecules out of the 
membrane and into the electrolyte solution can still occur.2  An additional limitation is the 
lack of control over the number of pores which insert into the bilayer. Pore insertion is 
typically achieved by adding a protein solution to one of the electrolyte-filled chambers. 
Once the pore has spontaneously formed and been inserted into the bilayer, excess non-
inserted protein is flushed out by changing the electrolyte solution. The process of 
insertion is completely random and can often result in the insertion of several pores. In 
this instance, the membrane must be broken, a new bilayer formed and insertion 
repeated. As αHL can only function when supported by a lipid bilayer,2 its use and 
commercialisation has been restricted. Consequently, alternative nanopores and sensing 
modalities have been sought. 
1.1.3. Solid-State Nanopores 
Solid-state nanopores are synthetic pores typically formed from inorganic materials or 
organic polymers.10 The most common solid-state systems are silicon-based.4 The pores 
are typically fabricated by using an ion beam to either drill or etch an opening into the 
material.2,4 Solid-state nanopores offer a more robust and durable alternative to biological 
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pores, enabling nanopore analysis to be performed over a wider range of experimental 
parameters such as temperature, pH and ionic strength.2 As a result of their superior 
stability, they are more readily integrated into sensing devices and are thus more 
amenable to commercialisation.10  
 Fabrication of nanopores from solid-state material presents another advantage 
over their biological counterparts; the ability to control the pore diameter and length. 
Whilst biological nanopores have fixed geometries, the diameter of solid-state nanopores 
varies depending on the fabrication techniques employed.4 Nanopores have been 
fabricated with diameters ranging from 50 nm (or larger) to as small as 1 nm; smaller than 
the inner constriction of αHL.4,10  This offers a mechanism through which the nanopore 
can be tuned according to the size analyte under investigation. Akin to biological pores, 
the specificity and sensitivity of solid-state pores can also be altered through chemical 
modification. For instance, it has been observed that silicon-based pores coated in 
aluminium oxide display enhanced sensitivity and electrical properties compared to 
untreated pores.20,21 The translocation speed of negatively charged biopolymers analysed 
using the treated pores, was reduced compared translocations through untreated pores. 
This was attributed to favourable electrostatic interactions between the biopolymers and 
the positively charged surface. The net effect was an improvement in the sensitivity of the 
pore and a reduction in the background noise. Similar affects can be achieved through 
chemical modification using organic reagents.22 
Although diameters comparable to biological pores have been achieved, attaining 
sensitivities comparable to biological pores remains a challenge. The sensitivity of 
nanpores is determined by two factors; the thickness of the pore (i.e. volume of the pore) 
and the level of background noise.4 Pore thickness determines how many analyte 
molecules can occupy the pore and hence whether single-molecule detection can be 
achieved. To date the thicknesses achieved using solid-state materials have been greater 
than the length of biological pores (> 10 nm). As a result, during nanopore experiments, 
perturbation of the electric current is generally attributed to the presence of more than 
one analyte molecule rather than a single molecule. Additionally, solid-state nanopores 
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exhibit much higher background noise than biological pores. A further limitation is the 
structural variability between fabricated pores. No two fabricated pores are exactly the 
same even if they undergo the same process with the same specifications.4 Consequently 
it is not possible to assure reproducibility between experiments performed using 
nanopores fabricated in different laboratories under identical conditions. This is in stark 
contrast to αHL which is produced by cells thus possesses a well-defined geometry and 
heterogeneity. 
 
1.2. Sensing of Nucleic Acids 
By far the most widely reported application of nanopore technology is as a potentially 
ultra-fast and cheap alternative to current DNA sequencing techniques. Since the 
successful completion of the Human Genome Project in 2003, the main goal of which was 
to elucidate the nucleotide sequence of a complete genome, a great deal of information 
has been gained about the genetic causes of disease and the effect of mutations.23,24 
Completion of the project also spurred the development of a new idea, ‘personalised 
genomic medicine’. The core of this idea is that a patients’ health can be managed by 
tailoring treatment to particular genomic attributes in addition to the traditional biological 
aspects.25 For instance, genomic data may enable earlier diagnosis, more effective 
prevention and treatment of disease and avoidance of drug side effects.4,25,26 However, 
such a strategy is highly dependent upon the ability to sequence an individuals’ genome 
cheaply and quickly. 
 
1.2.1. Current DNA sequencing Techniques 
Current commercially available sequencing technologies are all loosely based upon the 
Sanger method pioneered in the 1970s.27,28 For each of these technologies, a significant 
amount of sample preparation is required prior to sequencing. The DNA to be sequenced 
must first be isolated then split into smaller more manageable fragments. As the 
technologies do not possess the sensitivities required to directly detect and analyze the 
fragments, sample amplification is required. Depending on the nature of the sample, this 
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is achieved using bacterial host organisms or amplification enzymes.28 Sequencing is 
accomplished with the aid of short oligonucleotide fragments, termed primers, which are 
complementary to the DNA flanking the region of interest. A cyclic, multi-step reaction is 
performed in which the primer is extended. However, the extension of the primer is 
terminated prematurely due to the incorporation of one of four fluorescent nucleoside 
analogues. As termination occurs at every possible nucleotide position in the DNA, a 
mixture of extension products are obtained. The sequence is elucidated by high-resolution 
gel electrophoresis in combination with capillary electrophoresis. As the DNA fragments 
exit the capillary, the fluorescence emission of the fragments is measured and 
bioinformatics software used to re-assemble the sequence of the original DNA sample. 
While this approach has been the mainstay of DNA sequencing for many years, and was 
successfully used to complete the Human Genome Project, it is associated with some 
drawbacks. Namely, the amount of DNA that can be processed per unit time, that is, the 
throughput, is low. Indeed, the Human Genome Project took ten years to complete.23,29  
Second generation technologies emerged in response to the low throughput 
associated with the Sanger-based technologies (also known as first-generation 
methods).30 Second generation technologies are conceptually similar to the first-
generation methods in that sample amplification is required and fluorescent nucleotides 
are employed. However, sequencing is achieved in an array-based manner. Multiple 
copies of the DNA fragments of interest are immobilised onto a solid-support then 
sequentially flooded with fluorescent nucleotides. The support is then washed to remove 
excess reagents and subsequently scanned to determine which nucleotide has been 
incorporated. This can involve exciting the array with a laser and monitoring the 
fluorescence emission of the incorporated nucleoside. The cycle is repeated until the 
reaction is no longer viable.30 This approach has been successfully developed into 
commercial sequencing instrument by Solexa (now part of Illumina, San Diego). The data 
from each immobilised fragment is used to reassemble the sequence of the original DNA 
sample. As the tens of thousands of strands can be immobilised on a single support, the 
throughput is significantly increased compared to first-generation methods. Furthermore, 
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this approach also allows for a greater degree of parallelism.28 However, due to large 
number of washing and scanning cycles, second generation technologies can take a 
greater amount of time to garner sequencing results (typically several days). Second 
generation technologies are also limited by the read length, that is, the number of DNA 
bases that can be identified sequentially.28 As the DNA fragments utilised in second 
generation technologies are immobilised onto a solid-support, they are required to be 
significantly shorter in order to avoid any unfavourable steric interactions. However, the 
increased number of fragments is a potential source of sequencing errors as data from 
more fragments must be combined in order to determine the sequence of the original 
DNA sample. First generation technologies are able to achieve read lengths approaching 
1000 bases, whilst second generation can only achieve half that and have been shown to 
be ten-fold less accurate.28,30 
A drawback common to both first and second generation technologies is the cost. 
In 2011, it was possible to sequence and entire human genome in eight days for 
approximately $10,000.26 This estimation merely covers the cost of analysis and not the 
instrumentation which can vary from hundreds of thousands to millions of dollars.28 
Although these estimations are still significantly lower than the 3 billion dollars required 
to initially complete the Human Genome Project,23 in order for personalised genomic 
medicine to become a reality, complete sequencing would need to be performed within 
24 hours for $1000 or less. This was a challenge set by the US National Institutes of Health 
in 2004.31 Current technologies are also limited by the need to amplify the sample prior to 
sequencing. Not only does this increase the complexity, time and cost of sample 
preparation, but can also be an additional source of sequencing errors. Specifically as, 
these amplification steps are typically performed by enzymes, the fidelity of which will 
dictate the accuracy with which the DNA is copied.28  It is believed that these limitations 
could be mitigated or completely eliminated if a nanopore-based approach to sequencing 
was employed. 
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1.2.2. Nanopore Sequencing: Third Generation Sequencing Technology 
The use of nanopores as a means of sequencing DNA was initially proposed by Dekker et 
al. in the 1990s.10 It was believed that as DNA is a polyanionic molecule, in the presence of 
an applied potential, it would be electrophoretically driven through the pore in a 
sequential linear fashion. Each of the four DNA bases (A, T, C and G) was expected to 
generate distinct electrical signals reflecting differences in their chemical structure. Hence 
by monitoring changes in the ionic current that occurred as the DNA strand translocated 
the pore, the identity of the bases could be elucidated and the sequence of the DNA 
determined. Due to the sequence complementarity of double-stranded DNA (dsDNA), only 
one strand from the DNA duplex would need to be sequenced. This approach raised the 
prospect of faster sequencing as it would require very minimal sample preparation. 
Furthermore, the elimination of expensive reagents such as fluorescent nucleosides or 
polymerase enzymes was expected to lower the analysis costs. As the approach had very 
few infrastructure requirements, that is, was solely dependent upon the nanopore and 
electrophysiological equipment, the initial start-up costs were also expected to be 
significantly lower than optics-based approaches. This would enable DNA sequencing to 
be decentralised from large institutions to smaller laboratories. Nanopore devices could 
also be more readily miniaturised to produce hand-held or bench-top devises. Finally, by 
directly sequencing the DNA, fragments as long as 50,000 base pairs could be analysed 
sequentially which would greatly simplify the genome assembly process.31  
 
1.2.3. Nanopore Sequencing: Seminal Investigations 
Seminal experiments demonstrating the voltage driven transport of ssDNA and ssRNA 
were performed by Kasianowicz et al. using the αHL pore.32 αHL was chosen as the inner 
diameter could only accommodate ssDNA, and not dsDNA which with a diameter of 2.2 
nm, is too wide.10 Using polyuridine polymers (poly[U]) of varying lengths, it was 
demonstrated that the passage of individual DNA molecules could be detected as 
transient reductions in ionic conductivity. Furthermore, it was observed that the duration 
and magnitude of blockades were proportional to the lengths of the polymers, indicative 
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of the polymers translocating the pore in linear extended states. The realisation that 
nanopore recordings could be used to determine the lengths of individual 
oligonucleotides suggested that other properties of oligonucleotides could be measured 
as they translocated the pore. In theory, purine and pyrimidine bases passing through an 
ion channel should produce different electrical signals which reflected their size and 
chemical properties. This notion was substantiated in experiments performed using 
homopolymers of adenine and cytosine, which were of equal length.33,34 The nanopore 
recordings revealed that the patterns of blockades caused by poly[C] were easily 
distinguished from the patterns caused by poly[A] whether the polymers were analysed 
separately or in a mixture (Figure 3A).33 In further experiments which utilised co-polymers 
of poly [A] and poly [C], bi-level blockades where observed as the nanopore was able to 
detect the transition from an adenine to a cytosine nucleotide or more specifically from a 
purine to a pyrimidine nucleotide (Figure 3B).34  
 
 
 
 
This result was particularly appealing given the desire to sequence DNA by directly 
analysing a translocating DNA strand. However, it was subsequently realised that under 
standard experimental conditions, single-base resolution could not be achieved.33,34 The 
DNA strands were translocating the pore at average rates of approximately 1-20 
nucleosides per microsecond when driven by voltages of 120-150 mV;31 much too fast to 
enable individual bases to be resolved. It was hypothesised that by reducing the 
translocation speed so that each base occupied the detector for approximately 1 
Figure 3: Nanopore traces for poly[A], poly[U] and poly[C]. (A) Each polymer gave rise to distinct patterns 
of blockades. (B) Nanopore traces for co-polymer of poly[A] and poly[C]. Bi-level blockade were observed 
as the nanopore was able to detect the transition from adenine to cytosine (indicated by the arrows). 
Adapted from [33]. 
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millisecond or longer, it could be possible to resolve the bases.31 As a result, to date, 
nanopore research has been focused on reducing the translocation speed of ssDNA rather 
than obtaining sequence data. 
 
1.2.4. Approaches to Nanopore Detection of Oligonucleotides 
1.2.4.1. Employing Chemically Modified Oligonucleotides 
One strategy to facilitate the detection of oligonucleotides is to modify nucleotides with 
bulky chemical tags which act as ‘molecular brakes’3 during translocation. Whilst 
developing a nanopore-based method to detect DNA mutations, Mitchell et al. observed 
that chemical tags attached to individual bases increased the cross-sectional diameter of 
the translocating oligonucleotides and hence reduced the translocation speed as they 
passed the narrow inner constriction of the αHL pore.9 Using synthetic oligonucleotides 
carrying peptide tags of varying length, charge and hydrophobicity, it was demonstrated 
that characteristic electrical signatures specific to the composition of the tag could be 
obtained. The chemical composition of a representative tag is shown in Figure 4A. The 
presence of a single tag in the oligonucleotide reduced the translocation speed by a factor 
of 10. Further reductions in the translocation speed were observed when the 
oligonucleotides were modified with two peptide tags. Interestingly, each of the tags in 
the di-modified oligonucleotides acted independently to give characteristic electrical 
signatures. Hence the αHL pore was able to detect multiple separate bases. This 
observation raised the prospect of modifying each of the four DNA nucleotides with a 
different tag to facilitate base resolution during nanopore sequencing.  While such an 
approach would enable real-time sequencing, modifying all the bases of a genomic DNA 
sample would be challenging due to the small distances between the bases. The length of 
the linker and the size of the tags would need to be significantly reduced to avoid 
unfavourable steric interactions. However, such tagging approaches have shown greater 
utility in the nanopore-based detection of single-nucleotide polymorphisms (SNPs) where 
fewer bases in the oligonucleotide require modification. 
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SNPs are single mutations within DNA that result in the substitution of one nucleotide for 
another.35 Such mutations are the single greatest cause of genetic variability between 
individuals and as such generally have little or no effect on health. However, mutations in 
key regions of the genome have been shown to trigger the onset of certain diseases 
including cancer, confer resistance to drugs and render individuals susceptible to external 
factors such as toxins.36 Accordingly, SNPs can act as biological markers, enabling 
researchers to locate genes associated with diseases and conditions.35 Borsenberger et al., 
utilised peptide-tagged oligonucleotides to propose a nanopore-based method to detect 
SNPs.37  The approach is outlined in Figure 4B. Short peptide-tagged oligonucleotides were 
used as probes to bind sequence-specifically to longer SNP containing oligonucleotides. 
The probes bound to the regions flanking the suspected SNP. The presence of the SNP was 
determined by enzymatically incorporating a hexahistidine (His6)-tagged nucleotide 
analogue. Specifically, if the SNP was present, then the modified nucleotide would be 
incorporated. However, if the SNP was absent a natural nucleotide would be 
incorporated. Incorporation of the His6-tagged nucleoside enabled the SNP derived probes 
Figure 4: Nanopore analysis of chemically modified oligonucleotides. (A) Peptide-modified nucleotides have 
been used to reduce the translocation speed of oligonucleotides. The modification increases the cross-
sectional diameter of the DNA and gives rise to distinct electrical signals. (B) Peptide-modified nucleotides 
have been incorporated into oligonucleotide probes to enable nanopore-based detection of SNPs. (C) 8-
oxo-7,8-dihydroguanine, an oxidised derivative of guanine was detected using αHL pore. The oxidised base 
was derivatised with a range of amines in order to increase the signal-to-noise ratio. 
31 
 
to be isolated and subsequently characterised by nanopore analysis in which characteristic 
electrical signals were observed. 
In a similar fashion, modified nucleotides have also been used to detect 8-oxo-7,8-
dihydroguanine, an oxidised derivative of guanine that forms as a result of oxidative stress 
on cells. Oxidative stress, which is the underlying cause of many age-related disorders and 
diseased states, arises when reactive oxygen species oxidises cellular components.38 
Schibel et al.39 utilised a previously developed immobilisation technique40 to achieve 
single-base resolution of a number of guanine analogues, and in doing so avoided the 
issues related to the rapid translocation speed described above. In brief, a biotin molecule 
was directly attached to the 3'-end of the oligonucleotides and the resultant biotin-DNA 
(Btn-DNA) conjugates bound to streptavidin (Strep) protein. On application of voltage, the 
Strep-Btn-DNA complex was driven into the αHL pore. As Strep was too large to traverse 
the pore, the tethered DNA was held within the pore for 1-2 s to collect current blockage 
data, then released by reversing the applied potential. The capture and release cycle was 
repeated several times. The longer residence time enabled a single oxidised base to be 
distinguished when placed within a homopolymer sequence or a more biologically 
relevant heteropolymer. Akin to the studies described above, the oxidised guanine was 
derivatised with amines to form bulky spirocyclic adducts in order to facilitate 
discrimination within the nanopore (Figure 4C). In doing so, the amplitude of blockade 
increased by almost 10% in homopolymers and 2% in heteropolymers compared to the 
underivatised, unoxidisied control. These preliminary findings highlight the discriminatory 
abilities of the αHL pore as such small modifications were readily detected. With 
optimisation of the derivatising agents, it may be possible to detect the oxidized 
nucleoside in freely translocating DNA. This would provide a rapid means of quantifying 
the number of oxidised residues within a single DNA strand. Furthermore, information 
regarding the flanking sequences could also be obtained. Neither of these characteristics 
can be determined using enzymatic assays or HPLC which are typically used to analyse 
oxidised guanines. The authors also demonstrated the broader applicability of nucleic 
sensing for purposes other than sequencing. 
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1.2.4.2. Using an Engineered αHL Pore 
By engineering the αHL pore, its sensitivity can be greatly increased and varied to enable 
other sequencing approaches to be explored. One such approach is exonuclease 
sequencing. Sequencing is achieved through the detection of individual nucleotide 
monophosphates, cleaved from the end of ssDNA by the action of an exonuclease 
enzyme. The monomers are released and detected in sequential order reflecting the 
sequence of the original DNA strand (Figure 5A).  
 
Figure 5: DNA sequencing via the exonuclease approach. (A) Nucleotides are cleaved from ssDNA by an 
exonuclease enzyme (scissors) then detected by a pore modified with a cyclodextrin ring (turquoise). (B) 
Structure of cyclodextrin ring. For covalent attachment to the protein, a single amino group was coupled to 
the reactive bi-functional linker, succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and the resultant 
construct coupled to a cysteine residue engineered into the β-barrel [15]. 
This approach was pioneered by researchers in the Bayley group at the University of 
Oxford collaboration with Oxford Nanopore Technologies.15,41,42 In the wild-type αHL pore, 
the nucleotide monophosphates translocate the pore with minimal effect on the ionic 
current due to the incomparable dimensions of the inner constriction.41 To bring the 
dimensions of the pore closer to the size of the nucleotide monophosphates, an 
aminocyclodextrin adapter was covalently attached to the β-barrel (Figure 5B).15 Covalent 
attachment was achieved by engineering a single cysteine residue into the barrel and 
using a bifunctional linker, succinimidyl 3-(2-pyridyldithio)propionate (SPDP), to link the 
cyclodextrin ring via a disulphide bond.42 In doing so, the small nucleotides were able to 
modulate the ionic current by temporarily binding to the adapter as they translocated the 
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pore. On the basis of amplitude of blockade and duration the binding events, the natural 
nucleotide monophosphates and 5-methylcytosine, a nucleotide analogue which is 
essential in epigenetic studies,43–45 could be identified with 99.9% accuracy.15 This 
approach is one of two being developed for commercial purposes by Oxford Nanopore 
Technologies.46 However, it is obvious that there a number of problems that must be 
solved before the method can be established as a viable sequencing technique. Namely, a 
mechanism to ensure that each nucleotide is captured and traverses the pore in 
sequential order is required. As the exonuclease enzyme is added to the bulk-phase cis 
chamber,4 the probability of the nucleotides traversing in a random order is high. It has 
been proposed that this could be overcome through chemical attachment or genetic 
fusion of the enzyme to pore.15,31 This would enable each released nucleotide to be 
captured and funnelled directly into the pore. Similarly, a mechanism to ensure that the 
released nucleotide exits into the trans chamber and it not recaptured, is required. It has 
been demonstrated that the probability of a nucleotide exiting into the trans chamber is a 
function of applied voltage, with some nucleotides appearing to have a greater probability 
than others.15 For accurate sequencing, it is necessary that each nucleotide is captured 
and exits into the trans chamber with equal probability. Finally, to ensure that only a 
single nucleotide is present in the pore any one time, the turnover of the enzyme must be 
slower than the dwell time of the nucleotide. This will go towards ensuring the accuracy of 
the sequencing data. It may be necessary to alter exonuclease turnover through direct 
mutation or changes to physical conditions such as temperature and pH.15,41 
 
1.2.4.3. Utilising Enzymes as Molecular Motors 
Recently there has been a shift towards using enzymes to reduce and control the 
translocation speed of otherwise rapid ssDNA through pores. Such techniques take 
advantage of the highly processive nature of polymerase or exonuclease enzymes and 
their ability to move along ssDNA one base at a time. A schematic representation of the 
molecular motors approach is shown in Figure 6. In brief, an enzyme is added to the cis 
compartment of the nanopore resulting in an enzyme-DNA complex in bulk solution. 
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When a voltage is applied across the membrane, the free ssDNA is pulled into the lumen 
of the pore and the large enzyme-DNA complex resides on top of the pore. As the enzyme 
processes the DNA, the strand is pulled through the pore in a slow and controlled manner. 
Importantly, rather than a continuous smooth motion, the sequential nature of the 
enzymes results in a racheting effect as each base is paused within the pore as the enzyme 
completes its catalytic cycle.4,47 In order to function as a molecular motor for the purposes 
of DNA sequencing, enzymes must meet two key requirements.4,48 Firstly, the ability to 
form enzyme-DNA complexes which can withstand the forces generated as the complex is 
electrophoretically driven into the pore. Secondly, during DNA processing, the enzymes 
must generate a force greater than the force required to hold the complex on top of the 
nanopore. These requirements ensure that in the presence of an applied potential, the 
enzyme is able to move along the DNA strand without concomitant dissociation of the 
enzyme-DNA complex. Lieberman et al. recently advanced the field by demonstrating that 
the phi29 DNA polymerase (phi29 DNAP) was a suitable enzyme as it was able to meet 
both criteria (Figure 6).48 Phi29 DNAP, an enzyme responsible for viral replication, is able 
to catalyse the extension of DNA in the 5'→3', in addition to possessing exonuclease 
activity in the 3'→5' direction.49,50 Both the extension and exonuclease activity move the 
DNA in single steps which can be used to control DNA translocation through the pore. 
Furthermore, the enzyme is able to catalyse the incorporation of at least 70 kilobases of 
DNA after a single binding event, without the aid of any accessory proteins.48–50 Manrao et 
al. were able to build on the work of Lieberman et al. to associate observed modulations 
of electrical ionic current to sequence information.51 To achieve this, Phi29 DNAP was 
bound to ssDNA template that was hybridised to a primer (Figure 6B, 1). The primer had a 
terminal hairpin loop on the 5'-end to protect it from the actions of the enzyme. The 
technical hurdle of activating a single polymerase in the nanopore, whilst inhibiting the 
enzyme in the bulk solution prior to sequencing, was overcome by employing a ‘blocking 
oligomer’ (Figure 6B, 2).47,51 This short oligonucleotide fragment bound downstream of 
the primer, resulting in stable complexes in the bulk solution that readily dissociated once 
the complex had been captured by the nanopore. The dissociation process termed 
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unzipping, liberated the 3'-end of the primer to enable DNA synthesis (Figure 6B, 3). When 
the nucleotide triphosphates and divalent ions necessary for primer extension were added 
to the cis chamber, the enzyme catalysed the extension of the primer. In doing so, it acted 
as a motor racheting the DNA through the cis side of the pore a single-nucleotide at a time 
(Figure 6B, 4). Once DNA synthesis of the template strand was complete, both the DNA 
and phi29 DNAP exited to the cis side.  
 
Figure 6: Utilising Phi29 DNA polymerase as a molecular motor to sequence DNA. (A) Structure and 
dimensions of MspA pore. (B) 1, the DNA template (black) complementary base-pairs to the primer (blue). 
The ‘blocking oligomer’ (red) prevents extension of the primer in the bulk solution; 2, Applying a voltage 
causes the captured DNA-enzyme (green) complex to be drawn into the pore. This results in unzipping of the 
blocking oligomer; 3, The enzyme can now catalyse the incorporation of nucleotides into the deprotected 
primer; 4, As DNA synthesis occurs, the DNA complex is racheted into the cis chamber. When a nucleotide in 
the template is held within the key sensing region of the pore, a distinct electrical signal is obtained. (C) 
Representative electrical trace. Adapted from [52]. 
Rather than using αHL, a mutated version of the protein pore MspA, which has a slightly 
different geometry, was used (Figure 6A). In essence, the key sensing region in MspA is 
shorter than that of αHL so that as few as four nucleotides contribute to measured 
changes in electric current compared to 10-12 nucleotides in αHL.53,54 Due to these 
structural properties, Manrao et al. were unable to resolve individual nucleotides as they 
passed the inner constriction. However, they were able to translocate the DNA in single-
nucleotide steps at a rate appropriate for sequencing. With the aid of computer 
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algorithms it may be possible to decipher the electrical traces to gain single-nucleotide 
resolution.  
1.3. Sensing of Enzymatic Activity 
In addition to providing information on the structural properties of substrates, nanopore 
analysis can also be used to directly probe the mechanics and kinetics of enzymes 
themselves. To date, much of the information regarding enzyme activity and kinetics is 
garnered from large ensemble techniques which monitor changes in substrate or product 
concentration over time.55,56 These techniques do not possess the sensitivities required to 
examine individual enzyme molecules, but rather provide information on the average 
behaviour of a collection of molecules.57 Single-molecule techniques, such as nanopore 
analysis, provide a means of studying individual enzymatic reactions. As a result, they can 
give insight into individual reaction steps and intermediates which may be masked in 
ensemble techniques.44,55,57 A nanopore-based method for detecting enzymatic reactions 
would offer similar benefits as those discussed for DNA nanopore sequencing. Namely, it 
would obviate the need for sample amplification thus could potentially reduce the cost of 
analysis and simplify sample preparation. Furthermore, ultra low levels of enzyme activity 
could be detected, which would be beneficial for clinical diagnosis, where enzyme activity 
can be indicative of normal or abnormal cellular function.56 Finally, it would enable 
enzymatic reactions to be followed in real-time. A variety of different strategies have been 
described to assess enzymatic activity using nanopores. 
 
1.3.1. Probing Enzyme Mechanism 
The αHL nanopore has emerged as a tool for studying the catalytic cycle of polymerase 
enzymes at a single-molecule level. Using DNA-enzyme complexes, akin to those used to 
probe the enzymatic molecular motors described above, polymerase-catalysed primer 
extensions have been resolved at a single-nucleotide level.47,58 Furthermore, primer 
extension has been measured in real-time and the extent controlled by varying the 
applied potential.59 Nanopores have also been used to study the structural changes that 
occur as the enzyme selects nucleotides to pair against the DNA template.60 During primer 
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extension, DNA polymerase selects the correct nucleotide substrate from a pool that 
contains both complementary and non-complementary nucleotides.60,61 This selection 
process involves the formation of a series of enzyme-DNA complexes in which the 
nucleotides are scrutinised prior to the formation of the phosphodiester bond.61 It was 
observed that enzyme-DNA complexes formed with complementary and non-
complementary nucleotides could be distinguished based on their properties when 
captured on top of the αHL pore. Specifically, complexes formed with complementary 
nucleotides were more resilient to voltage-induced dissociation than those formed with 
non-complementary nucleotides. 
 
1.3.2. Determining Enzyme Kinetics 
Nanopore technology can also be used to estimate the kinetics of enzymes. Depending on 
the nature of the enzyme and its substrate, two different experimental platforms are 
possible. The enzyme can be characterised by monitoring its action on a substrate which is 
attached to the pore or alternatively, by monitoring its action on an unbound substrate 
free in solution. The former has been used on occasions when the substrate has been too 
large to enter the pore. For instance, Cheley et al. developed an approach to detect kinase 
enzymes and their inhibitors.62,63 A peptide inhibitor was covalently attached to the 
entrance of the β-barrel at the trans side of the membrane (Figure 7A). Binding of the 
enzyme to the peptide resulted in a partial block of the channel and subsequent 
disturbance in the ionic current. The peptide was placed in close enough proximity that 
the binding events that occurred in the bulk trans phase were transmitted to the interior 
of the pore.63 The relationship between applied potential and event duration and 
frequency, gave an estimation of the dissociation and association rate constants, and 
hence binding affinities. Given that nanopore technology is amenable to miniaturization 
and parallelisation, this approach could be used to develop large array-based devices for 
screening peptide inhibitors for the enzyme.  
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Macrae et al. utilised a similar approach to develop a strategy to detect and characterise 
the activity of alkaline phosphatase.52 Using a semi-synthetic pore, the ability of the 
enzyme to catalyse the hydrolysis of phosphate groups placed at the entrance of the pore, 
were detected. The approach is schematically represented in Figure 7B. Modulations in 
ionic current were not due to obstruction of the pore, but rather alterations in the ionic 
charge on the functional groups around the opening of the pore. When the negatively 
charged phosphate groups were present, a greater conductance was observed. This was 
attributed to an electrostatically induced local increase in cations near the negatively 
charged phosphate groups. Upon hydrolysis to neutral hydroxyl groups, a reduction in 
conductivity was observed. The Michaelis-Menton kinetics and catalytic efficiency were 
determined by following the conversion of substrate to product over time, in a range of 
enzyme concentrations. Using this approach, enzymatic activity could be detected with 
Figure 7: Determining enzyme kinetics using nanopores. (A) Genetically engineered αHL pore carrying a 
single inhibitory peptide (shown in yellow and turquoise). A subunit of the enzyme (blue) is docked onto the 
inhibitory peptide.62,63 (B) Charged-based detection of enzymatic activity. Alkaline phosphatise catalyses the 
hydrolysis of phosphate groups attached to the pore.52 The resultant local change is conductivity is detected 
by the pore giving rise to distinct modulations in the ionic current. (C) In-situ enzymatic digestion. In the 
absence of the enzyme (a), current modulations are due solely to the starting substrate. On addition of the 
enzyme, new blockade translocation events (b) with distinct amplitudes and duration are observed.14 
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only picomolar concentrations of substrate and pico- to nanomolar concentrations of 
enzymes. 
Zhao et al. took a different approach to the study the kinetics of the trypsin 
protease.14 Enzymatic digestion of a peptide substrate was performed in the solution; 
directly in the cis chamber (Figure 7C). The kinetics of the reaction was determined by 
measuring translocation events in the absence and presence of the enzyme. In the 
absence of the enzyme, only a single type of translocation events, corresponding to the 
intact substrate, was observed. However, upon addition of the enzyme to the cis chamber, 
two new types of translocation events were detected. These were attributed to the 
enzymatically released peptide fragments. By monitoring changes in the frequency of 
these blockades, the kinetics of the enzyme could be determined in real-time. However, 
this sensing approach was limited by the requirement for an engineered protein pore. In 
particular, the pores were modified to enable greater discrimination between the 
peptides. Such a requirement limits the broad applicability of this approach, as different 
substrates would necessitate different pore modifications. Furthermore, as the pore 
blockades originated from multiple peptides (i.e. the starting material and the released 
fragments) the data processing was somewhat lengthy and complicated.  
 
1.4. Sensing of Peptides 
Inspired by nanopore studies involving nucleic acids, researchers are increasingly utilising 
the knowledge gained to sense polypeptides directly. As this field of research has not been 
pursued as aggressively as nucleic acid research, comparatively little is known about the 
mechanics of peptide translocations. However, in general, it has been observed that 
single-molecule analysis of polypeptides is slightly more difficult to achieve. Whilst ssDNA 
is linear, possesses a dense net negative charge and can be driven through a nanopore 
with little effort, the same cannot be said of polypeptides.64 Polypeptides can be 
extremely heterogeneously charged containing positive, negative, polar and hydrophobic 
side chains, which can complicate nanopore experiments. If a peptide analyte does not 
possess enough, or the correct net charge, very few translocation events will be 
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detected.8 However, the lower charge densities of peptides can prolong the translocation 
time by 1-2 orders of magnitude, giving rise to increased resolution compared to nucleic 
acids.8 Furthermore, polypeptides can form a number of secondary structures in solution 
which can reduce the probability of entering the pore.65 Despite these experimental 
challenges, a nanopore-based approach to analyse peptides could be beneficial given the 
important role they play in many cellular process. Many methods are currently available 
to detect and characterise peptides including mass spectrometry, nuclear magnetic 
resonance (NMR) and HPLC.66–68 In addition to the advantages previously described, it is 
hoped that nanopore sensors will enable peptides to be detected in physiological 
conditions without the need for any pretreatment.65 Furthermore, studying the 
translocation of peptides through a nanopore may give some insight into the protein 
translocations that occurs in cells in vivo.69 
 
Polypeptides must overcome two large energy barriers in order to translocate a pore. The 
first energy barrier exists as the polypeptide enters the nanopore lumen from the aqueous 
phase and begins to translocate the pore. This is associated with a concomitant loss of 
conformational entropy. A second energy barrier is encountered as the peptide exits the 
other side of the pore back into the aqueous phase.70 Translocating nucleic acids also 
experience similar energy barriers.71 These energy barriers can be lowered by either 
structurally altering the nanopore or the polypeptide itself. Such modifications will in turn 
alter the kinetics of translocation. 
 Engineering electrostatic ‘traps’ into the interior cavity of the pore has been shown 
to reduce the energy barrier and facilitate translocation.69 These traps consisted of a ring 
of negatively charged aspartic acid residues at the entrance and exit of the αHL β-barrel 
(Figure 8). The ability of positively charged peptides to translocate pores which contained 
one, two or no traps, was assessed. In this study, the positively charged peptide was 
added to the trans chamber to avoid the entropic penalty associated with entering the 
vestibule on the cis side. It was observed that electrostatic traps placed at the trans 
entrance significantly increased the association rate constant, which is proportional to the 
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frequency of the single-channel current blockades (Figure 8B).65 Conversely, a trap placed 
at the cis entrance of the β-barrel had a greater affect on the dissociation rate constant, 
which is proportional to the inverse of the duration of the translocation events (Figure 
8C).65 When traps were placed at both ends of the β-barrel, significant increases were 
seen in both constants (Figure 8D). Furthermore, the net flow of polypeptides in the trans 
to cis direction was significantly increased compared to the unmodified and singly-
modified pores.  
 
Figure 8: Kinetics of polypeptide translocations in the presence of negatively-charged electrostatic traps. The 
frequency and duration of polypeptide-induced blockades were dependent upon the position of the traps. 
The results suggested that the traps behaved as binding sites for the polypeptides pulling 
them through the pore and thus promoting translocation events. Interestingly, it was also 
observed that the peptide-pore interaction was not solely dependent upon the traps, but 
also the nature of the peptides. Specifically, peptides which possessed more hydrophobic 
character exhibited lower association rate constants, that is, fewer translocation events. 
This suggested that energy barrier experienced by hydrophobic polypeptides was greater 
than their hydrophilic counterparts due to the hydrophilic nature of the pore interior. 
Thus the binding interaction between the pore and the peptide, and hence the nature of 
the pore, played a significant role in either facilitating or retarding translocation. 
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Similar results were obtained in a study in which aromatic residues were engineered 
into the inner constriction of the αHL pore.14,72 Analysis of peptides composed primarily of 
aromatic residues revealed that the duration and the amplitudes of the blockades were 
significantly increased, compared to results obtained using unmodified pores. This was 
attributed to the hydrophobic interactions between the aromatic residues. Essentially, the 
interactions retarded the translocation of the peptides, enabling them to occupy the inner 
constriction for a greater amount of time. A direct correlation was also observed between 
the length of the peptides and the translocation parameters. Intuitively, the findings were 
not unreasonable as longer peptides do diffuse more slowly than shorter peptides.72 
Furthermore, as described above, longer peptides are likely to experience a greater 
entropic penalty prior to translocation, which may also explain this observation. The effect 
of peptide structure on translocation was also investigated. Peptides that contained more 
aromatic residues possessed greater binding affinities with the pore. Interestingly, 
peptides which were of the same length but differed in sequence by only a single aromatic 
residue displayed a six-fold difference in the event duration and a two-fold difference in 
the blockade amplitude. Hence modifying the pore with aromatic residues had 
significantly increased the sensitivity and resolution such that a single amino acid 
difference could be discerned.  
 
1.5. Aims 
The overarching aim of this project was to develop novel sensing strategies which made 
use of native αHL pores and thus could be readily extended to solid-state nanopores. 
Solid-state nanopores are more robust and amenable to commercialisation, but cannot be 
modified to the same atomic-scale precision as biological pores thereby limiting their 
scope.2 Attempts were made to overcome this inherent discrepancy by developing sensing 
approaches where selectivity is not achieved via pore modification but through 
modification of the analyte. Two new sensing strategies are described in this thesis. They 
were both tested with native αHL pores to achieve consistency with existing studies. 
However, it is expected that they are also compatible with solid-state nanopores. Chapter 
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2 describes efforts to develop a novel nanopore-based strategy to detect the activity of a 
protease enzyme. Previously reported strategies14 have been based upon the detection of 
multiple peptide fragments generated as the enzyme acted upon a substrate in bulk 
solution, or required engineering of the pore to improve sensitivity. Using renin as a 
model protease enzyme, a simpler approach in which a single peptide fragment is 
enzymatically released and driven through the pore, was envisaged. It was hoped that 
such an approach would greatly simplify data analysis. Furthermore, by including a 
hexahistidine tag (His6-tag) at the terminus of the substrate and performing the enzymatic 
reaction in the presence of nickel-nitriloacteic (Ni2+-NTA) beads, the enzymatically 
released peptide could be captured and purified from the crude reaction mixture. This 
approach could provide a means of detecting an analyte directly within a complex 
biological matrix. Chapter 3 continues in the same vein, describing efforts to develop a 
nanopore-based strategy to characterise forensically important nucleotide repeat 
sequences, which are the basis of DNA fingerprinting. Nanopore analysis of ssDNA has 
been hampered by rapid translocation speeds and subsequent poor resolution of 
individual bases. It was imagined that a nanopore-based sensing strategy could be realised 
by using DNA strands modified with nucleotides bearing bulky adamantane tags. It was 
hypothesised that the modifications would increase the steric bulk of the DNA reducing 
the translocation speed and hence improving base resolution. Thus, the specific aims of 
this project were to synthesise nucleoside analogues, incorporate them into 
oligonucleotides and assess their transport through the nanopore. The motivation of the 
work presented in Chapter 4 deviates from that of the previous chapters, however it 
builds on the notion of employing nucleoside analogues to overcome challenges 
encountered in arena of chemical biology. The specific aim of this project was to 
synthesise photocaged derivatives of the nucleoside drug azacytidine, which is used to 
treat cancers that arise due to aberrant methylation of particular regions of the genome. 
Hypermethylation of these regions can abnormally enhance the function of some genes, 
such as the oncogenes, or cause other, such as tumour-suppressor genes, to be silenced. 
Whilst the drug is a potent anti-cancer agent, it is associated with some severe side-
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effects which limit its use. It was hypothesised that the side-effects could be mitigated 
with greater spatial and temporal control over drug release. 
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2 CHEMICAL TOOLS FOR NANOPORE ANALYSIS 
OF ENZYMATIC ACTIVITY IN BLOOD PLASMA 
2.1. Summary 
In this chapter, a label-free strategy to detect enzymatic activity via nanopore recordings 
is presented.  In short, multiple copies of peptide substrates were tethered via a flexible 
linker to microscale beads. Upon enzymatic cleavage of the immobilised substrate by a 
protease, soluble fragments were released. These were subsequently electrically detected 
as they translocated through the nanopore causing reversible blockades of the ionic pore 
current.  Initial proof-of-principle experiments were performed with the trypsin protease 
and a simple peptide substrate. The developed technique was applied to the detection of 
renin, a protease enzyme involved in blood pressure regulation, using His-tag analogues of 
its natural substrate, angiotensinogen. The strategy simplifies the currently used protocols 
for monitoring renin activity which are based on radioimmunoassays. Furthermore it 
enables the detection of an analyte within a biological sample; a feat which has been 
traditionally difficult to achieve using nanopores due to instability of the membrane by 
sample components such as plasma proteins, and low signal-to-noise ratios. The initial 
proof-of-concept using trypsin has been published in the Journal of Physics: Condensed 
Matter (J. Phys.: Condens. Matter, 2010, 22, 454103). The work describing the application 
to renin has been submitted to Analytical Chemistry. 
 
2.2. Introduction 
2.2.1. Overview of the Renin-Angiotensin-Aldosterone System 
The renin-angiotensin-aldosterone system (RAAS) is a physiological system which plays a 
major role in maintaining and regulating blood pressure, salt and water homeostasis.73 
Renin is a proteolytic enzyme which is released from the kidneys directly into the blood 
stream. Once in circulation, the enzyme acts upon its substrate, angiotensinogen to 
produce angiotensin I, a small decapeptide. Angiotensin I has no biological action itself, 
but is converted to angiotensin II by the action of angiotensin-converting enzyme (ACE), 
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an enzyme present primarily in vascular cells supplying the pulmonary system. 
Angiotensin II is considered the main effector peptide of the RAAS. It acts upon a number 
of different cells to ultimately induce an increase in blood pressure (Figure 9).74  
 
Figure 9: The renin-angiotensin-aldosterone system (ACE: angiotensin-converting enzyme). 
Adapted from [75]. 
The main stimuli for renin secretion are conditions of low blood volume and pressure 
(Figure 9). A fall in blood pressure immediately results in reduced blood flow through the 
kidneys. This change in pressure is detected mechanically by specialised cells termed 
baroreceptors, and chemically by mascula densa cells which detect the subsequent 
reduction in sodium levels. Both these changes trigger a feedback mechanism which 
results in increased renin secretion from a group of cells in the kidney called 
juxtuaglomerular apparatus, and ultimately, an increase in angiotensin II.75 Angiotensin II 
is one of the most potent vasoconstrictor agents known.76 It exerts its major affect by 
binding to receptors located on smooth muscles cells which line arteries and arterioles. 
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This causes the vessels to contract and consequently increases blood pressure. The 
aforementioned mechanism is a result of the systemic action of RAAS and the affects are 
exerted within a matter of minutes.77 
Components of the RAAS system may also be expressed locally within tissue, 
enabling angiotensin II to augment blood pressure indirectly.74,77 The main mechanisms 
through which this occurs are stimulation of the thirst centre of the hypothalamus which 
is located in the brain, and promotion aldosterone secretion from the adrenal cortex 
which is located on top of the kidney.75 Activation of these endocrine glands promotes a 
rise in blood volume and thus an increase in blood pressure. Specifically, when the thirst 
centre is stimulated, more water is absorbed from the intestines into the blood. 
Stimulation of the adrenal cortex, promotes release of aldosterone which subsequently 
causes the kidneys to retain more salt and consequently more water. The net effect is that 
an individual will drink more, retain more water, urinate less and thereby increase blood 
volume and restore renal perfusion. Such local affects are typically mediated over the 
course of several hours or days.77 
The RAAS system can also work in reverse. High salt intake can lead to high blood 
volume and pressure which in turn inhibits renin secretion. With less angiotensin II 
formation, less salt is retained by the kidneys and more water is excreted as urine. 
Unfortunately, one in three adults worldwide suffers from chronically high blood pressure, 
which may be attributed to elevated levels of renin secretion.78 In this case, the intake of 
salt must be lowered to match the impaired ability to excrete salt in urine. 
 
2.2.2. Biochemistry of the Renin-Angiotensin-Aldosterone System 
Renin is classified as an aspartic protease enzyme.79 This class of enzyme is characterised 
by inhibition by pepstatin, a hexapeptide from Streptomyces, and pH optima in the acid 
range due to the involvement of two conserved aspartic acids within the active site.79 
However, the designation of acidic protease is not properly applicable to renin, since its 
pH optimum is close to neutral when acting upon its natural substrates. The renin 
substrate, angiotensinogen, is a α2-globulin protein produced and released into circulation 
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by the liver.80 The substrate is a glycoprotein with 14% carbohydrate and a molecular 
weight of approximately 70 kDa.80,81 Seminal investigations by Skeggs et al.,82 showed that 
treating a substrate protein with trypsin releases a tetradecapeptide from the N-terminal 
of the protein. Furthermore, it was observed that this tetradecapeptide was in fact 
susceptible to the actions of renin and could mediate the affects of RAAS.  
 
Table 1: Comparison of the amino acid sequence of human angiotensinogen and angiotensin I. 
 
The amino acid sequence of the first 25 residues of human angiotensinogen were 
determined by Tewksbury et al., by Edman degradation of the protein (Table 1).83 
Interestingly, the identity of the fourteenth amino acid residue could not be determined 
suggesting that it was a site of carbohydrate attachment. It was observed that the first ten 
amino acids of human angiotensiongen corresponded to a previously reported sequence 
of human angiotensin I.84 Hence the scissile bond in human angiotensinogen was leu-val. 
Renin is known to be a species specific enzyme.85 Human angiotensinogen is the 
only naturally occurring substrate for human renin and is resistant to cleavage by non-
primate renin. Conversely, angiotensinogen isolated from most other species can be 
cleaved by human renin. This species specificity has been attributed to the differing amino 
acid sequences in positions P1'-P3' as the residues at the P5-P1 sites are identical among all 
angiotensinogens.86,87 [The notation of Schechter and Berger is used here,88 in which the 
residues of the substrate are numbered away from the scissile bond P1---Pn on the N-
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terminal side and P1'---P'n on the C-terminal side. Corresponding enzyme subsites are 
labeled Sn].  
 
2.2.3. Measurement of Plasma Renin Activity 
Abnormal renin secretion and irregularities in the RAAS have been implicated in a number 
of diseases and conditions.89,90 For this reason, measurement of circulating renin as an 
indicator of RAAS activity can be a useful clinical marker and diagnostic tool. As 
angiotensin II is the main effector of the RAAS system (Figure 9), one would expect renin 
evaluation to be based upon its production. However, due to its minute quantities and 
rapid degradation in the blood, measurement can be challenging. As a result, circulating 
renin is measured either directly using antibodies which recognise its active site, or 
indirectly in kinetic assays which measure the capacity of the enzyme to produce 
angiotensin I. These two approaches result in the determination of plasma renin 
concentration (PRC) and plasma renin activity (PRA), respectively.91 
 PRA is usually determined using radioimmunoassay of angiotensin I generated by 
endogenous enzyme and substrate.92  Typically, a blood plasma sample containing 
angiotensin I is placed in an antibody-coated tube and antibody-antigen complex 
formation ensues. 125I-labeled angiotensin I is added to the reaction vessel, and competes 
with unlabelled angiotensin I for a binding site. After incubation at 37 °C,92 the amount of 
radioactivity remaining on the reaction vessel is measured, from which the amount of 
unlabelled angiotensin I in the plasma sample can be estimated.93,92 The use of PRA is 
based upon the assumption that measuring the generation of angiotension I in vitro, 
assesses the action of renin in vivo.94 In order for this assumption to hold true, the plasma 
angiotensinogen levels and renin catalytic activity should be preserved as present in vivo. 
This can be achieved by carefully controlling the temperature whilst collecting plasma 
samples.95 Plasma samples must be collected and immediately stored at -20 °C to prevent 
cryoactivation of prorenin, the inactive precursor of renin, which can be activated when 
plasma is cooled to between -5 °C and 4 °C. The accuracy of the PRA can be further 
improved by subtracting background enzymatic activity. At ambient temperature, renin 
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will consume angiotensinogen and produce angiotensin I. Thus the amount of angiotensin 
I generated in this instance will need to be subtracted from that generated in the 
radioimmunoassay.92 Taking the aforementioned precautions prevents uncontrolled 
angiotensin I production and subsequently overestimation of renin activity.  
 PRC is also determined using a radioimmuno-based assay. However, the assay uses 
antibodies to measure the number of active renin molecules independently of their 
enzymatic activity.96 The assay makes use of two different antibodies: a less selective 
antibody that is immobilized on a solid support which is used to ‘capture’ angiotensin I 
from plasma; and a second, radioactive antibody reacts with the ‘captured’ angiotensin I 
to enable its quantification.95,97 This form of analysis can also be described as a sandwich 
assay as the analyte being measured is ‘sandwiched’ between two different antibodies.95 
Recently DiaSorin S.P.A. (Saluggia, Vercelli, Italy), introduced an alternative 
sandwich assay, in which the second antibody possesses chemiluminescent 
properties.92,98,99 This assay permits the direct measurement of renin using antibodies 
which are modified with acridinium esters. Once these antibodies have reacted with the 
‘captured’ renin, the resultant complexes are treated with an alkaline peroxide solution 
which initiates a chemiluminescent reaction. The amount of bound labelled antibody, is 
determined by relative light units, which are directly proportional to the concentration of 
the active renin in the sample.92 Chemiluminescent labels enable signal amplification and 
therefore offer increased sensitivity over standard PRC techniques. Furthermore, the 
process has been fully automated which enables higher throughput of samples. This is in 
stark contrast to radioimmuno-based techniques which are completely manual.97  
Chemiluminescent assays offer several other advantages over standard PRC assays. 
The most significant is elimination of the use of radioactive material. Use of isotopes 
requires that special measures be taken for their procurement and disposal. Furthermore, 
due to the hazards involved in using such materials, preparation of the starting materials 
can be time-consuming and require a high level of expertise.97 Additionally, whereas non-
isotopic labels have indefinite stability, radiolabels are inherently unstable and may only 
have a shelf-life of a few weeks or months.97 
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HPLC-based methods for the quantification of renin activity have also been 
developed. These typically make use of a fluorogenic peptide substrates which are 
hydrolyzed by renin to generate fluorogenic and non-flourogenic products.100 The amount 
of hydrolysis product is directly measured by reverse-phase HPLC, and the peak area 
compared to that of a standard in order to quantify the amount of peptide present. Assays 
based on fluorescence resonance energy transfer within peptide substrate, have been 
developed.101,102 The assays make use of peptide substrates that possess fluorescence 
doner and acceptor moieties at either the N- or C-terminal of a substrate analogue. In the 
intact peptide, the fluorescence is quenched due to favourable energetic overlap of the 
fluorophores excited state and the absorbance of the quencher. Cleavage of the substrate 
by renin liberates a fluorogenic peptide fragment from the proximity of the quencher. This 
results in a gradual increase in fluorescence, the rate of which is proportional to rate of 
peptide hydrolysis and thus the activity of the enzyme.  
While many techniques for measuring renin activity are currently available, they all 
require at least one component of the assay to be labelled. This represents a major 
limitation as the use of labels can increase the cost of an assay and complicate the 
preparation of components. It is envisioned that employing a nanopore-based approach 
will obviate the need for any labels and thus provide a simplified assay. Furthermore, it 
may permit the development of portable devices, which in turn could facilitate point-of-
care analysis.  
 
2.3. Aim  
In light of the current techniques available for the detection of renin activity, the ultimate 
aim of this project was to develop a nanopore-based technique which did not require 
engineering of the protein pore or labelling of any components. Furthermore, it was 
endeavoured that enzymatic digestion would liberate a single peptide fragment and thus 
vastly simplify data analysis. The proposed strategy is schematically summarised in Figure 
10.  Multiple copies of a peptide substrate are tethered via a flexible linker to microscale 
beads (Figure 10A). Upon enzymatic cleavage of the substrate by the enzyme (Figure 10B), 
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soluble fragments are released and subsequently electrically detected as they translocate 
through a nanopore (Figure 10C).  
 
Figure 10: Proposed strategy for nanopore-based technique to detect enzymatic activity. (1) Multiple copies 
of a peptide substrate, tethered via a flexible linker onto a microscale solid support. The substrate is cleaved 
by a proteolytic enzyme. For reasons of visual clarity, only one peptide substrate is shown. (2) The released 
peptide fragments (shown in red) are electrophoretically driven through the nanopore. (3) This gives rise to 
reversible blockades of an ionic pore current. 
 
It was hypothesised that by including a His6-tag at the terminus of the substrate and 
performing the digestion in the presence of nitrilotriacetic acid (Ni2+-NTA), the 
enzymatically released peptide could be captured and purified from the crude reaction 
mixture. It was hoped that this two-step approach would enable the analysis of peptides 
from a complex biological matrix such as human serum. This has traditionally been 
difficult to achieve using nanopores due to instability of the lipid bilayer and increases in 
background noise triggered by other molecules which can also block the pore.  
As this project involved a significant amount of peptide synthesis, a brief overview of 
the techniques, reagents and reaction mechanisms will be provided before presenting the 
results. 
 
2.4. Solid-Phase-Peptide Synthesis 
The peptides used during this investigation were synthesized via solid phase peptide 
synthesis (SPPS), using Fmoc-chemistry.103–105 SPPS involves the construction of a peptide 
chain in the C→N-terminal direction on an insoluble solid support.106 The principles of 
SPPS are illustrated in Figure 11. The C-terminal amino acid of the target peptide is 
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attached to the support through its carboxyl group. The protecting group masking the α-
amino group is removed (deprotected) and the soluble by-products removed by washing 
and filtration. An excess of the second amino acid is added, the carboxyl terminal of which 
is activated towards amide bond formation. Activation is typically achieved through the 
use of a coupling agent (in situ). The N-α-amino protecting group of the resultant 
dipeptide is removed and the coupling process repeated until the desired peptide is 
synthesised. After each coupling step, excess amino acids and soluble by-products are 
removed. In the final step, the bond between the peptide and the resin is cleaved. The 
peptide is liberated into solution where is can be isolated and purified.  
 
Figure 11: Principle of solid phase peptide (SPPS) synthesis. All non-reacting functional groups are protected 
during the synthesis. The N-α-protecting group (blue circle) is typically protected with Fmoc. The side-chain 
protecting groups (black circle) are typically orthogonal with the bond between the peptide and the solid 
support. Hence the peptide can be liberated from the solid-support and side-chain deprotected 
simultaneously. Green circle is a C-terminal activating group. 
Generally, the bonds between the peptide, the solid-support and side-chain protecting 
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groups, are such that liberation and deprotection occur simultaneously. The N-α-amino 
protecting groups can be removed independently and selectively in the presence of the 
side-chain protecting groups. Hence these groups are said to be orthogonal. In Fmoc SPPS, 
orthogonality is achieved by use of the base-labile Fmoc group for protection of the α-
amino group, and acid-labile side-chain protecting groups. The bond to the resin is usually 
also acid labile. Fmoc cleavage is traditionally achieved with 20-50% piperidine in DMF, 
whereas global side-chain deprotection and release of the peptide with 95% TFA. The 
protecting groups most commonly used in this project have been summarised in Table 2. 
 
Table 2 Common side-chain protecting groups used in Fmoc-SPPS.106 
Entry 
Side-chain 
functionality 
Protecting 
group 
Abbreviation 
1 
Arg 
 
HN NH2
NH
 
O
SHN
O O  
Pbf 
2 
Asp 
 
OH
O
 
 
O
O
 
OtBu 
3 
His 
 
NHN


 

NN

 
 
Trt 
4 
Ser/Tyr 
 
OH 
 
O  
 
tBu 
5 
Lys 
 
NH2 
 
N
H
O
O
 
Boc 
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The solid supports or resins employed in SPPS are typically polystyrene-based.104 The 
resins are able to swell in solvents to allow reagents to access reactive sites and enable 
the synthesis and release of the peptide. In addition to this, the resin must be chemically 
inert and resistant to degradation during synthesis. The most important feature of resins 
is that they can be readily functionalised with linkers to which the C-terminus of a peptide 
is attached. The linker serves as a reversible attachment between the peptide chain and 
the solid support, and also protects the C-terminal α-carboxyl terminal during synthesis.106 
The choice of linker dictates the ease with which the peptide is liberated from the resin 
and also the functional group at the C-terminus. Most linkers are designed to release the 
peptide with either a carboxylic acid or an amine upon treatment with TFA.106 The loading 
of the resin, that is, the concentration of the linker functional groups, determines the 
theoretical yield of the final peptide. The linkers used throughout this investigation are 
summarised in Table 3. 
The concentration of TFA employed dictates whether the peptide is released in a 
completely deprotected state, or with the side-chain protecting groups intact. The 
strength of the acid required to release the peptide is dependent on the nature of the 
linker and the leaving group. In general, peptides are more easily liberated from linkers 
which are electron-rich. Conversely, electron-poor linkers may require the use of a 
stronger acid such as HF. Regardless of the acid which is used, peptide deprotection and 
liberation results in a reaction medium which is rich in electrophilic alklyating agents. 
These species’ can alkylate electron-rich functional groups on the peptide such as 
hydroxyls and thiols. These unwanted reactions can be minimised by performing the 
deprotection and liberation steps in the presence of scavengers. The most commonly used 
are thiols such as 1,2 ethanedithiol (EDT), silanes such as triethylsilane (TES) and water.  
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Table 3 Linker resins used for the synthesis of peptides. 
Entry Linker Cleavage conditions Loading 
1 
 
Wang resin 
 
HO
O
 
 
90-95% TFA v/v 0.65 mmolg-1[a] 
2 
 
2-Chlorotrityl chloride resin 
 
Cl
Cl
 
 
 
1. 90-95% TFA v/v[c] 
2. 20% TFE:DCM v/v[d] 
0.60 mmolg-1[b] 
3 
 
PEGA 
 
 
 
Enzymatic digestion[e] 0.20 mmolg-1[f] 
4 
HMBA 
 
HO
H
N
O  
 
0.1 M NaOH (aq) 0.089 mmolg-1[g] 
[a] This loading refers to the pre-loaded glycine derivative which was utilised in this investigation. [b] This 
loading refers to the unsubstituted resin. The resin was loaded with the desired amino acid prior to peptide 
synthesis. Refer to the Materials and Methods section for details. 
[c]
Applying these conditions 
simultaneously liberates and side-chain deprotects the peptide. 
[d]
 Applying these conditions liberates a fully 
protected peptide. 
[e]
 The peptides were directly attached to PEGA via a permanent amide bond. Peptide 
fragments were liberated by enzymatic digestion. Peptides attached via HMBA linker could be released by 
treatment with 0.1 M NaOH. [f] Refers to the loading of the un-substituted resin. [g] This is an approximation. 
The loading was determined by monitoring Fmoc deprotection after peptide synthesis. 
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Amide bond formation requires activation of the carboxyl terminal of the incoming amino 
acid. This is typically achieved with the use of coupling agents which render the carbonyl 
of the carboxylic acid more electrophilic and thus more susceptible to nucleophilic attack 
by the amine of the growing peptide chain. The most commonly used coupling agents are 
uronium salts which are preferred for their solubility, stability and comparatively lower 
side reactions.107,108 The most popular reagent of this class is N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU). Its mechanism of action is shown 
in Figure 12. The deprotonated acid reacts with the uronium salt to generate an activated 
acyl-uronium species and 1-hydroxybenzotriazole (HOBt). HOBt readily reacts with the 
activated acid to generate a more reactive benzotriazolyl (OBt) ester which undergoes 
nucleophilic attack by the amine to generate an amide bond.  
R' OH
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R' O
O
N
N
N
O N
N
-PF6
R O
O
N
N
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O
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Figure 12: Amide bond formation mediated by HBTU. A tertiary base is employed to deprotonate the 
carboxyl terminal of the peptide. The reaction is performed in one-pot. 
 
2.5. Results and Discussion 
2.5.1. Proof-of-Principle Experiments using Trypsin 
Initial proof-of-principle experiments were performed using a simple peptide, Y3KIG4, and 
58 
 
the trypsin protease.109 The peptide sequence was designed by considering the specificity 
of trypsin as well as the requirements for nanopore analysis. Trypsin is a pancreatic serine 
protease which cleaves peptides selectively at the carboxyl-side of lysine and arginine 
amino acid residues. Its specificity arises due to an electrostatic interaction between these 
residues, which are positively charged at physiological pH, and a negatively charged 
aspartate residue within the active site (which located in the S1 catalytic pocket).
110 The 
rate of enzymatic hydrolysis is also determined by the amino acid at the carboxyl side of 
the scissile bond, that is, position P1'.110,111 In particular, the enzyme favours large 
hydrophobic residues, such as isoleucine, in this position.112 Taking these factors into 
consideration, it was expected that the enzyme would cleave the peptide between the 
isoleucine and lysine residues to liberate an Y3K fragment (Figure 13A).  
 
Figure 13: The approach to electrically detect trypsin activity via nanopore recordings. (A) Multiple copies of 
a peptide substrate, tethered via a flexible poly(ethylene) glycol linker onto a solid support, are cleaved by 
trypsin enzyme. The sequence of the substrate and the cleavage site are shown. For visual clarity, only a 
single substrate molecule is shown. (B) The released peptide fragments are electrophoretically driven 
through the αHL pore giving rise to reversible blockades of the ionic pore current. Drawing not to scale. 
The detection of the peptide by nanopore analysis was considered by placing three 
tyrosine residues at the N-terminus. It was anticipated that these bulky residues would 
increase the extent of pore blockade and thereby facilitate identification of the intact 
peptide and the released fragment. Additionally, as a result of the lysine residue, the 
peptide was expected to carry a net positive charge which would facilitate the 
electrophoretic passage through the pore when a negative transmembrane potential was 
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applied (Figure 13B). Finally, four small glycine residues where placed at the C-terminus. It 
had previously been reported that these residues acted as a ‘spacer’ to aid the synthetic 
incorporation of the bulky tyrosine and isoleucine residues, and increase the steric 
accessibility of the protease.113 
 
2.5.2. Preparation of Immobilised Substrate via Convergent Solid-Phase Peptide 
Synthesis 
In order to determine whether the model peptide was indeed a suitable substrate for 
trypsin, digest reactions were performed using a soluble form of the peptide. The peptide 
was synthesised using standard Fmoc-based SPPS on a Wang resin (Table 3, entry 1) pre-
loaded with glycine, and HBTU coupling chemistry. The peptide was isolated in a crude 
yield of 77% which corresponded to a mass of 59 mg. A small subset of the peptide was 
purified by preparative HPLC, characterised by LC-MS analysis then subjected to the action 
of trypsin. A ratio of 1:50 enzyme:peptide was employed and the reaction mixture 
incubated at 37 °C for 18 h. An aliquot of the resultant solution was analysed by HPLC 
which showed a decrease in the peak area of the Y3KIG4 peptide and the emergence of a 
new peak (Figure 14B). MS analysis confirmed that the latter was indeed the Y3K fragment 
(Figure 14B). The release of the fragment was certainly due to the action of the enzyme as 
blank experiments in which the peptide was incubated in buffer in the absence of trypsin 
did not produce any peptide fragments. This notion was supported in a supplementary 
experiment in which Y3KG5 was incubated with trypsin. Substitution of the isoleucine for a 
glycine residue inhibited the release of the Y3K fragment. This experiment also confirmed 
the importance of having a hydrophobic amino acid residue in the S1' binding site of the 
enzyme.    
60 
 
 
Figure 14: (A) MALDI trace of solution phase digestion of Y3KIG4. M corresponds to the undigested substrate. 
(B) HPLC trace of digestion mixture. The peak at 12.4 min corresponds to the Y3K fragment. The peak at 14.0 
min corresponds to intact, undigested substrate. HPLC analysis was perfomed on a Varian Pursuit XRS C18 
column and UV absorbance measured at 254 nm. See Materials and Methods for details. 
Having shown that Y3KIG4 was a substrate for trypsin, efforts were made to synthesise the 
substrate on a PEGA (bis 2-acrylamidoprop-1-yl polyethyleneglycol cross-linked with 
dimethyl acrylamide) resin (Table 3, entry 3). PEGA is one of the most widely used resins 
for heterogeneous (i.e. on-bead) enzymatic assays.114 It possesses 2-aminopropyl groups 
at the end of polyethylene glycol chains, which are attached to a polyacrylamide core 
(Table 3, entry 3).113 This feature enables the resin to be readily functionalised using 
standard coupling chemistry. Furthermore, the presence of PEG chains inside the resin, 
furnishes it with hydrophilic properties which enable it to swell in a range of organic 
solvents and aqueous media.115 Accordingly, the swelling property of the resin determines 
the ability of an enzyme to diffuse through the resin and access the immobilised substrate. 
PEGA1900 which was used in this investigation, is freely permeable to enzymes with a 
molecular weight of up to 35-45 kD.116 Thus the resin was ideally suited for assays 
involving trypsin and renin which have molecular weights of 23.3 kD117 and 42.0 kD80, 
respectively. 
 
 The initial attempts to synthesise Y3KIG4 on PEGA resin were based on the convergent 
solid-phase peptide synthesis (CSPPS). CSPPS involves the synthesis of small fully 
protected peptide fragments using standard SPPS described above (Figure 11). After 
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purification, the fragments are coupled together on a solid-support to construct a larger 
peptide. The target peptide is then deprotected and can be cleaved from the resin. Thus 
the aim was to synthesise the fully protected Y3KIG4, couple it to PEGA then remove the 
protecting groups to give the immobilised substrate.  
Synthesis of the fully protected peptide was achieved using standard SPPS with 
polystyrene resin bearing a 2-chlorotrityl linker (Table 3, entry 2). In a slight alteration to 
conventional SPPS, the final Fmoc deprotection was not performed. Furthermore, 
cleavage of the peptide from the resin was achieved in far milder conditions using 20% 
TFE/DCM (v/v) which enabled the fully protected peptide to be isolated in 30% crude 
yield. Dissolution of a small amount of the crude material into neat DMSO enabled 
analytical HPLC and LCMS analysis to be performed. However purification by preparative 
HPLC was ruled out as addition of water to the DMSO solution resulted in precipitation of 
the peptide. Using analytical HPLC, the purity of the protected peptide was determined as 
69% ( 
Figure 15B). Indeed, peaks with retention time of 18.27 and 24.92 min were 
observed. LCMS analysis revealed that these were the Fmoc-deprotected product (1246 
m/z [M+2Na]2+) and the desired fully-protected peptide (1468 m/z [M-H]-), respectively ( 
Figure 15A). A partially protected adduct with mass 1353 m/z was also observed. 
This corresponded to the fully protected peptide minus a tert-butyl protecting group 
(Table 2, entry 4).    
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Figure 15: (A) Mass spectrometric analysis of fully protected Y3KIG4. 1468 m/z [M-H]
-; Fmoc-deprotected 
product, 1246 m/z [M+2Na]
2+
; partially protected adduct (minus tert-butyl protecting group), 1353 m/z. (B) 
HPLC analysis of the crude fully protected Y3KIG4. The peak at 25 min corresponds to the desired peptide. 
HPLC analysis was perfomed on a Varian Pursuit XRS C18 column and UV absorbance measured at 254 nm. 
See Materials and Methods for details. 
 
The crude peptide was subsequently coupled to the PEGA resin via an amide bond. The 
peptide was dissolved in the minimum amount of DMSO producing a highly concentrated 
solution to which HOBt and N,N'-diisopropylcarbodiimide (DIC) were added. The activated 
peptide solution was added to the PEGA resin and the resultant suspension shaken at 
room temperature. Completeness of the coupling step was determined by testing the 
resin for the presence of free amines using the Kaiser test. The test is based on the 
reaction of ninhydrin with primary amines, which gives a characteristic dark blue colour.118 
The resin gave a negative result, indicating that no free amines were present and thus 
coupling was complete. The bound peptide was subsequently Fmoc-deprotected by 
incubation with 20% piperidine/DMF (v/v), and side-chain deprotected using standard 
cleavage cocktail comprised of TFA:TES:water, 95:2.5:2.5. Fmoc deprotection was 
monitored by analytical HPLC which revealed a peak corresponding to the dibenzofluvene-
piperidine cleavage product (Figure 16, 2), confirming that deprotection had occurred. 
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Figure 16: Removal of N-Fmoc group with piperidine. The reaction proceeds via initial abstraction to give a 
stabilized dicyclopentadiene anion, which on elimination gives rise to dibenzofluvene, 1. 1 is the scavenged 
by piperidine to give adduct 2. The products of the deprotection reaction absorb UV strongly, thus provide a 
method of monitoring this reaction. Adapted from [119]. 
The Fmoc-deprotection solution was used to estimate the loading of the resin, which in 
turn, was used to estimate the yield of the coupling. The UV absorbance of the 
deprotection solution was measured in triplicate using equation (1)120i: 
 
                                 (1) 
 
The loading was estimated to be 0.03 mmolg-1. As the unsubstituted PEGA resin was 
purchased with a loading of 0.2 mmol g-1, the coupling yield was determined as 15%. The 
relatively low yield was unexpected considering that the Kaiser test suggested that no free 
amines were present on the PEGA resin. The loading may have been improved by 
performing a second coupling using a fresh solution of the activated peptide however this 
was not possible as the supply of peptide was limited. Synthesis of the protected peptide 
was performed using 120 mg of chlorotrityl resin pre-loaded with glycine (resin loading: 
0.8 mmolg-1) and typically yielded only 17-60 mg of material (12-42% yield). One plausible 
                                                             
i
 This is only a rough estimation the equation calls for the use of the dry weight of the resin. However, the 
64 
 
explanation of the low yields is the hydrophobic nature of the protected peptide. It was 
hypothesized that the cleaved peptide was interacting with the resin rather than being 
released into solution. Attempts were made to extract the peptide from the resin by 
suspending the resin in DMSO. However, subsequent HPLC analysis revealed that the very 
little additional peptide was released. The low yield could also be attributed to the poor 
swelling properties of PEGA in DMSO. The protected peptide was soluble in DMSO but 
completely insoluble in aqueous solutions or DMF. Conversely, PEGA displays optimum 
swelling in water and DMF but does not swell in DMSO.121 The swelling properties of PEGA 
are summarised in Figure 17. It is likely that the coupling reactions only took place on the 
outer surface of the resin, which was accessible to the peptide. 
 
Figure 17: Swelling properties of PEGA and other resins [121]. 
2.5.3. Enzymatic Digestion of Substrate Prepared by CSPPS 
Having successfully produced PEGA-bound substrate, albeit in a low yield, a 
heterogeneous enzymatic assay was performed using trypsin. Incubation of the PEGA 
derivative with the enzyme did indeed result in the release of a single fragment as 
determined by HPLC analysis (Figure 18). MS analysis identified the peptide to be of the 
sequence Y3K. This confirmed that the cleavage site correlated to that of the soluble 
peptide and indicated that the resin did not interfere with the activity of the enzyme. The 
purity of the released peptide was surprisingly high considering that the protected peptide 
had not been purified. 
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Figure 18: HPLC trace of Y3K enzymatically released from PEGA-Y3KIG4. HPLC analysis was perfomed on a 
Varian Pursuit XRS C18 column and UV absorbance measured at 214 nm. 
 
2.5.4. Preparation of Immobilised Substrate via Manual Solid-Phase Peptide Synthesis 
Although the PEGA-bound substrate was successfully prepared using the CSPPS-based 
approach, an alternative method through which larger quantities of PEGA-substrate could 
be prepared, was required. Manual solid-phase peptide synthesis (MSPPS) directly onto 
the PEGA resin was seen as a better alternative. 
 The principle behind MSPPS is the same as automated SPPS. A peptide is 
assembled through repetitive coupling and deprotection of N-α-protected amino acids on 
a solid support; however, there are some significant differences. Most notably, during 
MSPPS, the coupling efficiency of each step is carefully monitored and can be improved 
upon. Monitoring is typically achieved using a qualitative technique in which a reagent 
reacts with free amino groups to produce a chromophoric compound (e.g. Kaiser test).105 
Any observed reduction in the coupling efficiency can be improved by performing an 
additional coupling until tests show that the reaction is complete. A further distinction 
from automated SPPS is that unreacted amino groups are chemically blocked (capped) at 
each step. Regardless of the efficiency of the coupling agent used, each step of the 
synthesis will contain peptides to which couplings have failed, giving rise to deletion 
peptides.105 The number of deletion sequences can be reduced by treating the resin with 
acetic anhydride, in the presence of an organic base. As a result of these practices, 
peptides synthesised using MSPPS can benefit from improved yield and homogeneity. 
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Furthermore, MSPPS offers greater control over synthesis and can often be performed on 
a larger scale compared to automated SPPS. 
Using MSPPS, PEGA-Y4KIG4 was synthesised starting with 2.33 g of PEGA. With the 
exception of the first step, only a single coupling reaction was needed to drive each step 
to completion (as determined by the Kaiser test). Amide bond formation was mediated by 
HOBt/DIC rather than HBTU/DIPEA, as the former has greater solubility in DMF compared 
to the latter. At each step, capping was performed and Fmoc-deprotection monitored by 
HPLC. The loading of the resin was estimated as 0.16 mmolg-1 using equation 1 and 
spectroscopic analysis at 290 nm of the dibenzofluvene-piperidine adduct formed upon 
deprotection of the terminal tyrosine residue. The coupling yield was determined as 80% 
which is almost 5-times higher than yield achieved using CSPPS-based approach to peptide 
synthesis. 
 
2.5.5. Enzymatic Digestion of Substrate Prepared by MSPPS 
The PEGA derivative was incubated with trypsin and the supernatant subsequently 
analysed by HPLC and MS analysis. Analytical HPLC showed that a single peptide fragment 
had been released; the purity of which was slightly greater than that released from the 
CSPPS-based substrate. MS analysis identified the peptide to be of sequence Y4K.
ii  
 
 
 
                                                             
ii
An additional tyrosine residue was coupled. 
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Figure 19: Kinetics of substrate cleavage by trypsin. (A) HPLC traces for the time-dependent enzymatic 
release of the YK4 peptide fragment from PEGA. Y-axis: absorbance at 214 nm (B) Kinetics of enzymatic 
cleavage of PEGA-bound Y4KIG4 (solid squares) and in solution (empty circles). The data points are the 
averages of the peak areas from two independent experiments. Adapted from [109]. 
The rate of Y4K generation in the homogenous and heterogeneous assays was assessed by 
HPLC (Figure 19). In both instances, the amount of peptide increased with incubation 
time, as would be expected for an enzymatic digestion (Figure 19A). The resulting kinetics 
yielded an apparent initial rate constant of 2.6 x 10-3 min-1 for the cleavage from PEGA 
(Figure 19B, solid squares). By comparison, cleavage of soluble peptide substrate under 
otherwise comparable conditions proceeded with a higher rate constant of 4.0 x 10-3 min-1 
with a 1.9-times higher amount of the peptide at the endpoint (Figure 19B, empty circles). 
The difference in kinetics likely reflects the longer diffusion time of the enzyme to the 
bead surface. Porous supports generally have a high loading of functional groups, which 
are distributed over the surfaces inside the support so that enzymes need to penetrate 
the support for successful catalysis.122 These accessibility problems do not occur in 
homogenous assays. 
 
2.5.6. Nanopore Analysis 
The solution of Y4K peptide fragments released from the PEGA resin was examined using 
the αHL nanopore. As discussed earlier, nanopore analysis is an electrical approach to 
sense individual molecules that temporarily reduce the ionic current flowing through a 
nanoscale pore. The passage of the analyte through the pore is termed a ‘translocation 
event’ and the analyte is said to have caused a ‘blockade’. In practical terms, modulations 
of the ionic current are measured using electrophysiology data acquisition software called 
pClamp. The software analyses the details of the electrical traces and deposits the data 
into a spreadsheet for further numeric-graphical analysis using software called Clampfit. 
To ensure a statistically valid analysis, the blockade data are fitted to the appropriate 
distributions.123 Three translocation parameters are obtained: the amplitude (or size of 
the blockade, A), the dwell time (or duration of translocation events, τoff) and the duration 
between events (τon) (Figure 20).  
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Figure 20: Definition of the amplitude, dwell time τoff and inter-event interval τon. 
The amplitude of blockade, A, is expressed as a percentage or a fraction of the open 
channel current with units of picoamperes (pA). pClamp measures the amplitude of 
individual events and the data plotted and fitted to a Gaussian distribution. In an 
experiment involving the analysis of a single analyte, the majority of translocation events 
will have similar amplitudes. Specifically, there will be very few events with 
uncharacteristically large (complete blockade of the pore) or small (incomplete 
translocations) amplitudes.123 The peak of the Gaussian curve is taken as the statistical 
average blockade for that set of results. The average dwell time, τoff, is derived by plotting 
the individual τoff values against the number of translocation events within the data set. 
The data are fitted to a Poisson distribution which describes an exponential decay for 
which the exponential decay constant is the characteristic value. A logarithmic scale is 
applied to the y-axis and the average τoff taken from the decay constant. The time 
between events, τon, is determined in the same way as τoff. τon is dependent upon the 
concentration of the analyte being analyzed; the two variables are directly proportional. 
Consequently, in order to compare τon values determined from independent nanopore 
experiments, experiments are often performed with samples that have similar 
concentration. In situations where this is not possible, the τon value can be normalised for 
concentration after it has been determined.  By taking the inverse of τon, the frequency of 
occurrence (Foo) of translocation events can be determined. Thus Foo corresponds to the 
frequency of translocation events per unit time. The nanopore data reported throughout 
this thesis was generated from at least three independent nanopore recordings, and at 
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least a thousand translocation events analysed. This was to ensure the statistical validity 
of the results.  
Nanopore analysis of Y4K peptide solution was conducted in 2 M KCl solution 
buffered with 50 mM Tris at pH 8.0, with a potential of +100 mV at the trans side of the 
αHL pore with the cis side grounded. This configuration amounted to an effective negative 
potential at the cis side relative to the trans side. Under these conditions, in the absence 
of any peptide, the αHL pore exhibited an open channel current of 191 ± 8 pA. 
Furthermore, the lysine residue, which has a pKa of 10.5,124 was expected to carry a net 
positive charge and be driven through the pore. Indeed, addition of the peptide fragment 
solution to the trans side, with a final concentration of 1.03 μM, caused short current 
blockades. The translocation parameters were derived from the analysis of 3700 
translocation events of four independent recordings.  
 
Figure 21: Characteristics of Y4K-induced pore blockades. (A) Histogram of the amplitude normalized to the 
open-channel current. (B) Dwell time (τoff). (C) Inter-event interval (τon). Data from one recording with 1565 
events was used to generate this figure [109]. 
The amplitude was normalised to the open channel current to yield a histogram 
distribution which was fitted to a Gaussian curve (Figure 21A). The average amplitude was 
determined as 38.8 ± 1.9%, which is similar to the pore blockades found for peptides in 
other studies.8,125  Thus the result was consistent with the translocation of the Y4K 
fragment through the inner constriction of αHL pore. However, the possibility that the 
peptide temporarily blocked the pore without fully translocating it could not be ruled out. 
The τoff data was fitted to a single exponential decay and yielded an average of 87 ± 15 μs 
(Figure 21B). This value is in line with the timescales for the translocation of similar small 
peptides through non-modified αHL pores.8,125  The final translocation parameter τon, was 
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determined as 430 ± 70 ms, which corresponded to a frequency of occurrence of 2.3 ± 0.2 
s-1. After normalising for the peptide concentration, the translocation frequency was also 
found to be within the ranges observed in other studies. 8,125  The observed translocation 
events were certainly due to the action of the Y4K fragment, as control experiments in 
which the chemically synthesised fragment was analysed, yielded similar results. The 
results are summarised in Table 4. In particular, the translocation parameters of the 
enzymatically released fragment fall within experimental error of the chemically 
synthesised fragment. Furthermore, translocation of the intact, undigested peptide could 
also be ruled out, as the chemically synthesised peptide yielded characteristically different 
amplitude of blockade; the blockade of the intact peptide was almost twice that of the 
released fragment. 
 
Table 4: Translocation parameters for enzymatically released Y4K peptide fragments and 
synthesised controls. 
 Source of Y4K fragment  
Translocation 
parameter 
Enzymatically 
released 
Chemically 
synthesised[a] 
Y4KIG4
[a] 
τoff 87 ± 15 μs 100 ± 20 μs 110 ± 11 μs 
τon 430 ± 70 ms 442 ± 63 ms  512 ± 105 ms 
Foo 2.3 ± 0.2 s
-1 2.3 ± 0.3 s-1 3.2 ± 1.5 s-1 
Amplitude 38.6% 32.8% 58.6% 
                                                     [a] Synthesised using standard SPPS.  
 
 
2.6. Sensing Strategy Applied to the Detection of Renin Activity 
The newly developed sensing strategy was applied to the detection of renin activity in the 
presence of plasma proteins. Akin to the proof-of-principle studies, the PEGA-bound 
substrate was treated with renin to release a soluble peptide fragment. The sequence of 
the bound substrate was derived from the first 14 amino acid residues on the N-terminus 
of human angiotensinogen (Table 1). Due to difficulties in isolating and purifying human 
angiotensinogen, experiments requiring a natural substrate are usually performed with 
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the tetradecapeptide (Ang0, Table 1).86 Investigations have shown it to be a suitable 
substrate for renin and resistant to cleavage by proteases commonly found in plasma.86 A 
hexahistidine (His6) tag was placed at the N-terminus of the substrate to enable enzymatic 
digestion and downstream purification to be performed in a single reaction vessel. The 
sensing approach is summarised in Figure 22. In brief, angiotensin I-His6 (AngI-His6) was 
released as a result of enzymatic activity and concomitantly bound to nickel-nitriloacetic 
acid beads (Ni2+-NTA, N, Figure 22A). After washing the beads to remove residual plasma 
proteins (Figure 22B), the bound AngI-His6 was eluted by addition of imidazole (Figure 
22C). Finally, the purified peptide solution was subjected to nanopore analysis (Figure 
22D).  
 
Figure 22: Sensing of renin activity in the presence of plasma proteins. (A) The peptide substrate is 
immobilized onto PEGA, P, via a flexible linker. Only a single substrate molecule is shown for clarity. AngI-
His6 (shown in red) is released by the action of renin and concomitantly bound by Ni
2+-NTA, N, beads. (B) The 
unbound plasma proteins (brown circles) are removed by washing the beads. (C) Bound AngI-His6 is eluted 
from Ni
2+
-NTA by the action of imidazole (blue circle). (D) The purified peptide solution is subjected to 
nanopore analysis. The analyte required for nanopore analysis is generated using two different types of 
beads within a one-column format.  
The PEGA-bound substrate was prepared by MSPPS as described above. However, rather 
than coupling the peptide directly onto the resin, a cleavable 4-hydroxymethylbenzoic 
acid (HMBA, Table 3, entry 4) linker was employed. Although preparation of the trypsin 
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substrate PEGA-Y3KIG4 had proceeded smoothly, the lack of a cleavable linker meant that 
the progress of the synthesis could not be followed. Kaiser test analysis gave an indication 
of the coupling efficiency; yet, the purity of the peptide could not be determined until 
enzymatic digestion. The cleavable linker enabled the growing peptide to be cleaved from 
the resin at periodic intervals during the synthesis, and the purity to be assessed by HPLC 
or MS analysis. This was particularly important after the coupling of proline as removal of 
the N-α-Fmoc group, resulted in a secondary amine which gave rise to a brown 
colouration of the beads rather than the characteristic blue in the Kaiser test.118 The 
peptides were liberated from the resin using a solution of aqueous sodium hydroxide 
which nucleophilically attacked the ester bond between the peptide and the HMBA linker 
(Figure 23A). Once synthesis was complete, the loading of the resin was determined as 
0.089 mmolg-1 which corresponded to a yield of 48% based on the initial loading of PEGA. 
 
2.6.1. Developing the Sensing Approach: Control Reactions. 
The PEGA-bound substrate was initially subjected to renin digestion in the absence of 
plasma proteins. The reaction was monitored by analytical HPLC over the course of several 
hours. The resins were washed and equilibrated in the MOPS-NaOH-BSA buffer (pH 8.0) 
prior to the addition of renin, then incubated at 37 °C. The results are shown in Figure 23. 
Within 5 min of incubation, a new peak with retention time of 15.36 min emerged (Figure 
23B). Using MALDI analysis, this was identified as AngI-His6. The peak increased in 
magnitude with longer incubation times, confirming that release was due to the action of 
the enzyme (Figure 23C). Furthermore, HPLC analysis showed that the enzymatically 
released peptide co-migrated with the chemically synthesised peptide, further 
corroborating the identity of the peptide (Appendix 1). 
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Figure 23: Digestion of PEGA-bound Ang0. (A) Structure of PEGA-HMBA-Ang0-His6 and renin cleavage site. 
(B) HPLC trace for the time-dependant enzymatic release of AngI-His6 peptide from PEGA tR = 15.36 min 
corresponds to AngI-His6. tR = 20 min corresponds to BSA present in the buffer. (c) The peak area of the 
released AngI-His6 was normalized to that of BSA. HPLC analysis was perfomed on a Varian Pursuit XRS C18 
column and UV absorbance measured at 214 nm. 
 
Control experiments, in which the PEGA-bound substrate was incubated in the absence of 
renin, were also performed. As expected, the AngI-His6 was not detected however the 
reaction mixture did show traces of Ang0-His6, the undigested intact substrate. This was 
attributed to hydrolysis of the ester bond between the peptide and the linker by the 
hydroxyl ions, which were used as a buffering agent. Hydrolytic cleavage was also 
observed in the presence of other buffers (25 mM sodium acetate and 50 mM Tris-base), 
but not in plain un-buffered water. These results were surprising, as the use of the HMBA 
linker in biotransformations has been widely reported,126,127 but to our knowledge, 
hydrolytic cleavage of the ester bond has not been observed. The rate of hydrolytic 
release from the resin was monitored in a time-course experiment. Using the same 
experimental conditions as those employed in digestion experiments, aliquots of buffer 
were removed at regular intervals then subjected to HPLC analysis. With the aid of a 
calibration curve, the amount of intact substrate released at each time-point was 
estimated. At 24 h, the amount of hydrolytically released peptide accounted for only 5% 
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of the amount released enzymatically. Hence for these investigations, the amount of 
hydrolytically released peptide was deemed to be negligible.   
The ability of AngI-His6 to bind to and be eluted from Ni
2+-NTA beads was 
determined using a soluble form of the peptide. A buffered solution of the peptide was 
added to a suspension of Ni2+-NTA beads, which had previously been thoroughly washed 
and equilibrated. As MOPS contains a tertiary amine which could potentially reduce the 
Ni2+ to elemental nickel,128 the experiment was performed in sodium phosphate buffer. 
After incubation for 24 h, the suspension was filtered, the beads thoroughly washed, and 
elution achieved by the addition of 250 mM imidazole buffer. The amount of peptide 
recovered was estimated as 48%. This was extrapolated from the area of the HPLC peak 
and a calibration curve. The experiment was also performed in the presence of BSA (0.18 
mgml-1), the protein required to stabilise renin during digest experiments. BSA was not 
detected in the eluted solution confirming that the protein did not bind to Ni2+-NTA. In 
terms of the sensing approach, this observation was seen as beneficial as the removal of 
BSA from the eluted AngI-His6 solution would result in less background noise in the 
nanopore traces. 
The one-pot reaction using the PEGA-Ang0-His6 (Figure 22, A-C) was performed in a 
similar manner to the control experiments. To the PEGA-bound substrate, Ni2+-NTA beads 
were added followed by 5 U of renin. After incubation at 37 °C overnight, the suspension 
was transferred to a spin column and the supernatant removed. The mixture of beads 
were washed with water then treated with the imidazole solution. The HPLC trace of the 
supernatant featured a peak with a retention time corresponding to that of AngI-His6. The 
identity of the peptide was confirmed by MALDI-MS. Hence it was shown that AngI-His6 
could be enzymatically released by renin, concomitantly captured by Ni2+-NTA and 
subsequently eluted in a clean fraction.  The release of AngI-His6 was certainly due to the 
action of renin, as blank experiments in which renin was not included did not yield any 
peptide fragments, but trace amounts of the hydrolytically released substrate was 
detected. 
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In order to simulate in vivo conditions, the digestion of PEGA-bound Ang0-His6 was 
performed in presence of human serum proteins. Plasma is the straw-coloured fluid 
portion of the blood which is responsible for keeping the cellular components in 
suspension. It is composed primarily of water and dissolved solutes, but also contains 
organic molecules such as hormones, enzymes, antibodies and a variety of proteins.75 
Blood serum has exactly the same composition as blood plasma, but lacks fibrinogen, an 
anticoagulant. Two problems were anticipated from the use of human serum in our 
sensing approach. First was the contamination of the eluted AngI-His6 with serum 
proteins. As the protein concentration of serum is high, approximately 1 mM,129 the beads 
would need to be thoroughly washed to prevent carry-over and subsequent complications 
in nanopore analysis. Secondly, human plasma is known to contain histidine-rich proteins 
which bind to Ni2+-NTA.130 It was possible that these proteins could be eluted with AngI-
His6 and also cause contamination. In order to achieve good resolution, and hence 
selective elution, a gradient of imidazole would be needed.  
Optimisation experiments were performed to determine the ideal concentration of 
imidazole to elute AngI-His6 and the plasma proteins separately. Suspensions of Ni
2+-NTA 
were incubated with buffered solutions of AngI-His6 and plasma proteins. The suspensions 
were subsequently filtered using a spin column and the beads washed ten times with plain 
water then treated with increasing concentrations of imidazole. The resultant aqueous 
washes and elution filtrates from the experiments involving serum proteins were analysed 
by SDS-PAGE. The wash and elution solutions from experiments involving AngI-His6 were 
analysed by and analytical HPLC. The results are shown in Figure 24.  
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Figure 24: SDS-PAGE analysis of the wash solutions and HPLC analysis of the imidazole elution solutions. 
After 3.5 h incubation, the supernatant was removed by centrifugation. The Ni
2+
-NTA beads were washed 
with plain water (10 x 500 μL) then increasing concentration of buffered solutions of imidazole (500 μL, 
containing 50 mM sodium phosphate, 300 mM NaCl, 1-500 mM imidazole, pH 8.1). (A) SDS-PAGE analysis of 
the wash solutions. Lane 1: Ladder; Lane 2: Blank; Lane 3: Reaction filtrate. Contains the unbound AngI-His6 
and plasma; Lane 4: Blank; Lane 5: Wash 1; Lane 6: Wash 2; Lane 7: Wash 5; Lane 8: Wash 6; Lane 9: 1 mM 
imidazole; Lane 10: 5 mM  imidazole; Lane 11: 10 mM  imidazole; Lane 12: 50 mM imidazole, Lane 13: 100 
mM imidazole; Lane 14: 250 mM imidazole; Lane 15: 500 mM imidazole. The gel was stained with 
Coomassie blue. (B) HPLC analysis of the imidazole elution solutions. HPLC analysis was perfomed on a 
Varian Pursuit XRS C18 column and UV absorbance measured at 214 nm. 
 
 In Figure 24A, Lane 3 corresponds to the reaction filtrate thus contains unbound plasma 
proteins. The high protein concentration of human serum is indicated by the intensity and 
the size of the band. The two flanking lanes (Lane 2 and 4) were left empty to 
accommodate any overspill from Lane 3. A significant amount of protein can be seen in 
the well at the top of Lane 3. These are most likely proteins which are too large to migrate 
through the gel. Lanes 5-8 contain wash solutions 1, 2, 5 and 6, respectively. After the 
beads had been washed six times with plain water, (Figure 24A, Lane 8), almost no protein 
was visible. Lanes 9-15 contain the imidazole elution solutions. At 1 mM imidazole (Lane 
9), almost no His-rich serum proteins were eluted. Elution of the His-rich proteins began 
to occur at 5 mM imidazole (Lane 10) and the majority occured at 50 mM imidazole (Lane 
12). Between 100-500 mM imidazole (Lanes 13-15), no new His-rich proteins were eluted.  
The elution solutions of AngI-His6, were analysed by analytical HPLC (Figure 24B). Akin to 
the experiment with the serum proteins, the Ni2+-NTA beads were washed with plain 
water then treated with increasing concentrations of imidazole. Between 1-10 mM 
imidazole, no peptide was detected. Elution began to occur at 50 mM imidazole and the 
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majority at 250 mM imidazole.  No peptide was eluted at 500 mM imidazole.  
These results suggested that optimum resolution would achieved if the beads were 
first washed with plain water seven times to remove the majority or all of the unbound 
serum proteins (Figure 24A). A significant amount of the His-rich plasma proteins could be 
removed by treating the beads with 10 mM imidazole (Figure 24A, Lane 11). Finally, 
elution of AngI-His6 could be achieved using 250 mM imidazole. Using this protocol, the 
eluted AngI-His6 would most likely contain a small amount of His-rich serum proteins 
(those eluted at 50 mM imidazole, Figure 24A, Lane 12) however all of the eluted peptide 
would be recovered. Using the Bradford assay for protein concentration, it was 
determined that after the seventh aqueous wash, the protein concentration had been 
reduced by 300-fold. Furthermore, performing four washes with 10 mM imidazole 
reduced the protein concentration by further 250-times. Hence, the concentration of 
plasma proteins in the final elution solution was almost 10,000-fold lower than in human 
serum. 
 
The final control experiment was to determine whether the endogenous enzymes within 
the human serum were still active. Human serum contains a range of enzymes including 
renin and angiotensinogenases which could act on the PEGA-bound substrate and skew 
the ensuing nanopore results. To determine whether this was the case, the PEGA-bound 
substrate was incubated with Ni2+-NTA and human serum without any additional enzyme. 
The beads were washed and eluted as described above, then subjected to HPLC and MS 
analysis. In this instance, no AngI-His6 was detected, suggesting that that the endogenous 
enzymes were not active. As the human serum utilised in this investigation was purchased 
rather than taken directly from a donor, the most plausible explanation for these 
observations were the age of the serum and the manner in which it was processed. 
Specifically, the serum could have been collected then stored for several weeks prior to 
purchase, during which the enzymatic activity could have waned. This is in contrast to 
current clinical practises, in which a blood sample is taken and analysed immediately after 
collection to ensure the activity of the enzyme.92 Additionally, purchased serum is sterile 
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filtered prior to vending to remove any bacteria or fungus which may have contaminated 
the sample. While, the filter is large enough to enable the passage of proteins including 
enzymes, if the proteins precipitated or aggregated they would not be able pass through 
the filter. Purchased serum is also treated with EDTA, which could have sequestered ions 
essential to the activity of the enzymes, thus rendered them inactive. Once the sensing 
technique is fully developed, it will be used to measure the activity of endogenous renin. 
However, so as to avoid any complications, in these early investigations, it was important 
that any AngI-His6 generated and subsequent translocations in nanopore analysis were 
due solely to the added renin.  
 
2.7. Nanopore Analysis 
The enzymatically released AngI-His6 generated using the optimised conditions and a 
synthesised standard of the peptide, were analysed using the αHL nanopore. The 
recordings were performed in 1 M KCl solution buffered with 50 mM Tris-HCl at pH 8.5. A 
potential of +100 mV was applied to the trans side of the αHL pore with the cis side 
grounded. Under these conditions, the αHL pore displayed an open channel current of 
104.13 ± 8.8 pA (n = 3) and the peptide possessed a slight net positive charge.  
 A synthesised standard of AngI-His6 was added to the trans chamber at a final 
concentration of 24 μM. The translocation parameters were derived from the analysis of 
7800 events over 4 independent recordings. The peptide was characterised by a τoff value 
of 0.96 ± 0.18 ms and average amplitude of 83 ± 1.6%. The average τon was determined as 
158.2 ± 12 s which corresponded to a frequency of occurrence of 6.34 ± 0.49 ms-1.
 Having fully characterised the synthesised standard, nanopore analysis was used to 
monitor the enzymatic release of AngI-His6 from PEGA, over time. As the frequency 
occurrence gives an indication of the relative concentration of an analyte, the frequency 
was expected to increase with the enzymatic digestion time. A time-course experiment 
was performed in which the PEGA-bound substrate was incubated with renin in the 
absence of Ni2+-NTA and plasma proteins. Aliquots of the supernatant were periodically 
removed, subjected to nanopore analysis and the frequency of occurrence determined. 
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The results are summarised in Figure 25.  
 
Figure 25: Monitoring enzymatic release of AngI-His6. (A) Visual inspection of the electrical traces. The 
frequency of the translocation events increases with time. (B) Summary of the translocation parameters. (C) 
Plot of frequency of occurrence with digestion time.  
In line with the expected results, the frequency of the translocation events increased with 
time (Figure 25A). A 30-fold increase in the frequency of the translocation events was 
observed over 24 h (Figure 25B). The amplitudes of blockade and the τoff values were on a 
par with those of the synthesised standard, providing further evidence that the observed 
translocations were due to enzymatic release of the peptide. In Figure 25A, the sample at 
t=0 min was the supernatant prior to the addition of the enzyme, thus contained solely 
the MOPS-BSA buffer. As expected, no translocation events were observed as no peptide 
fragments were released. The result also showed that the BSA present in the buffer did 
not interfere with the nanopore recordings. Thus the serum protein contaminants 
discussed in section above are unlikely affect nanopore analysis. As the change in Foo was 
readily detected (Figure 25C), this experimental approach represented a viable enzymatic 
assay. 
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2.8. Conclusion 
In this chapter a new method of electrically detecting enzymatic activity has been 
presented. The approach involves the enzymatic release of peptides from a solid support 
followed by nanopore analysis. In previously reported nanopore-based techniques, the 
electrical signals originated from multiple peptide fragments which complicated data 
analysis.14 The presented approach is far simpler as the pore blockades originate from a 
single peptide. Furthermore, in the absence of any enzyme, no electrical signals are 
observed which confers enhanced sensitivity. As a non-engineered version of the αHL 
pore was utilised, the approach can be applied to a wide range of enzymes and substrates. 
Engineering of the pore would limit the broader applicability of the approach as the 
modifications would need to be tailored for different substrates. Furthermore, it would be 
more difficult to extend the approach to solid-state nanopores. Solid-state nanopores are 
more robust and amenable to commercialisation, however, cannot be engineered to 
atomic-scale precision. Hence, nanopore-based techniques developed using non-
engineered αHL pores can be more readily applied to solid-state pores. 
 
Using the described approach, the kinetics of peptide release mediated by trypsin was 
determined. A disparity was observed between the rates of peptide release in 
homogenous (solution-phase) and heterogeneous (on-bead) reactions, with 
heterogeneous reactions occurring 35% slower than homogenous. This was attributed to 
the enzyme having difficulty accessing the immobilised substrates. In the future, this could 
be overcome by employing solid-supports that possess higher surface-to-volume ratios, 
such as controlled-pore glass, or employing longer linkers.113 Alternatively, introducing 
positive charges into the PEGA resin has been shown to improve its swelling properties 
and thus enhance biotransformations.120  
 The activity of renin enzyme was successfully detected in the presence of human 
serum. Employing a His-tag analogue of the naturally occurring substrate facilitated 
downstream purification from plasma proteins, which are known to disrupt the plasma 
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membrane during nanopore analysis (Stefan Howorka, unpublished data). Purification of 
the released Ang I-His6 was optimised so that a minimal amount of plasma protein was 
applied to the nanopore chamber. The increase in the frequency of peptide release was 
readily detected with no interference or cross-selectivity from the plasma proteins. Hence 
the developed approach processes the attributes required for enzymatic testing. 
 
2.9. Materials and methods 
All protected amino acids, chlorotrityl and Wang resins used for solid phase peptide 
synthesis were purchased from Novabiochem Merck Biosciences. O-(benzotriazol-1-yl)-N, 
N, N', N'-tetramethyluronium hexafluorophosphate (HBTU) and 4-hydroxymethylbenzoic 
acid (HMBA) were also purchased from NovaBiochem Merck Biosciences. PEGA1900 
(poly(ethylene glycol) amide with a molecular weight of 1900 Da) was purchased from 
Varian Inc. in a slurry of 24% ethanol with a free loading of 0.2 mmol g-1 NH2 dry resin. All 
organic solvents and water were purchased from Fischer Scientific. The acetonitrile and 
water were of HPLC grade quality. 1,3-diisopropyl carbodiimide (DIC), acetic anhydride, 
1,8-diazabicycloundec-7-ene (DBU), 2,2,2-Trifluoroethanol (TFE) and N, N-
diisopropylethylamine (DIPEA) were purchased from Sigma. Piperidine, 1-
hydroxybenzotriazole (HOBt), triethylsilane (TES) and trifluoroacetic acid (TFA) were 
purchased from Alfa Aesar. All buffer components were purchased from Sigma, were of 
reagent grade or higher and were filtered through a 0.2 micron filter prior to use. 
QIAshredder microcentrifuge spin columns and Ni2+-NTA agarose beads were purchased 
from Qiagen. Modified trypsin (treated with L-(tosylamido-2-phenyl) ethyl chloromethyl 
ketone, TPCK) and native human kidney renin was purchased from New England Biolabs 
and Calbiochem, respectively. Both enzymes were used without any further purification. 
The purity of the peptides was assessed using analytical HPLC and MS analysis. HPLC 
analysis was performed using reverse phase Varian ProStar system with a Model 210 
solvent delivery mode and a Model 320 dual wave-length detector. The mobile phase A 
consisted of 0.1% (v/v) TFA in water and mobile phase B consisted of 0.1% (v/v) TFA in 
acteonitrile. The UV absorbance was monitored at 214 and 254 nm. Analytical HPLC 
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analysis was performed using a Varian Pursuit XRS C18 column (250 x 4.6 mm). The 
gradient started with 2% eluent B and rose linearly to 60% B over 20 min with a flow rate 
of 1 mL min-1. Semi-preparative purification was performed using a Phenomenex Luna C18 
column (250 x 10 mm). The gradient started with 2% eluent B and rose linearly to 60% B 
over 30 min with a flow rate of 5 mL min-1. Fractions containing the product were pooled, 
the solvent was removed under reduced pressure to approximately 1 mL and the solution 
lyophilised overnight. ESI-MS analysis was performed using a Waters Aquity Ultra 
performance LC-MS system equipped with an Aquity UPLC BEH C18 column (50 x 2.1 mm, 
1.7 mm beads). MALDI-MS analysis was performed using Waters Micro MX machine. For 
MALDI analysis, the peptides were concentrated and desalted via aspiration through C18 
Ziptip tips (Millipore) and eluted using a 50% ACN solution. The eluted peptides were 
mixed with α-cyano-4-hydroxycinnamic acid matrix then spotted onto a MALDI plate. The 
spots were allowed to dry prior to analysis. SDS-PAGE analysis was carried out in a tris-
glycine buffer system. Ten microlitre aliquots of each sample were mixed with an equal 
volume of loading dye. The loading dye was composed of SDS (1 g), Coomassie Blue G-250 
(2 mg), and glycerol (3 mL) with 0.5 M Tris-base pH 6.8 (6 mL) then made to a total volume 
of 10 mL with H2O. The gels were run in native conditions (4% stacking gel, 12% separating 
gel) at 200 mV for 1 h. The gels were visualized by Comassie Blue G-250 staining according 
to standard protocols.131 The protein concentration was determined using a Bradford 
Protein Assay kit from Bio-Rad.  
 
 
 
2.9.1. Peptide synthesis 
Y4KIG4, Y4K, angiotensinogen, angiotensin I, angiotensinogen-His6 and angiotensin I-His6 
controls were synthesised using standard Fmoc solid-phase peptide synthesis with 
HBTU/DIPEA coupling chemistry on a Syro automated system. Y4KIG4 and Y4K were 
synthesised using Wang pre-loaded with glycine. The angiotensin derivatives were 
synthesised using pre-loaded chlorotrityl resins. Angiotensinogen and angiotensinogen-
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His6 were synthesised using chlorotrityl resin preloaded with serine, whilst angiotensin 
and angiotensin-His6 were synthesised using chlorotrityl resin preloaded with leucine. 
2.9.1.1. Loading of chlorotrityl resin 
Fmoc-protected amino acid (1.2 eq) was dissolved in anhydrous DCM (5 mL) and DIPEA (4 
eq) added. To the solution, chlorotrityl resin (1.20 mmol g-1 loading) was added and the 
resultant suspension was agitated at room temperature for 2 h using a Merrifield bubbler. 
After this time, the suspension was filtered and washed with the following: 
DCM/MeOH/DIPEA (17:2:1, 3 X 10 mL), DCM (3 X 6 mL), DMF (2 X 6 mL), and finally DCM 
(2 X 6 mL). The resin was then dried in a desiccator overnight. The loading of the resin was 
estimated using DBU method.132 Briefly, 2 mg of the resin (approx 10 μmol with respect to 
the Fmoc group) was suspended in 2% DBU/DMF (2 mL). The suspension was shaken at 
room temperature for 1 h, after which it was diluted to 10 mL with ACN. An aliquot of this 
solution (2 mL) was diluted to 25 mL with ACN and its absorbance at 304 nm measured. 
The loading of the Fmoc-Ser(tBu)-Cltr resin was determined to be 0.67 mmol g-1 
corresponding to a coupling yield of 56%. The loading of the Fmoc-Leu-Cltr resin was 
determined to be 0.64 mmol/g corresponding to a coupling yield of 53%. 
2.9.1.2. Automated peptide synthesis to produce a fully deprotected peptide 
Four equivalents of coupling agent and amino acid were used in the coupling step of 40 
min duration. Fmoc deprotection was carried out by shaking the resin in 40% piperidine 
for 3 min. After completion of the synthesis, the peptide was liberated from resin and 
simultaneously using a cleavage cocktail composed of TFA/TES/H20 (95:2.5:2.5) for 3 h. 
The peptide solution was collected and the peptide precipitated out by the addition of ice-
cold diethyl ether. After centrifuging the solution to a pellet, the supernatant was 
decanted, replaced with fresh diethyl ether and the peptide re-suspended in the diethyl 
ether. This centrifugation, re-suspension purification process was repeated two additional 
times. The pellet was then dissolved in the minimum amount of deionised water, frozen 
on an acetone/dry ice bath and lyophilised overnight. The identity and purity of the 
peptides was determined by HPLC and MS analysis.  
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2.9.1.3. Automated peptide synthesis to produce a fully protected peptide 
Four equivalents of coupling agent and amino acid were used in the coupling step of 40 
min duration. Upon completion of the synthesis, the protected peptide was liberated from 
the resin using a cleavage cocktail of 20% TFE in DCM for 30 min. The suspension was 
filtered then resuspended in fresh cleavage cocktail for an additional 30 min. This was 
repeated once more. The combined filtrates were concentrated in vacuo to a volume of 
approximately 2 mL. The peptide was precipitated from solution with the addition of ice-
cold diethyl ether. After centrifuging the solution to a pellet, the supernatant was 
decanted, replaced with fresh diethyl ether and the peptide re-suspended in fresh diethyl 
ether. This centrifugation, re-suspension purification process was repeated two additional 
times. The pellet was dried under vacuum overnight. For analytical HPLC and MS analysis, 
approximately 1 mg of material was dissolved into DMSO (3 mL).  
2.9.1.4. Coupling of protected peptide to PEGA resin 
The protected peptide (5 eq relative to the free amines on the resin) was dissolved in the 
minimum amount of DMSO. To the resultant solution, HOBt (5 eq) which had been 
dissolved in anhydrous DMF, was added. The resultant mixture was added to the resin 
followed by DIC (5 eq) to initiate amide bond formation. After 2 h, Kaiser test (see section 
2.9.1.6) on a small subset of beads indicated that coupling was complete. The resin was 
filtered and washed with anhydrous DMF (3 x 3 mL). Fmoc deprotection was achieved by 
shaking the resin in 20% piperidine/DMF for 1 h. The loading of the resin was determined 
by spectroscopic analysis of the Fmoc deprotection solution. 
 
2.9.1.5. Manual peptide synthesis 
Coupling of 4-hydroxymethylbenzoic acid to PEGA resin 
HMBA (3 eq) and HOBt (6 eq) were dissolved into anhydrous DMF (4 mL) and the solution 
added to the PEGA resin (3.0 g, wet weight). The resultant solution was gently shaken 
before the addition of DIC (4 eq). The suspension was shaken at room temperature for 2 h 
after which a small subset of beads were removed, washed with ethanol, then tested for 
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free amines using the Kaiser test. If the beads tested positive for free amines (a blue 
colouration of the beads), the reaction was allowed to proceed overnight. If the coupling 
was not complete after the overnight reaction, the beads were filtered, washed with 
anhydrous DMF and the reagents replenished. Once the reaction had gone to completion, 
the beads were filtered then subjected to a series of wash cycles: 1 M NaOH:DMF (1:1 v/v, 
10 mL) for 15 min, 3 x DMF:H2O (1:1 v/v, 10 mL) followed by anhydrous 3 x DMF (10 mL). 
The filtered resin was stored at 4°C. 
Synthesis of immobilised renin substrate (PEGA-AngiotensinogenH6) 
HMBA-PEGA was weighed into a solid phase extraction tube (SPE) and washed with DMF 
(3 x 10 mL) then re-suspended in anhydrous DMF (10 mL). The first amino acid (3 eq. 
relative to amount of NH2 initially on the PEGA resin), DIC (4 eq) and DMAP (0.1 eq) were 
added to the suspension. After shaking at room temperature for 2 h, the resin was filtered 
then re-suspended in fresh DMF (10 mL) and the reagents replenished. Completion of the 
reaction was confirmed by Kaiser test. Once free amines were detected, the resin was 
washed with DMF (3 x 10 mL), and then acetic anhydride (6 eq) in anhydrous DMF (10 mL) 
was added to acetylate hydroxyl groups on the resin. The suspension was shaken at room 
temperature for 1 h after which the resin was filtered and washed with anhydrous DMF (3 
x 10 mL). The Fmoc group was removed from the coupled amino acid by incubating with 
piperidine/DMF (20% piperidine, 10 mL). After shaking for 1 h, the suspension was filtered 
and the resin washed with more Fmoc cleavage solution (10 mL) followed by anhydrous 
DMF (3 x 10 mL). A small subset of beads was subjected to the Kaiser test to ensure that 
the terminal amine was released. The subsequent amino acids were coupled in the same 
manner, however, the coupling steps were performed only once for 1 h. Furthermore, 
after the incorporation of proline, Kaiser test for free amines gave rise to a brown 
colouration of the beads rather than the characteristic blue (due to the secondary amine 
on proline).105 Further confirmation for the incorporation of proline was provided by 
cleaving the peptide from a subset of resin (see below for details) and analysing by MS. 
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 Once synthesis of the peptide was complete, the side chain protecting groups were 
removed by suspending the resin in a TFA cleavage cocktail (TFA/TES/H2O, 95:2.5:2.5, 10 
mL) initially for 10 min then for 2 h in fresh cleavage solution. The resin was then filtered 
and washed with H2O, DMF and DCM (3 X 5 mL each), and dried in a dessicator in 
preparation for the enzymatic reactions. 
 In order to determine the purity of the coupled peptide, a small subset of beads 
were released from the resin by treating with 0.1 M NaOH for 2 h at room. The filtrate was 
collected, neutralised with HCl and analysed by HPLC and LCMS. The released peptide was 
found to be >95% pure, and the coupling yield determined using the DBU method 
described above.   
 
2.9.1.6. Kaiser test 
Approximately 2 mg of the resin-bound peptide was washed with ethanol then 
transferred to a 1 mL tube from Eppendorf. Two drops of each of the Kaiser Test solutions 
was added and the tube then placed in a heat block at 100 °C for 15 min. The test 
solutions were composed of: I (0.001 M KCN, 2 % v/v pyridine), II (5 % w/v Ninhydrin in t-
BuOH), and III (80 % v/v phenol in t-BuOH). A blue colour indicated a free amine, whereas 
yellow indicated a protected amine. 
 
 
 
 
 
 
Table 5: Summary of peptides synthesised. 
Peptide 
Mass [m/z] HPLC retention 
Time [min] 
Expected Observed 
Angiotensinogen 1733.0 1733.8 16.90 
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Angiotensin I 1296.5 1296.5 16.40 
Angiotensinogen-Histag 2555.9 2556.1 15.30 
Angiotensin I-Histag 2119.3 2120.3 15.36 
 
2.10. Enzymatic reactions 
2.10.1. Tryptic digestion of Y3KIG4 
For the enzymatic cleavage of peptide tethered on PEGA-beads, 2 mg of dried resin 
(containing 0.43 mg of peptide substrate assuming a load of 0.16 mmol g-1) was 
suspended in water (1320 µL). The resin was allowed to equilibrate and swell for 30 min. 
The trypsin enzyme pellet (20 µg) was dissolved in 20 µL of HPLC grade water to a final 
concentration of 1 µg µl-1, and 8.6 µL of the solution was added to the resin suspension 
(enzyme : peptide ratio 1 : 50 (w/w)). The suspension was shaken on a heat block at 37 °C 
overnight, after which the solution was placed on ice and subsequently stored at -20 °C. 
The peptide content in the supernatant was analysed via HPLC. The control experiment on 
the enzymatic cleavage of soluble peptide was conducted by employing a ratio of 1:20 
enzyme:peptide. To 1970 μL of deionised water, 20 μL of peptide solution (1 μg μl-1) 
followed by 10 μl trypsin solution (0.1 μg μl-1). The solution was incubated at 37 °C before 
being analysed by HPLC and mass spectrometry.  
2.10.2. Solution-phase digestion using renin 
For the time-course experiments, 4 mg of dried resin was suspended in 50 mM MOPS 
buffer (1400 μL, pH 6.8) containing 0.18 mg mL-1 BSA The suspension was equilibrated at 
37 °C for 1.5 h with gentle shaking to ensure that the beads had swollen and dispersed. 
The reaction was started by the addition of renin solution (5U, 0.2U μl-1). At regular 
intervals, 50 μL aliquots were withdrawn and immediately placed on ice then stored at 4 
°C until HPLC, MS or nanopore analysis. Analytical HPLC was used to determine the degree 
of proteolysis. The peaks area of the released peptide were normalised to the peak area of 
BSA in the buffer, and a calibration curve used to determine the amount of peptide 
present. 
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2.10.3. Solution-phase digestion in the presence of human serum and Ni2+-NTA 
PEGA-angiotensinogenH6 (4 mg) was suspended in 1 mL ddH2O then equilibrated at 37°C 
for 1 h with gentle shaking. Ni2+-NTA slurry (200 μL) were centrifuged (10 min, 0.8 rpm) to 
remove the storage solution then re-suspended in ddH2O (1 mL), washed and re-
centrifuged. This equilibration and washing process was repeated two additional times. 
The beads were washed and equilibrated a third time with sodium phosphate buffer (100 
mM, pH 7.4, 0.19 mg mL-1 BSA, 1 mL). The washings were removed and replaced with 
fresh phosphate-BSA buffer (400 μL). The PEGA-angiotensinogenH6 suspension was 
centrifuged (10 min, 0.8 rpm), the water removed and replaced with the Ni2+-NTA-buffer 
suspension. To the resultant mixture, human serum (125 μL) was added followed renin 
solution (5U, 1.25 U μL-1). The resultant suspension was incubated at 37 °C, with gentle 
shaking at 950 rpm for 18 h. The suspension was transferred to a QiaShredder spin column 
(the inner homogenising frit removed), and centrifuged (30 s, 0.8 rpm) to separate the 
supernatant. The beads were washed with ddH2O (7 x 500 μL), then wash solution (10 mM 
imidazole, 300 mM NaCl, 50 mM sodium phosphate, pH 7.9, 4 x 500 μL), then treated with 
elution solution (250 mM imidazole, 200 mM NaCl, 50 mM sodium phosphate, pH 7.9, 4 x 
500 μL). The beads were incubated with each wash and elution solution for 1 min, with 
gentle shaking, before centrifugation to collect each filtrate in a fresh tube. The eluted 
peptides analysed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), HPLC and MALDI MS.  
 
2.11. Nanopore analysis 
Single-channel current recordings were performed by using a planar lipid bilayer 
apparatus as described in [133]. Briefly, a bilayer of 1,2- diphytanoyl-sn-glycero-3-
phosphocholine (Avanti Polar Lipids) was formed on an aperture (80 µm in diameter) in a 
Teflon septum (Goodfellow Corporation, Malvern, PA) separating the cis and trans 
chambers of the apparatus. Each compartment contained 2 M KCl, 50 mM Tris-HCl, pH 
8.0, unless otherwise stated. Gel-purified heptameric αHL protein (final concentration 
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0.01–0.1 ng mL-1) was added to the cis compartment to achieve insertion of a single 
channel into the bilayer. Subsequently, peptide-containing samples were added to the 
trans side. Transmembrane currents were recorded at a holding potential of +100 mV 
(with the cis side grounded) by using a patch–clamp amplifier (Axopatch 200B, Axon 
Instruments, Union City, CA). For analysis, currents were low-pass filtered at 20 kHz and 
sampled at 50 kHz using a Digidata 1200 A/D converter (Axon Instruments), as described 
in [134]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 SIZING NUCLEOTIDE REPEAT SEQUENCES USING 
NANOPORE TECHNOLOGY 
 
3.1. Summary 
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The aim of this project was to establish a nanopore-based strategy to size forensically 
important nucleotide repeat sequences, which are the basis for DNA fingerprinting. Short 
nucleotide repeat sequences occur throughout the genome. The number and the length 
of a repeat sequence, within a given region of the genome is characteristic for an 
individual. To date, the rapid speed with which non-modified single stranded DNA 
translocates the pore has prevented resolution of individual bases and hence the 
development of a nanopore-based sensing strategy. It was envisaged that such a strategy 
could be realized by employing DNA strands modified with nucleotides bearing 
adamantane tags. The modification could be performed in such a way that a single 
adamantane tag is incorporated per repeat sequence. It was hoped that chemical 
modification would increase the steric bulk of the DNA strands to reduce the translocation 
speed in ensuing nanopore analysis. The resultant unique electrical signatures could be 
analysed to determine the length and number of repeat sequences and thus discriminate 
between individuals. A successful nanopore-based sensing strategy would enable the 
rapid pre-screening of forensic samples in a point-of-care setting, and development of 
portable devices for use at the scene of a crime. The modified nucleotides were 
successfully synthesised and incorporated into oligonucleotides using a protocol published 
in the Journal of Organic and Biomolecular Chemistry (Org. Biomol. Chem., 2009, 7, 3826–
3835). However, nanopore analysis did not yield the expected results. Unique electrical 
signatures were not obtained although a correlation between the number of tags and the 
translocation speed was observed.  
 
 
 
3.2. Introduction 
3.2.1. DNA structure 
DNA (2'-deoxyribonucleic) is the molecular store of genetic information in nearly all living 
organisms.124 It is a linear polymer composed of phosphorylated monomer units. Each 
monomer is composed of a pentose sugar (2'-deoxy-D-ribofuranose), a phosphate group, 
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and a nitrogenous heteroaromatic base.124 Four different bases are commonly found in 
DNA; the two purines adenine (A) and guanine (G) and the two pyrimidines cytosine (C) 
and thymine (T). The structure of these heterocyclic compounds and the numbering 
system for the carbon and nitrogen atoms is shown in Figure 26. The pyrimidines have a 
single ring containing four carbon atoms and two nitrogen atoms. Conversely, purines 
have a fused pyrimidine-imidazole ring system. Bases are typically coupled to the 1'-
carbon of the 2'-deoxyribose sugar via a glycosidic bond giving rise to a nucleoside 
monomer. Nucleotides are phosphorylated derivatives of nucleosides. The phosphate 
groups are bound via a phosphodiester linkage to either the 5' or 3' position of the sugar 
(Figure 26). 
 
Figure 26: General structure of a DNA nucleoside and the chemical structures of pyrimidine and purine 
bases. The arrows indicate hydrogen-bonding sites. Each base has hydrogen-donating capabilities, 
represented by the arrows pointing away from the structures, and hydrogen acceptor capabilities 
represented by the arrows pointing towards the structure. Adapted from [135]. 
Individual monomer units are linked together through phosphodiester bonds. Specifically, 
5′-phosphate group of one nucleotide is covalently attached to the 3′-hydroxyl group of 
another. When several nucleotides are linked in this way, the resulting polymer is termed 
an oligonucleotide. As all the monomers in an oligonucleotide have the same orientation, 
oligonucleotide chains are said to have directionality (Figure 27). One end of the chain is 
said to be the 5'-end as the 5'-hydroxyl group is free. The other end of the chain is said to 
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be the 3'-end as the 3'-hydroxyl is free. Each phosphate group which participates in a 
phosphodiester linkage has a pKa of approximately 2. As a result, at near neutral pH, DNA 
will exist as a polyanion.124,136 By convention, the sequence of an oligonucleotide is 
defined by reading the sequence of the nucleotide bases in the 5'→3' direction.  
 
Figure 27: Formation of phosphodiester bond. The hydroxyl group of the growing chain performs a 
nucleophilic attack on the α-phosphorous of the incoming nucleotide. The DNA duplex is maintained by 
specific hydrogen bonding pattern between the Watson-Crick base-pair; GC and AT. DNA strands are said 
to be anti-parallel as one strand runs in the 5'→3' and the other in the 3'→5'.  
In living organisms, DNA rarely exists as a single oligonucleotide chain, but rather as a pair 
of oligonucleotides which are tightly associated in a helix, each coiled around a central 
axis.137 The two DNA strands are held together by hydrogen bonding between the base 
pairs (Figure 27). To maintain the geometry of the double helical structure, a larger purine 
monomer base-pairs with a smaller pyrimidine. Accordingly, G and C always pair via three 
hydrogen bonds and A and T via two hydrogen bonds (Figure 27). Hence, the 
polynucleotide chains are complementary and can serve as templates for each other. The 
complementary strands are said to be antiparallel as one runs in the 5'→3' direction and 
the other in the 3'→5' direction. The helical structure of DNA is impart due to the anti-
parallel relationship between the strands, but is mainly attributed to the interactions 
between the base-pairs.124,137 In the helix, the base-pairs are stacked one above another 
and are almost perpendicular to the long axis of the molecule. The non-covalent 
interaction that exists between the bases is termed the stacking interaction. This 
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interaction brings the base-pairs closer together, resulting in a hydrophobic interior that 
causes the sugar phosphate backbone to twist into a helix.124,137 DNA typically exists as a 
B-DNA; a right-handed helix. Due to the manner in which the bases stack and the sugar-
phosphate backbone twists, the double helix has two grooves of unequal width. These 
grooves are called the major and minor groove.  
3.2.2. DNA Fingerprinting 
DNA fingerprinting describes the technique employed by forensic scientists to identify 
individuals based on differences within their genetic makeup. Within human cells, DNA is 
found within the nucleus and organized into threadlike structures called chromosomes. 
The DNA material within the chromosomes is composed of ‘coding’ and ‘non-coding’ 
regions. The coding regions are known as genes and contain all the information necessary 
for a cell to make vital proteins. The genes in turn are composed of exons, the protein-
coding regions, and introns, the intervening sequences. Identifying and mapping all the 
genes, was the focus of the Human Genome Project, which announced a final reference 
sequence for the human genome in 2003.138 One of the most surprising findings of the 
project was that humans have less than 30,000 protein-coding genes rather than the 
50,000-100,000 previously thought.138,139 Furthermore, it has since been observed that 
the genetic diversity between individuals is very small. Only a fraction of the DNA 
sequence (0.3%, approximately 10 million nucleotides) varies between individuals to make 
them unique.139 It is these variable regions of the genome which are exploited for human 
identity purposes. Methods have been developed to locate and characterize the genetic 
variation at specific sites within the genome.139  
 The most widely used method for genetic fingerprinting is based upon the 
detection of nucleotide repeat sequences that occur within introns. Nucleotide repeat 
sequences are sets of nucleotides that are repeated in tandem. These are found 
throughout the genome. The number of repeat units and the length of the repeat vary 
significantly from one individual to the next. These regions are often referred to as 
satellite DNA.140 A schematic representation is shown in Figure 28. Thousands of these 
satellite regions have been characterized and catalogued, as a result, some are now 
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commonly used as markers for forensic DNA fingerprinting. This typically involves 
comparing DNA isolated from biological evidence (e.g. blood or hair) found at the scene of 
a crime, to DNA isolated from a suspect or a victim. The DNA is analyzed for the presence 
of a specific set of nucleotide repeat sequences (markers) and their lengths determined in 
order to identify an individual. When the core repeat unit is of medium length (typically 
between 10-100 nucleotides), this is referred to as a minisatellite or a VNTR (variant 
number tandem repeat).141  
 
Figure 28 Schematic representation of a microsatellite (STR) DNA marker. PCR primers are designed to 
target the flanking sequence regions. The number of tandem repeat units in the repeat region varies among 
individuals making them useful markers for identification. Adapted from [139].  
These were first exploited as a molecular tool in the early 1980s to develop the first 
example of genetic fingerprinting called restriction fragment length polymorphism 
(RFLP).142,143 The technique was based upon the ability of restriction enzymes, to 
recognize and cleave the DNA at sites flanking specific minisatellites. Digestion of genomic 
DNA with these enzymes generated DNA fragments of varying lengths which were then 
resolved by gel electrophoresis. The separated fragments were then denatured, that is, 
rendered single stranded, in the gel by treatment with a strong alkaline solution. A nylon 
membrane was placed over the gel, and the DNA transferred by capillary action. A DNA 
fingerprint was obtained after the hybridization of a radiolabled oligonucleotide probe 
that was able to bind specific minisatellites by complementary base pairing. The DNA 
fingerprint was subsequently visualized by audioradiography and compared to that of 
either the victim or the suspects found at the scene of a crime. By comparing the repeat 
sequences at multiple positions of the genome, or loci, the power of discrimination 
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between individuals was greatly increased. However, this approach was extremely labor 
intensive and interpretation of the data required a great deal of expertise. Furthermore, 
the process did not easily lend itself to automation. The entire process was time 
consuming; requiring almost one month to generate each fingerprint.144 An additional 
limitation was that its success was highly dependent upon the quality of the DNA sample. 
The technique could only be applied to whole DNA samples in which the restriction sites 
were intact. As a result, the technique was often incompatible with DNA samples from 
criminal cases which are often degraded or contaminated. The demand for rapid 
turnaround times and high volumes of sample processing soon saw RFLP superseded by 
techniques based on the polymerase chain reaction (PCR). 
 PCR is an enzyme catalysed cyclic-process in which a specific region of DNA is 
replicated repeatedly to yield many copies of a particular sequence.145 During each cycle, 
a copy of the target DNA sequence is generated for every molecule of the starting DNA. 
The boundary of amplification is determined by short oligonucleotides called primers. 
These are complementary to the DNA sequence flanking the region to be copied. They 
bind to the target DNA sequence by complementary base pairing, then are extended at 
their 3'-end by enzymes, in a manner analogous to the biological process of DNA 
replication. As PCR progresses, the DNA generated is itself used as a template for 
replication so that the amount of DNA is increased exponentially.139,144 PCR-based 
strategies for amplifying nucleotide repeat sequences have several advantages over RFLP 
analysis. Firstly, PCR requires only trace quantities of DNA. Typically, 25 ng of DNA is 
sufficient for PCR compared to 300-500 ng required for RFLP analysis.144 Thus PCR is 
ideally suited to forensic DNA analysis where DNA samples are only available in small 
quantities. Secondly, PCR is able to generate a large quantity of a relatively pure product 
within a shorter time frame. Finally, degradation of the DNA sample is less of concern as 
PCR targets smaller segments of the DNA.  
The method of DNA fingerprinting used today is based upon PCR amplification of 
short tandem repeat (STR) regions within introns. STRs or microsatellites, are regions 
within DNA in which the repeat units are 2-6 base pairs in length (Figure 28). STR repeat 
96 
 
sequences are named by the length of the repeat unit. For example, dinucleotide repeats 
have two nucleotides repeated in tandem. Trinucleotides have three nucleotides in the 
repeat unit, tetranucleotides have four, and so on and so forth.139 STRs are favored over 
VNTRs as genetic markers as they occur more abundantly throughout the genome.141 To 
improve the discrimination between individuals, multiple STRs must be analyzed. The 
difference in the length of the STRs enables an individual to be identified quite accurately, 
and the more STR regions analyzed, the more discriminating the test becomes. In the UK, 
forensic DNA analysis involves the characterization of 11 markers within the genome.146 
These markers can be amplified simultaneously in the same PCR reaction by adding 
primers which are complementary to the flanking region of each. The ability to amplify 
multiple regions of DNA simultaneously is termed multiplexing. The advantage of 
multiplexing is that the cost and time required for DNA fingerprinting can be greatly 
reduced. The DNA fragments which are produced are considerably smaller than those 
produced in RFLP, as a result, are more readily separated by electrophoretic methods. 
Separation and detection of the STR fragments is readily automated, which is an 
important benefit as the demand for DNA testing has increased. In practice, the STR 
fragments are labeled with multiple fluorescent dyes through the use of labeled primers. 
Separation of the fragments is commonly achieved by capillary electrophoresis with 
concomitant detection of the fluorescent emission signals from the attached dyes. The 
spectra produced show the fluorescent intensity of each of the fragments versus the time 
taken for the fragment to reach the detector. Genotyping software is then used to identify 
and size each of the fragments based on their peak heights and areas. The data is 
compared to that generated from a control sample, and a DNA fingerprint generated. 
Using this approach a DNA fingerprint can be generated within a few hours, which is vast 
improvement over RFLP. 
Although PCR and fluorescence-based techniques have become the gold standard for 
DNA fingerprinting, in recent times there has been a demand for alternative technologies 
which enable point-of-care analysis. As current techniques require large optical 
components, DNA fingerprinting can only be performed by centralized laboratories. This 
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often results in a delay in obtaining results and hence a reduced response time. 
Furthermore, the current technologies often require a high start-up cost (more than 
$50,000), a fact that prohibits its use by some laboratories.139 The cost of analysis is also 
increased by the use of expensive reagents such as fluorophores. It is envisaged that the 
demand for portable or handheld devices can be satisfied through the electrical detection 
of STRs using nanopore technology. A nanopore-based strategy would not require costly 
or large optical components and is more amenable to miniaturisation. 
 
3.3. Aim 
The ultimate aim of this project was to apply nanopore analysis to the detection of 
forensically important DNA samples. A successful strategy could be used to pre-screen 
DNA samples at the scene of a crime. Due to rapid translocation speeds, it is not possible 
to discriminate between nucleotides as DNA moves through the pore. Our strategy makes 
use of chemically modified nucleotides to reduce the translocation speed of DNA strands 
and takes advantage of the repetitive nature of STRs to count their number. The nanopore 
sensing strategy is outlined in Figure 29. 
 
 
Figure 29: Proposed strategy to size nucleotide repeat sequences. (A) A nucleotide repeat region of DNA is 
enzymatically copied in the presence of adamantane-modified nucleotides. A single modified nucleotide is 
incorporated per repeat unit. (B) The resultant DNA strand gives rise to distinct step-like modifications as it 
translocates the nanopore. The number of repeat units is determined by simply counting the number of 
step-like modifications. In this example, four tags have been incorporated into the tetranucleotide repeat, 
resulting in four step-like modifications in the electrical trace.  
Akin to the current technique, a copy of the STR will be made using PCR (Figure 29A). 
However, rather than using the naturally occurring nucleotides, PCR will be performed 
with an adamantane-modified nucleotide. As a result, the enzymatically copied DNA 
strands will also be modified or ‘tagged’. The PCR is performed in such a way that a single 
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modified nucleotide is incorporated per repeat unit. Essentially, the number of chemical 
tags will mirror the number of repeat units. The number of tags/repeat units is then 
determined using nanopore analysis by threading the tagged DNA through the pore 
(Figure 29B). Due to their size, the chemical tags should occlude the ionic current in the 
pore, giving rise to distinct step-like modifications in the electrical traces each time a 
tagged repeat translocates the inner constriction of the pore. Determining the number of 
repeat units will simply entail counting the number of step-like modifications observed in 
the electrical traces. The non-tagged DNA template will simply pass through the pore with 
minimal affect on the ionic pore current. With several pores working in parallel, each one 
analysing a different STR, the throughput will be increased and thus deliver a rapid 
turnaround time. Furthermore, as the strategy does not require modification of the pore, 
it can be readily applied to solid-state nanopores which are ideally suited for robust 
portable sensors. Support for this sensing strategy comes from preliminary work 
performed within our research group. In particular, a synthetic DNA strand bearing two 
peptide tags was shown to give rise to distinct step-like current blockades within the 
nanopore (Figure 30).9  
 
 
 
 
 
 
It was anticipated that adamantane would be an ideal tag in our sensing strategy. With 
dimensions of approximately 4 Å cubed,147 adamantane would effectively increase the 
diameter of single stranded DNA to 1.3 nm; close to the diameter of the inner constriction 
of the αHL pore. This, combined with the rigidity of the structure, would facilitate the 
Figure 30: Electrical traces for an oligonucleotide modified with two tyrosine peptide tags. As each tag is 
sequentially pulled through the nanopore, step-like alterations in the ionic current are observed. Step 1 
(red) corresponds to the presence of leading non-modified region of the oligonucleotide strand. As the 
first bulky tag passes through the inner constriction, the ionic current is reduced (step 2). The 
intermediate non-modified region of the oligonucleotide causes the ionic current to increase (step 3). 
Finally, as the second tag translocates the inner constriction, another reduction in the ionic current is 
observed (step 4). Adapted from [10]. 
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formation of a bulky oligo-tag segment large enough to temporarily block the flow of ions 
through the pore.  
In summary, the first specific aim of this project was to synthesise adamantane-
modified nucleotides and assess their incorporation into DNA strands by PCR-based 
techniques. Secondly, to synthesise synthetic oligonucleotides bearing adamantane-tags 
and subject them to nanopore analysis to determine whether step-like current blockades 
could be detected.  
 
3.4. Results and Discussion 
3.4.1. Synthesis of Chemically Modified Nucleosides  
The structural and functional diversity of DNA can be greatly expanded by employing 
chemically modified nucleotides as monomer units. Chemical modifications can be 
introduced directly onto the base, through substitution of the hydroxyl groups on the 
sugar or substitution of the oxygen atoms of the phosphate groups.148 In order to maintain 
the biological function of DNA, chemical modifications should be such that the 
fundamental structure of the monomer, for example the hydrogen-bonding capability or 
key functional groups, are unaltered. Yet, there are instances in which it has been 
advantageous to modify crucial positions of the monomer. For example, some 
chemotherapeutic agents used to alleviate the symptoms of AIDS are 
nucleoside/nucleotide analogues which lack or have a modified 3'-hydroxyls.149,150 
Incorporation of these analogues into the growing 3'-end of a DNA stand prevents the 
formation of the 3'-5' phosphodiester bond with the next incoming nucleotide. These 
analogues effectively terminate DNA synthesis and prevent the HIV virus from replicating. 
If it is not the intention to disrupt the process of DNA replication, modifications are 
introduced into the base. The most attractive sites for modification are C5 and N7/C8 of 
pyrimidines and purines, respectively (Figure 26).151–153 Both positions are located in the 
major groove of the double helix, thus chemical modification is unlikely to perturb base 
pairing which is essential in maintaining the structural integrity of the helix.151 
Modification of these positions has vastly increased the number of applications of DNA in 
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molecular biology. For example DNA sequencing,154 detection of single-nucleotide 
polymorphisms155 and fluorescence in situ hybridization,156 are all techniques which make 
use of chemically modified DNA. In many cases, chemically modified nucleotides bearing 
functional tags are enzyamatically incorporated into DNA strands. This is termed pre-
modification as the incorporated nucleotide is already functionalised. The approach is 
complemented by a two step post-modification strategy in which nucleotide precursors 
carrying linkers are first enzymatically introduced into the DNA then covalently derivatised 
with a functional tag. By employing the post-modification approach, a wide range of 
coupling chemistries can be exploited. For instance, click chemistry157 Diels-Alder 
cycloaddition,153 maleimide or amide158  couplings. Furthermore, this approach enables 
DNA to be functionalised with the large tags which are not readily accepted by 
polymerase enzymes. With regard to the post-modification approach, the substituents 
must protrude from the major groove of the DNA duplex into solution to facilitate 
coupling between the linker and the tag. 
  
Nucleotide analogues bearing non-biogenic substitutions at either C5 or N7/C8 can be 
chemically synthesised using palladium-catalysed cross-coupling reactions.159 These 
reactions are favoured as the mild conditions employed enable the derivatisation of 
sensitive molecules. For the Suzuki-Miyaura and Sonagashira reactions, halogenated 
nucleosides are used in combination with substituents carrying terminal aryl/vinyl boronic 
acids and terminal alkynes, respectively.160,161 
The synthesis of the adamantane-derivatised nucleosides and their corresponding 
nucleotides is outlined in Figure 31.  
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Figure 31: Synthesis of adamantane-modified nucleotides. (i) Adamantane methylamine, then Method A: 
EEDQ, DMF, 18 h or Method B: HBTU, Et3N, cat. DMAP, DMF 18 h; (ii) 5-iodo-2'-deoxyuridine, CuI, Et3N, 
Pd(PPh3)4, DMF, 16 h; (iii) POCl3, proton sponge, 2 h; (iv) nBu3NH
+.H3P2O7
-, 0.1 M TEAB, 45 min. 
In order to determine the effect of spacer lengths in our sensing approach, three different 
adamantane-modified nucleosides were synthesised (Figure 31, 3a-c). The admantane-
acetylene moieties (Figure 31, 2a-c) were generated by standard amide bond formation 
between adamantane methylamine and the appropriate acetylene-carboxylic acid. The 
synthesis of 2b and 2c was mediated by HBTU, whilst the synthesis of 2a, was achieved 
using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). The moieties’ were 
isolated in good yields, 71%, 97% and 83%, for 2a, 2b and 2c, respectively. Attempts to 
synthesize 2a using HBTU often resulted in no reaction or poor yields; 38% was the 
highest yield obtained. The use of N,N'-dicyclohexylcarbodiimide (DCC), also resulted in 
similarly poor yields. Specifically, the desired product was isolated in 36% yield whilst the 
self-condensation by-product, formed as a result of a reaction between the O-acylisourea 
intermediate and another equivalent of the acid, was isolated in 34% yield. In our hands, 
EEDQ gave the most satisfactory yields with the greatest purity. The self-condensation 
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product was not detected and the desired product could be isolated in reasonable purity 
after a simple acidic wash. 
 
The modified nucleosides (Figure 31, 3a-3c) were prepared by Sonogashira cross-coupling 
reaction between 5-iodo-2'-deoxyuridine and adamantane-acetylene moieties for a pre-
modification approach of DNA. 5-iodo-2'-deoxyuridine was chosen as the model 
nucleoside as it is considerably cheaper than other halogenated pyridmidines nucleosides. 
Furthermore, as it lacks an exocyclic amine (as found in cytosine or thymine, Figure 26), 
the synthetic strategy would be simpler as no protecting groups would be required. The 
Sonogashira cross-coupling reaction was performed according to the method of Hobbs.162 
Specifically, tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) was employed as the 
catalyst and the reaction performed in DMF in the presence of triethylamine (Et3N) and 
copper iodide (CuI). Importantly, a ratio of 2:1, Pd(0) to Cu(I) was employed to ensure that 
the reaction proceeded at maximum efficiency.162 Furthermore, when a higher ratio of Pd 
was used, the reaction mixture turned black within 1 h and lower yields were obtained. 
Purification of the crude material by flash chromatography was complicated and the 
product was often contaminated with catalyst. Conversely, when a ratio of 2:1 was used, 
the reaction mixture remained a yellow/green colour for almost the entire duration of the 
reaction (on average 16 h). As Pd(PPh3)4 is light and moisture sensitive, the reaction 
vessels were wrapped in aluminium foil and thoroughly dried, and the DMF degassed with 
argon prior to the reaction. Exposure of the reaction mixture to air or moisture caused the 
oxidation of the Pd which in turn resulted in a lower yield. Taking all of the above 
precautions, the modified nucleosides were obtained in yields of 63%, 53% and 30% for 
3a, 3b and 3c, respectively. 
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Figure 32: Mechanism of Sonogashira coupling. The Pd(0) undergoes oxidative addition to the nucleobase 
(the aryl halide) and in the process is oxidised to Pd(II). The addition of CuI as co-catalyst gives better results 
as CuI activates alkynes by forming a copper acetylide, which is more reactive and undergoes 
transmetallation with the palladium complex. The ligands attached to the Pd are converted from the trans 
to the cis isomers in an isomerism step. Finally, reductive elimination occurs to afford the product and 
regenerate the catalyst. 
The identity and the purity of the nucleosides were confirmed by NMR analysis. The 1H 
spectra of each of the products were similar to that of the starting materials minus the 
terminal alkynyl protons. The alkynyl protons gave signals between 2-4 ppm in the starting 
adamantane-acetylene moieties, however the corresponding signals were absent in NMR 
traces of the modified nucleosides. A similar observation was made in the 13C NMR 
spectra. The terminal alkynyl carbons were found between 69-76 ppm in the starting 
adamantane-acteylene moieties, but in the modified nucleosides the corresponding 
carbon was shifted further downfield to between 74-88 ppm. The C5 cabon was also used 
as a diagnostic signal. The C5 carbon in the starting iodouridine gave a signal at 
approximately 69 ppm. By comparsion, the C5 carbons in the modified nucleosides shifted 
further down field to 97-101 ppm.  
NOESY NMR analysis was able to give an indication of conformation of the 
nucleoside about the glycosidic bond. In solution, the base of a nucleoside is able to rotate 
about the glycosidic bond which enables it to occupy either of two principle 
orientations.136 These are shown in Figure 33. In the anti conformation, the H6 
104 
 
(pyrimidine) or H8 (purine) atoms lie above the sugar ring, whereas in the syn the O2 
(pyrimidine) or N3 (purines) lie above the sugar.136 Typically, the naturally occurring 
nucleosides occupy the anti conformation which enables them to form hydrogen bonds to 
their complementary base-pair in the double helix.163,164 In pyrimidines, preference for the 
anti conformation has been attributed to favourable interactions between the molecular 
orbitals of the H5-H6 double bond and the lone pairs of electrons of the sugar O4'.165 As 
the sugar ring is not planar, but puckered out of plane, the syn-anti conformation can be 
elucidated from the NOE interactions between H6, H1', H2' and H3' protons. A syn 
conformation is expected to result in an NOE interaction between H1' and H6, whilst an 
anti conformation is expected to result in an interaction between H6 and H2'/H3' (Figure 
33).136,166  
 
Figure 33: Possible conformation of nucleosides and diagnostic NOE interactions. 
NOESY analysis for each of the modified nucleosides showed that interactions occurred 
between H6 and the H1', H2' and H3' protons (Appendix 2). The result suggested that, at 
times, H6 came in close proximity with each of the protons, reinforcing the notion of free 
rotation about the glycosidic bond. However, the major interaction was between H6 and 
H2'. This interaction was 4-timesiii larger than the interaction between H1', H2' and H3' 
suggesting that the modified nucleosides preferentially adopted the anti conformation, 
akin to the starting 5-iodo-2'-deoxyridine.163 Consequently, it was assumed that if the 
nucleosides were well tolerated by the polymerase enzyme, they should be able to 
hydrogen bond to their complementary base-pair without significantly altering duplex 
                                                             
iii
 NOESY analysis performed with the help of Dr. Abil Aliev, UCL Chemistry. 
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stability. Conclusive evidence about the conformation could be provided by circular 
dichroism or x-ray crystallography. 
 
3.4.2. Phosphorylation of Nucleosides 
To be of use in our sensing strategy, the modified nucleosides were converted to their 
corresponding triphosphate derivatives. This would enable them to serve as substrates for 
the DNA polymerase (DNA pol) enzyme used to replicate the forensically important DNA 
fragments (Figure 29). Phosphorylation of nucleosides is a non-trivial and complicated 
process for several reasons.167,168 Firstly, as the synthesis involves the use of a 
combination of ionic and hydrophobic reagents, finding the appropriate reaction media 
which can solubilise both classes of reagents, can be challenging. Secondly, purification 
procedures require the separation of ionic, hydrophilic and hydrophobic species. 
Additionally, both the glycosidic and the phosphodiester bonds are susceptible to 
hydrolytic cleavage; the rate of which is accelerated by acidic and basic media, and 
elevated temperatures.  
 Among the many published phosphorylation approaches, the adapted Yoshikawa 
procedure is a popular method for generating nucleotides.136,167 The original Yoshikawa 
procedure,169,170 involves reaction of the nucleoside with phosphorous oxychloride (POCl3) 
to yield the highly reactive phosphorodichloridate intermediate (Figure 34, 6). The 
intermediate is then hydrolysed using a trialkylammonium bicarbonate buffer to afford 
the monophosphate (Figure 34, 8). In a slight adaptation, the phosphorodichloridate 
(Figure 34, 7) intermediate can be used directly in reactions with a pyrophosphate salt to 
yield a nucleotide triphosphate.167,171 The Yoshikawa procedure typically makes use of 
trimethyl- or triethylphosphate as the solvent. These are favoured for their ability to 
solubilise nucleosides, nucleotides and reagents to give homogenous reaction 
mixtures.167,169 Furthermore, they have been shown to accelerate the rate of 
phosphorylation.169 It is thought that this occurs through the formation of a highly reactive 
complex with POCl3.
169,172 In a further modification of the original phosphorylation 
procedure, 1,8-bis(dimethylamino)naphthalene (Proton-Sponge™, Sigma-Aldrich)173 is 
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often added to the reaction to neutralise the liberated hydrogen chloride (HCl) which 
ordinarily would facilitate degradation of the nucleotide.174 
 Within our research group, the Yoshikawa procedure was investigated with the 
view of improving the regioselectivity and yield.153 Published protocols typically called for 
the use of an unprotected nucleoside with POCl3 for up to 14 h,
169,174 followed by 
incubation with a pyrophosphate salt. Under these conditions, phosphorylation occurred 
predominantly at the 5'-hydroxyl, however the regioselectivity was not perfect and in our 
hands, significant amounts of the 3'-phosphate and 3',5'-diphosphates were observed. 
While 3'-protection strategies could be enlisted to address this issue, the use of 
unprotected starting material was seen as key to minimising the complexity of the 
synthesis. The unsatisfactory results prompted a detailed investigation into the 
phosphorylation of unprotected nucleosides as a function of reaction duration, 
temperature and molar excess of POCl3.
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Figure 34: The Yoshikawa phosphorylation via the phosphorodichloridate intermediate yields mono- and 
triphosphorylated nucleotides. (i) proton sponge, POCl3, (Me)3PO; (ii) TEAB; (iii) nBu3NH
+·H3P2O7
-,TEAB. R=H 
or acetylene linker. Where R = H or a chemical tag. 
 
Using 5-iodo-2'-deoxyuridine as a model nucleoside, the formation of the 
monophosphate, which is crucial to the success of triphosphorylation, was monitored by 
107 
 
analytical HPLC. The nucleoside was reacted with 1.5 equivalents of POCl3 at 0 °C, similar 
to published conditions.152 At regular intervals, aliquots of the reaction mixture were 
withdrawn, treated with triethylammonium bicarbonate buffer (TEAB) to hydrolyse the 
phosphorodichloridate intermediate, and then subjected to HPLC analysis. Surprisingly, 
the 5',3' diphosphate (Figure 35, peak A) and 3'-phosphate derivatives (Figure 35, peak C) 
were observed after just 3.5 min of reaction. Continued incubation led to further increases 
in the desired 5'-monophosphate and the diphosphate, but no significant changes in the 
3’-phosphate. Kinetic analysis found that a reaction time of between 3 and 7 min was 
ideal to obtain high levels of the desired monophosphate and low levels of the by-
products.iv This short time scale was in stark contrast to published protocols.169 
Investigations into reaction temperature revealed that conducting the reaction at -13 °C 
as opposed to 0 °C, also significantly reduced by-product formation. Furthermore, 
employing a ratio of 1:1 POCl3 to nucleoside, completely avoided the formation of any by-
products but this was at the expense of decreased yield of the desired 5'-monophosphate. 
Conversely, increasing the ratio to 3:1 POCl3 to nucleoside, neither affected by-product 
nor product formation. Accordingly, the optimum conditions were determined as 1.5 
equivalents of POCl3, reaction time of less than 10 min and a reaction temperature below 
0 °C. The optimised conditions were successfully applied to a range of modified 
nucleosides (Figure 37) to obtain their nucleotide derivatives in 33-73% yield. 
                                                             
iv
 Experiment performed by Dr. Vinciane Borsenberger 
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Figure 35: HPLC traces for the reaction of 5-iodo-2'-deoxuridine with 1.5 equivalents of POCl3 at 0°C. Peak A: 
5',3'-diphosphate; Peak B: 5'-monophosphate; Peak C: 3'-phosphate; Peak S: Starting nucleoside. Y-axis: 
Absorbance at 260 nm. Adapted from [153]. 
The optimised Yoshikawa procedure could not be directly applied to the synthesis of the 
adamantane modified nucleotides (Figure 31, 4a-c). In particular, formation of the initial 
phosphorodichloridate intermediates required careful monitoring by either TLC or 
analytical HPLC to ensure successful triphosphorylation. Figure 36A shows HPLC traces for 
the reaction of 3b with POCl3. Aliquots of the reaction mixture were withdrawn at regular 
intervals, treated with 0.1 M TEAB to form the monophosphate, and then subjected to 
analytical HPLC analysis. The traces reveal that maximal formation of the monophosphate 
was achieved within 2 h as opposed to 10 min which was observed in the optimisation 
experiments (Figure 36A). A plausible explanation for this is that the 5'-hydroxyl of the 
nucleosides are sterically hindered by the adamantane functional groups and thus less 
available for reaction. As the other optimised conditions were adhered to (1.5 equiv. 
POCl3 and temperature below 0 °C), minimal amounts of the 5',3'-disphosphorylated or 3'-
phosphate, were observed. Final transformation to the triphosphates (Figure 31, 4a-c) was 
achieved by the addition of a pre-mixed solution of tributylamine and tributylammonium 
pyrophosphate in DMF. The reaction was stopped after approximately 45 min by the 
addition of 0.1 M TEAB buffer. After washing with organic solvent, the crude material was 
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initially purified by preparative HPLC to remove traces of the pyrophosphate salt and the 
proton sponge (Figure 36B).  
 
 
 
 
 
 
 
Further purification was achieved by ion exchange chromatography using a linear gradient 
of 0.1-0.8 M TEAB for elution. A typical ion exchange trace is shown in Figure 36C. Peaks 1, 
2, 3 and 4 correspond to the mono-, di-, tri- and tetraphosphates species, respectively. 
Fractions containing the nucleotide triphosphates were pooled and concentrated in vacuo 
to give 4a, 4b, and 4c (Figure 37) as triethylammonium salts in 12%, 2% and 5% yields, 
respectively. Given that for each nucleotide, formation of the phosphordichloridate 
intermediates went to near completion, the isolated yields of the triphosphates were 
surprisingly low. This was attributed to loss of material during ion exchange 
chromatography. 
Figure 36: (A) HPLC traces showing the formation of the phosphorodichloridate intermediate of 3c. Maximal 
formation occurs within 2 h. The peak between 17.5 and 19 min is due the proton sponge. Analytical HPLC 
analysis was performed using Varian Pursuit C18 column. See Materials adn Methods for details. (B) HPLC 
trace showing the crude reaction mixture for the triphosphorylation of 3c. Peak 1: pyrophosphate salts; 
peak 2: a mixture of mono-, di-, tri and tetraphorphorylated derivatives of 2b; peak 3: proton sponge. 
Preparative HPLC was performed using a Polaris C18 column. See Materials and Methods for details. (C) 
Representative ion exchange trace. Peak 1, 2, 3 and 4 correspond to the mono-, di-, tri and tetra-
phosphorylated nucleosides, respectively. Performed using Resource S anion exchange column packed with 
methyl sulfonate (strong cation exchanger). See Materials and Methods for details. 
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Figure 37: Structure of adamantane-modified nucleotides 
In an attempt to improve on the isolated yields of 4a-c, another approach towards the 
synthesis of the nucleotides was investigated. As formation of the initial 
phosphorodichloridate intermediates occurred with relative ease and near quantitative 
yields, it was hypothesised that an approach, in which the nucleoside monophosphates 
were isolated en route to the nucleoside triphosphate, would be higher yielding. The 
phosphorylation procedure based on the morpholidate chemistry of Khorana et al., is one 
such approach.175,176 In this approach, the nucleoside monophosphate is isolated and 
converted to the phosphoromorpholidate. Triphosphorylation is achieved via a tetrazole-
catalysed condensation between a pyrophosphate salt and the activated nucleoside.177 
The validity of the approach was assessed using 5-iodo-2'-deoxuridine as a model 
nucleoside. The synthetic scheme is outlined in  
Figure 38. 
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Figure 38: Triphosphorylation using morpholidate chemistry. (i) POCl3, proton sponge, (MeO)3PO; then 0.1 
M TEAB; (ii) Morpholine, 2,2'-dipyridyl disulfide, PPh3, DMSO; then NaI (iii) tetrazole, nBu3NH
+
·H3P2O7
-
; then 
0.1 M TEAB. 
5-Iodo-2'-deoxyridine-5'-monophosphate, 10, was synthesised in 48% yield using the 
Yoshikawa procedure described above. The progress of the reaction was monitored by 
analytical HPLC, which suggested that near complete conversion was achieved within 2 h. 
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Again, the moderate isolated yield was attributed to the loss of material during ion 
exchange chromatography. The phosphormorpholidate 11 was prepared in 70% yield via 
an oxidation-reduction condensation reaction. The proposed mechanism is outlined in 
Figure 39. It is thought that triphenylphosphine nucleophilically attacks the 2,2'-dipyridyl 
disulfide generating a arylthiophosphonium-thiolate salt 13 and releasing pyridine 
dithione.178,179 The salt is in turn attacked by the monophosphate resulting in intermediate 
14. The nucleoside monophosphate is subsequently primed for nucelophilic attack by 
morpholine, resulting in the phosphoromorpholidate 11. The driving force for the 
production of 11 is the generation of triphenylphosphine oxide. The 
phosphoromorpholidate was precipitated from solution as the sodium salt by the addition 
of sodium iodide in acetone, and used without any further purification. The reaction was 
catalysed by 1H-tetrazole which is thought to activate the monophosphate by protonation 
of the leaving nitrogen and concomitant nucleophilic catalysis via the highly reactive 
phosphotetrazolide 15 (Figure 39). It is this species which reacts with the pyrophosphate 
salt.168,177 In this instance, tetrazole serves as both a Bronsted acid (pKa = 4.9)
136 and a 
nucleophile. Studies have shown that both properties are required for effective catalysis, 
as the use of a nucleophile (e.g. dimethylaminopyridine) or acid (e.g. acetic acid, which 
has a similar pKa), alone was inferior to the use of tetrazole.
177 Disappointingly, only trace 
amounts of the desired triphosphate, 12, formed (detectable by ion-exchange 
chromatography and MS analysis). As a result, the morpholidate approach was not applied 
to the adamatane-modified nucleosides rather, the Yoshikawa procedure was used. 
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Figure 39: Proposed mechanism for triphosphorylation via a morpholidate chemistry. B: 5-iodouridine 
3.4.3. Enzymatic Incorporation of Modified Nucleosides 
The ability of the chemically modified nucleosides to serve as a substrate for DNA 
polymerase was evaluated using template-directed primer extension assays. The principle 
of the assay is schematically summarised in Figure 40A. A primer, a short DNA strand, is 
hybridised to complementary section of a longer DNA strand. The unhybridised section of 
the longer DNA strand then serves as a template to direct the extension of the primer. 
This extension is mediated by a DNA pol enzyme which sequentially adds nucleotides to 
the 3'-end of the primer. In the presence of all four nucleotides, the primer is extended to 
the same length as the template. However, if at least one of the bases is lacking, primer 
extension is terminated prematurely and giving rise to short fragments. The sequence of 
the unhybridised section of the template used in this investigation is shown in Figure 40.  
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Figure 40: Template-directed primer extension. (A) The primer and template form a duplex, and the non-
hybridised section of the template directs the polymerase-catalysed addition of nucleotides to the 3' of the 
primer. (B) dNTP mixes of varying composition determine the number of incorporated nucleotides 
comprising the nucleotide analogue dU*TP. Adapted from [
153
]. 
 
As the template contained three adenine bases (underlined in Figure 40A), the primer 
could be extended by incorporating up to three modified deoxyuridine residues, dU*TP. 
The sequence of the template was designed so that the extension could be controlled by 
the inclusion or omission of particular bases (Figure 40B). For instance, dNTP mix 0 lacked 
a uridine and thymine, either of which could be the first nucleosides incorporated into the 
primer. As a result, no extension was expected to occur for dNTP mix 0. Conversely, as 
dNTP mix F contained a full set of natural bases, the primer should be extended by 12 
nucleotides to the same length as the template. By comparison, as dNTP mix H lacked 2'-
deoxyguanosine triphosphate, dGTP, the primer should only be extended halfway i.e. by 
six nucleotides. In this fashion, the ability of the enzyme to catalyse the extension of the 
primers by six or 12 nucleotides, in the presence of the nucleotide analogues, was 
assessed. The primer extension products were evaluated by gel electrophoresis. In this 
type of analysis, the extension products are applied to wells at the top of a gel, and an 
electric field is applied. The fragments migrate towards the anode at different rates 
depending on their molecular weight, or specifically, according to how far they have been 
extended. Hence shorter fragments, which were not fully extended, move faster and 
further than those that are. The gels are visualised using a DNA-specific stain to determine 
the incorporation efficiency, that is, the ability of the enzyme to extend the primers. For 
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instance, if the enzyme is able extend the primer to the same length as the template; both 
stands should migrate to the same position in the gel giving rise to a single bright band. 
Thus it could be concluded that the enzyme has a good catalytic efficiency. In cases where 
short extension fragments are produced, two or more distinct bands can be observed. 
Typically, the higher band corresponds to the template whereas the lower bands 
correspond to the extension fragments, as these have lower molecular weights. In this 
instance, the bands would most likely be fainter in appearance as there are fewer 
oligonucleotides migrating at either position. In most cases, incorporation of the natural 
and modified nucleotides gives rise to clearly defined bands. However, if the extension 
products are poorly resolved the bands may appear as smears.180 
Prior to evaluating the substrate properties of the adamantane-modified 
nucleotides, a systematic study on the effect of C5 substituent on the enzymatic 
incorporation, was performed. A series of C5-modified 2'-deoxyuridine triphosphates, 
which possessed different functional substitutions, were synthesised via Sonogashira 
cross-coupling using the corresponding acetylene-based linkers and Yoshikawa reaction, 
as described above. The modifications included amine and carboxyl functionalities, alkyne 
and diene groups, as well as bulky Diels-Alder coupled peptide tags (Figure 41). 
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Figure 41: 2'-Deoxyuridine-5'-triphosphate bearing different substituents at position 5 of the pyrimidine. R' 
are peptide tags; R'1=H6, R'2=GVKRKKKP, or R'3=GKDDDDYD. The nucleotides were used to study the effect of 
substituent length, charge and bulkiness on enzyme catalysed incorporation into DNA. Adapted from [153].v 
 
Primer extension assays using the Deep Vent exo- polymerase enzyme and subsequent gel 
electrophoresis showed that the enzyme was able to catalyse the incorporation of the 
majority of the nucleotides, with efficiency similar to that of the naturally occurring 
nucleotides.  The gel analysis is summarised in Figure 42. 
 
                                                             
v
 Nucleotides b, e, f, and g were synthesised by Dr. Vinciane Borsenberger. 
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Figure 42: Denaturing PAGE analysis of extension reactions with modified nucleotides using Deep Vent exo- 
(B,C) and Taq (D, E) for dNTP mixes 6 and 12 as defined in Figure 40, conducted at 57 °C. (A) Control 
reactions with dNTP mixes 0, F, H, as defined in Figure 40 Lane 1 and 2 contain template, T, and primer, P, 
respectively. (F) Shows the extension conducted at 70 °C using mix H, and mixes 6 or 12 containing 
nucleotides a or c. Adapted from [
153
]. 
 
Panel A shows the results of the control experiments which were performed to confirm 
the viability of the primer extension assays. In Figure 42A, lane 1 and 2 correspond to the 
36 nucleotide-long template and 24 nucleotide-long primer, respectively. By comparison, 
lane 4 shows the results of the positive control, dNTP mix F, where primer extension was 
performed using all four naturally occurring nucleotides. The primer was fully extended 
and thus co-migrated with the template resulting in a single band. Conversely, dNTP mix 
H, which was designed to direct the extension by 6 nucleotides, resulted in an up-shift of 
the primer band (Figure 42A, lane 5). In line with the expected results, no extension was 
observed for dNTP mix 0 (Figure 42A, lane 3). Both the modified nucleotides and 2'-
deoxythymidine triphosphate, dTTP, were omitted from the primer extension assay, as 
result only the starting template and primer were observed. This control excludes the 
possibility of non-specific incorporation of a natural nucleotide in the place of a modified 
nucleotide. 
 The ability of the enzyme to extend the primer by six nucleotides and thus 
incorporate two modified nucleotides was evaluated. The results are shown in Figure 42B. 
The enzymatic reaction with a, b, d, e, f, and peptide-tagged analogues g-R1, g-R2, g-R3 
proceeded successfully, as indicated by a major up-shifted band stemming from the 
extension of the primer (Figure 42B, lanes 1, 2, 4 to 9). Enzymatic incorporation of 5-
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ethynyl-2'-deoxyuridine, b and diene-modified nucleotide f has been observed in other 
studies.157 These two nucleotides hence served as positive controls and references for the 
extension assay. The extended primers carrying the modified nucleotides migrated at 
about the same height as the strand from natural nucleotide mix H (compare Figure 42B, 
lanes 1, 2, 4 to 6 with Figure 42A, lane 5). The absence of any tag-induced gel shift 
attributed to the low mass of the chemical tags. This notion was supported by the results 
of primer extension assays using the peptide-modified nucleotides g-R1, g-R2, and g-R3. 
The extended primer showed a significant gel shift (Figure 42B, lanes 7 to 9) reflecting the 
approximately ten-fold higher masses of the peptide tags compared to the other chemical 
tags. These results confirmed that in each case the enzyme was able to extend the primer 
by six nucleotides and thereby incorporate two modified nucleotides (Figure 40B, dNTP 
mix 6). Interestingly, almost no incorporation occurred for the amino-propargyl derivative 
c (Figure 42B, lane 3). It was hypothesised that the inability of c to serve as substrate was 
most likely related to the terminal amino group of the substituent at position 5 (see below 
for further explanation).  
 Similar results were observed for the extension of the primer by 12 nucleotides to 
incorporate three modified nucleotides (Figure 42C). The primer was fully extended using 
nucleotides a, b, d, e and f (Figure 42C, lanes 1, 2, 4 to 6), while the amino-propargyl c was 
not accepted as substrate for the enzyme (Figure 42C, lane 3). A lower incorporation 
extent was found for peptide-modified nucleotides g-R1, g-R2, and g-R3 (Figure 42C, lanes 
7 to 9). In particular, it seemed that the addition of a third nucleotide into the partly 
extended primer occurred at a lower efficiency. This was most likely due to steric reasons. 
The first and the third tagged base were separated by 10 bases, which correspond to 
almost one complete helical turn.124 Consequently, the peptide tags were most likely 
positioned on the same side of the duplex which is sterically crowded.  
 The incorporation efficiency was also assessed using the Taq pol under the same 
conditions as those used with Deep Vent exo-. The results of the primer extension are 
shown in Figure 42D and Figure 42E. Extension of the primer by six nucleotides was mostly 
complete for a, b, d, e, f, g-R1, and g-R2 (Figure 42D, lanes 1, 2, 4 to 8). In comparison to 
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reactions with Deep Vent exo-, the extent of incorporation by Taq was slightly lower. This 
was particularly evident in reactions involving e (Figure 42D, lane 5), where several minor 
bands stemming from the premature termination of the primer, were observed. As in the 
case of Deep Vent exo-, amino-propargyl nucleotide c was a poor substrate for enzymatic 
polymerisation by Taq (Figure 42D, lane 3), even though another study reported good 
incorporation, albeit with a different enzyme, Tth.181 The low incorporation for g-R3 
(Figure 42D, lane 9) was attributed to the partial hydrolysis of the triphosphate. This was 
most likely caused by the low pH of the nucleotide solution due to the acidic peptide tag 
(Figure 41). The assays for the extension of the primer by 12 nucleotides (Figure 42E) 
supported the previous findings. With the exception of nucleotides c (Figure 42E, lane 3), 
g-R1 and g-R2 (Figure 42E, lanes 7 and 8) the nucleotides analogues were suitable 
substrates for Taq pol.  The poor incorporation of g-R3 (Figure 42E, lane 9) was also 
attributed to hydrolysis of the triphosphate. 
 The poor incorporation of amino-propargyl nucleotide c was investigated with a 
molecular model of a polymerase.vi A model was constructed using the X-ray structure of 
the T7 DNA polymerase, which like Taq, belongs to the type A family of polymerases.182 
The X-ray structure of T7 DNA polymerase is a ternary complex with the double stranded 
DNA template containing a single stranded overhang, and an incoming dTTP nucleotide 
complementary to adenine in the overhang.153,182 The model of the active site is shown in 
Figure 43. The protein is shown in grey and the DNA template in magenta. The nucleotide 
5-(3-amino-propynyl)-2' deoxyuridine 5'-triphosphate c was placed in the same position as 
dTTP in the X-ray file. Visual inspection of the active site revealed that the primary amino 
group of the nucleobase is close to two charged amino acids. As measured from its 
nitrogen atom, the amino-propargyl group is 4.5 Å away from the nitrogen of lysine at 
position 522, and 4.7 Å away from the closest oxygen of aspartic acid at position 519. 
Based on the importance of substrate recognition by key residues in DNA polymerases, it 
was proposed that an electrostatic interaction between the amino group and the charged 
residues inhibited the activity of the polymerase activity. In particular, the electrostatic 
                                                             
vi
 Modelling performed by Dr. Hugh Martin. 
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attraction of amino-propargyl to Asp, and the electrostatic repulsion to Lys, was most 
likely altering the position of the pyrimidine base within the active site thereby affecting 
the ability of the polymerase to accept the nucleotide as a substrate.  
Several observations are consistent with the notion that electrostatic interactions 
cause the poor acceptance of amino-propargyl nucleotide c. Firstly, abolishing the ionic 
interaction by neutralising the amino group of c via acylation with hexa-2,4-dienoic acid 
(thereby yielding nucleotide e, Figure 41) resulted in an improved incorporation efficiency 
(lanes 5 in Figure 42B and C). In addition, weakening the interaction by increasing the 
temperature of polymerisation from 57 °C to 70 °C improved the acceptance of c by the 
enzyme, as seen for dNTP mix 6 (Figure 42F, lane 4) and dNTP mix 12 (Figure 42F, lane 5). 
While the ionic interaction between nucleotide and enzyme is a plausible explanation, 
other reasons cannot be completely ruled out. For example, a modified nucleotide added 
to a DNA strand could affect the interaction between primer and template strands and 
thereby affecting DNA duplex stability.181 Further work using point-mutated enzymes 
would be required to unequivocally clarify whether the charged residues in the active site 
are the key to the poor acceptance of amino-propargyl derivative c. 
 
 
Figure 43: Molecular model of the active site of the T7 DNA pol from the A-type family. The model shows 
the electrostatic interactions between the amino group of 5-(3-amino-propynyl)-2'-deoxyuridine 5'-
triphosphate 3c and the side chains of aspartic acid and lysine. The protein is in grey, the DNA strand of the 
template is in magenta, and the two Mg2+ ions are represented as green spheres. The metal ions 
electrostatically interact with the triphosphate moiety of the nucleotide. The nucleotide 3c was placed into 
the position of the incoming dTTP nucleotide in the crystal structure of the ternary protein·DNA·dTTP 
complex (PDB ID 1T7P) [
153
,
182
]. 
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Based on the primer extension assay results of the nucleotide analogues above, 
predictions could be made about the ability of the adamantane-modified nucleotides (4a-
c, Figure 31) to serve as substrates for the DNA pol. As 4a-c were uncharged and the 
adamantane functionality smaller than the Diels-Alder functionality (Figure 41, g-R1-3), it 
was hypothesised that the nucleotides would be well tolerated by the enzyme. This was 
indeed found to be the case. Figure 44 shows the results of the primer extension assays 
using 4a-c. 
 
 
 
 
 
 
Akin to the primer extension assays described above, lanes 1 and 2 show the results of the 
control experiments, dNTP mix F and dNTP mix 0, respectively. The ability of the enzyme 
to catalyse the full extension of the primer and hence incorporate three modified 
nucleotides was assessed in a step-wise manor. Lane 3 (Figure 44) shows the extension of 
the primer by a single modified nucleotide (see Figure 40 for sequence of template and 
Figure 44: Denaturing PAGE analysis of extension reactions with adamantane-modified nucleotides (4a-c) 
using Deep Vent exo-. Lane 1: dNTP mix F; positive control in the presence of natural nucleotides. Lane 2: 
dNTP mix 0; negative control primer extension without dTTP or modified nucleotide. Lane 3: dNTP mix 1; 
extension of the primer by one modified nucleotide. Lane 4: dNTP mix 3; extension of the primer by 3 
nucleotides. Lane 5: dNTP mix 6; extension of the primer by six nucleotides and concomitant incorporation 
of two modified nucleotides.  Lane 6: dNTP mix 12; full extension of the primer and concomitant 
incorporation of three modified nucleotides. See Figure 40 for the sequence of the template and primer. 
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primer). For each of the assays (Figure 44A-C), a slight gel shift was observed suggestive of 
single nucleotide incorporation. Greater gel shifts were observed as the primer was 
extended by three (Figure 44, Lane 4), six (Figure 44, Lane 5) and 12 (Figure 44, Lane 6) 
nucleotides. The latter two extensions resulted in the incorporation of two and three 
modified nucleotides, respectively (Figure 40). Similar to nucleotides g-R1-3, the fully 
extended primer containing 4c migrated above the template due to the increased 
molecular weight and thus slower electrophoretic mobility of the nucleotide compared to 
the other chemical tags (Figure 44C, Lane 6). Interestingly, shorter extension products 
were not observed, suggesting that DNA pol was able to incorporate 4c with a greater 
efficiency compared to g-R1-3. Hence incorporation of the third modified nucleotide was 
not sterically hindered by the first. The minor band observed in Figure 44B, lane 6, was 
attributed to partially hydrolysis of the nucleotide. 
 
3.4.4. Oligonucelotide Synthesis 
Having shown that the adamantane-modified nucleotides were readily incorporated into 
DNA by the action of DNA pol, efforts were made to chemically synthesise modified DNA 
strands that possessed nucleotide repeat sequences.vii These modified DNA strands would 
subsequently be used to test the sensing approach. The sequence of the synthesised 
oliogonucleotides is shown in Table 6. The sequences are based upon the complementary 
sequence of pentanucleotide STR called PentaD, which is used as a genetic marker for 
forensic DNA fingerprinting.183 In each of the strands, a single modified nucleoside, U*, 
was incorporated per repeat unit.  
 
 
 
                                                             
vii Oligonucleotide synthesis was performed at the University of Southampton with the help of Dr. Jonathan 
Burns. 
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Table 6: Sequence of PentaD STR and synthesised oligonucleotides. 
Entry Sequence 
PentaD 5'-AAA AAA A AAAGA AAAGA AAAGA AAA AA-3' 
1 3'-TTT TTTT T TU*TCT TTTCT TTTCT TTT TT-5' 
2 3'-TTT TTT T TU*TCT TU*TCT TTTCT TTT TT-5' 
3 3'-TTT TTT T TU*TCT TU*TCT TU*TCT TTT TT-5' 
 
Chemical synthesis of DNA was achieved using automated solid-phase chemistry. Reactive 
groups on the nucleosides were protected to prevent unwanted side reactions during 
synthesis. The 5'-hydroxyl was protected with dimethoxytrityl (DMT) ether, whilst the 
exocyclic amine of cytosine was protected with a benzoyl group (Figure 45A).184 The 
reactive phosphate on the 3'-position was protected by β-cyanoethyl group and chain 
elongation occurred via phosphate-triester chemistry (Figure 45C). The four essential 
steps of solid-phase oliognucleotide synthesis have been summarised in Figure 45B.185  
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In brief, the 5'-O-DMT protecting group was removed from the resin-bound 
deoxynucleoside using a weak acid to yield an orange DMT cation (Figure 45B, step 1).184 
The highly chromophoric DMT cation was used to determine the coupling efficiencies 
throughout the synthesis. This initial deprotection step is termed deblocking. Chain 
elongation (Figure 45B, step 2) occurred via the formation of a phosphite triester 
internucleotide bond with the incoming nucleoside. The relatively stable and unreactive 
3'-phosphoramidite was activated to the highly reactive phosphitylating agent by 
tetrazole. As tetrazole is a weak acid (pKa 4.6),136 it was able catalyse the reaction without 
compromising the DMT protecting groups. The mechanism of activation is shown in Figure 
45C. Any unreacted 5'-hydroxyls were then capped or acetylated (Figure 45B, step 3) using 
acetic anhydride and N-methylimidazole. Finally, the phosphorous in the phosphite 
triester internucleotide linkage was oxidised from +3 oxidation state to +5 in the 
corresponding phosphate triester (Figure 45B, step 4). Oxidation was achieved with iodine 
and water in THF, and pyridine added to neutralise the liberated hydrogen iodide. Further 
repetitions of this cycle afforded the oligonucleotides with the desired length and 
sequence. At each step of the synthesis, the resin was washed with anhydrous ACN to 
prevent carryover of reagents. The final products were liberated from the resin and 
concomitantly deprotected by treating the resin with ammonium hydroxide at 50 °C 
overnight. The benzoyl protecting group on cytosine was removed via an addition-
elimination reaction at the carbonyl group of the ester bond. Conversely, the 2-cyanoethyl 
group was removed from the phosphate by a β-elimination reaction. Lyophilisation of the 
ammonia solution afforded the crude oligonucleotides which were subsequently purified 
by HPLC and characterised by MS analysis. 
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Figure 46: Synthesis of 5'-DMT-5-adamantane modified nucleoside phosphoramidites. (i) DMT-Cl, Et3N, cat. 
DMAP, pyridine; (ii) CuI, Et3N, Pd(PPH3)4, adamantane-acetylene linker, DMF, 16 h; (iii) CEP-Cl, DIPEA, DCM, 
2 h. 
Synthesis of the phosphoramidite derivatives of the adamantane-modified nucleosides 
(3a-c, Figure 31) is outlined in Figure 46. The 5'-hydroxyl of 5-iodo-2'-deoxyuridine, 13, 
was protected as the DMT-ether using DMT-Cl and Et3N in anhydrous pyridine. The 
resultant protected nucleoside, 14, was isolated from the crude reaction mixture by flash 
chromatography in 30-68 % yield. In order to minimise loss of the DMT-group during 
purification, flash chromatography was performed using silica gel which had been 
neutralised with Et3N. The residual base was removed from the product by co-evaporation 
with HPLC-grade MeOH. Using the Sonogashira cross-coupling reaction, the adamantane-
acetylene linkers were coupled to the DMT-protected nucleoside. Purification of the 
resultant nucleosides (15a-c) was more cumbersome than had initially been anticipated. 
TLC analysis of the crude reaction mixtures showed good resolution between the desired 
nucleosides and by-products that had formed. Indeed, DMT-containing compounds were 
readily visualised by exposure of the TLC plates to concentrated HCl vapours. However, 
126 
 
despite using the same solvent system as that used for TLC analysis, flash chromatography 
resulted in mixed fractions with almost no resolution. Neither employing a gradient 
elution strategy, nor performing purification under gravity, improved the resolution. The 
purified nucleosides were finally isolated in clean fractions, by using a mixture of silica 
gels. Using 15% (w/w) silica gel Type H with silica gel Type G, and employing a gradient 
elution strategy under gravity, sufficiently reduced the migration rate of the crude 
material through the column and thus improved the resolution. Silica gel Type H has 
smaller particle size (10-40 μm) compared to silica Type G (40-60 μm), and essentially 
acted as a filter to reduce migration speed and increase resolution. Using the optimised 
conditions, nucleosides 15a, 15b and 15c were isolated in 71%, 56% and 32%viii yields, 
respectively. Formation of the phosphoramidites 16a-c, was achieved according to 
standard phosphitylation methods using 2-cyanoethylchloro-N,N-
diisopropylphosphoramidite (CEP-Cl) in dry DCM as the reagent. The phosphoramidites 
were precipitated from the crude reaction mixture, dried under a stream of nitrogen, and 
then dissolved to a final concentration of between 0.02-0.04 M in ACN/DCM mixture (1:1, 
v/v). Due to the extreme sensitivity of the phosphoramidites, they were synthesised 
immediately prior to commencement of DNA synthesis and used crude. No 
characterisation was performed bar TLC analysis which showed that formation of the 
phosphoramidites was complete within 2 h. DNA synthesis was performed with 100-fold 
molar excess of the phosphoramidites over the resin bound nucleoside. This was 
necessary to counteract the loss of active material through oxidative and hydrolytic 
degradation. Without a sufficient molar excess, degradation of phosphoramidite would 
ultimately have led to a reduced coupling efficiency and overall yield. Indeed, MS analysis 
of residual phosphoramidite solution of 15b (Figure 47) showed traces of phosphonate 
and monophosphate hydrolysis products in addition to the starting phosphoramidite. 
These findings were corroborated by 31P NMR analysis in which signals were observed at 
150.2 ppm, 35.5 ppm, 8.1 ppm and 3.3 ppm, which in accordance with literature 
                                                             
viii
 15c was synthesised by Xiu Yao, a Master’s student within our research group. 
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reports,186–188 correspond to the phosphoramidite, phosphonoamidate, the phosphonate 
and monophosphate, respectively. 
 
 
 
Using the nucleoside phosphoramidites 16a and 16c, a range of oligonucleotide strands 
were synthesised and subsequently analysed via nanopore analysis.  
 
3.4.5. Nanopore Analysis 
 
During nanopore analysis, the electric field applied to single-stranded oligonucleotides 
causes the DNA strands to rearrange from a randomly coiled state within the vestibule of 
the pore, to a liner extended state prior to translocation.32 Whilst in this linear state, it is 
thought that chemical tags placed at position C5 are held perpendicular to the 
oligonucleotide (Figure 48A).9 As the modified oligonucleotide translocates the pore, the 
tag is repositioned so that it lays parallel to, or flush against, the oligonucleotide (Figure 
48B). In doing so, a bulky oligo-tag segment is formed which essentially increases the 
cross-sectional diameter of the oligonucleotide. ssDNA which has an average cross-
sectional diameter of 0.9-1.2 nm9 is known to translocate the αHL pore, whose inner 
Figure 47: 31P NMR analysis of residual 15b. NMR spectra recorded at 121.4 MHz in CDCl4. 
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constriction measures 1.3 nm in diameter,6 with minimal affect on the ionic current.32 
Several hypotheses were made regarding the tranlocation of the adamantane-modified 
oligonucleotides. Firstly, the inclusion of an adamantane tag, which has dimensions of 
approximately 4 Å cubed,147 would increase the cross-sectional diameter of the 
oligonucleotides to approximately 1.3-1.6 nm. As this is closer to the diameter of the inner 
constriction of the α-HL, the bulky oligo-tag segment was expected to occlude the ionic 
current during translocation, resulting in detectable disturbances in the electronic trace. 
Secondly, as the non-modified regions of the oligonucleotide, adjacent to the oligo-tag 
segments, translocated the pore, the flow of ions would be restored as these regions are 
equivalent to non-modified ssDNA (Figure 48C). In essence, it was hypothesised that step-
like disturbances would be observed in the electrical traces as the tagged oliognucleotide 
translocated the pore. The number of steps observed should reflect the number of 
chemical tags in the oligonucleotide and hence the number of repeat units in the STR. 
Step-like behaviour has been observed previously in work by Mitchell et al., who analysed 
peptide-tagged DNA strands.9  
 
Figure 48: Translocation of tagged oligonucleotides and origin of step-like modifications in electrical traces. 
Adapted from [9]. 
Finally, it was hypothesised that the resolution of the ‘steps’ would be dependent upon 
the length of the linker between the oligonucleotide and the adamantange tag. An overly 
long linker could possibly span the entire STR repeat unit and interact with the preceding 
tag. This would ultimately reduce the resolution of the ‘steps’ in the electrical traces as 
the intermittent non-modified regions would not be detected. Conversely, if the linker 
was excessively short, the oligo-tag region may be insufficiently large for detection via the 
nanopore. In extended ssDNA, the distance between the bases is 0.5 nm.189 Thus in a 
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pentanucleotide repeat sequence, the distance between a modified nucleotide in one 
repeat unit and the next is approximately 2.5 nm. It was hypothesised that nucleoside 4c 
(Figure 44, longest linker) would offer the best resolution as the distance between C5 and 
the bottom of adamantane is approximately 1.74 nm.  Hence the nucleoside should 
enable the detection of the intermittent non-modified region of the oligonucleotide in 
addition to forming an oligo-tag segment sufficiently large to block the flow of ions. For 4a 
(Figure 44, shorest linker), the distance between C5 and the bottom of adamantane is 1.17 
nm. It was hypothesised that linker would be too short of offer good resolution. 
 
The modified oligonucleotides were subjected to nanopore analysis and the transloction 
parameters determined. The recordings were performed in 1 M KCl with 50 mM Tris, pH 
8.0 and applied voltage of +100 mV at the trans side. In the absence of any 
oligonucleotide, α-HL displayed a constant open channel current of 110 ± 8.4 pA (n=2). 
 
 
 
 
Addition of the oligonucleotides to the cis side of the pore led to detectable disturbances 
of the ionic current which were attributed to the net negatively charged oliognucleotides 
translocating the pore, towards the positively charged trans side. Each oligonucleotide 
was characterised using data generated from 3 independent recordings with at least 1000 
translocation events. Step-like modifications of the ionic current were not observed; 
Figure 49: Reprentative traces for oligonucleotides modified with short adamantane linkers, 4C. The 
electrical signals from oligonucleotides with one (O4) and two (O5) O4 modified nucleotides did not display 
any significant difference. Oligonucleotides with three modified nucleotides (O6) showed similar electrical 
signals as O4 and O6. However, several signals also possessed one or two ‘shoulders’. 
130 
 
representative electrical traces are shown in Figure 49. The translocation parameters for 
each oligonucleotide are summarised in Table 7.  
Table 7: Translocation Parameters of Adamantane-Modified Oligonucleosides. 
Oligo 
Name 
Modified 
nucleotide 
Number 
of STR 
repeats[b] 
Amplitude [%] 
τoff                
[ms] 
O1 4c[c] 1 90.6 ± 0.01 5.0 ± 0.02 
O2 4c 2 89.6 ± 3.49 12.3 ± 0.08 
O3 4c 3 95.1 ± 1.68 8.9 ± 0.03 
O4 4a[d] 1 85.9 ± 0.50 3.5 ± 0.16 
O5 4a 2 86.8 ± 0.70 2.7 ± 0.17 
O6 4a 3 92.3 ± 0.30 4.3 ± 0.14 
ssDNA[a]  N/A  N/A 91.7 ± 1.1 0.18 ± 0.06 
N/A: Not applicable. 
[a] 27mer ssDNA. Data taken from reference [9] 
[b]Oligonucleotide sequence: 1 STR, 3'-TTT TTT TTU*TCT TTTCT TTTCT TTT TT-5'; 2 STRs, 3'-TTT TTT TTU*TCT 
TU*TCT TTTCT TTT TT-5'; 3 STRs, 3'-TTT TTT TTU*TCT TU*TCT TU*TCT TTT TT-5' 
[c]Long linker 
[d]Short linker 
 
It was observed that the event duration, τoff, for O1, that is the oligonucleotide modified 
with a single long linker, was 5.0 ± 0.02 ms. Whilst that of O4, the oligonucleotide 
modified with a single short linker, was 3.5 ± 0.16 ms. Hence modification with the longer 
linker effectively increased the translocation time almost 1.5-fold. A similar observation 
was made for oligonucleotides O3 and O6. In general, the translocation speeds of 
oligonucleotides modified with short linkers (O4-O6) were faster than those modified with 
long linkers (O1-O3). For instance, the presence of three long linkers in O3 effectively 
increased the translocation time by almost 2-fold, versus three short linkers in O6. 
Furthermore, it was observed that the event duration of O3 and O6 were, 44% and 19% 
longer than those of O1 and O4, respectively. Therefore, the presence of three modified 
nucleotides always increased the event duration irrespective of the linker composition. 
This was attributed to the increased resistance experienced by the translocating 
oligonucleotide. These findings support the notion that, firstly, modulation of the ionic 
current is due to steric hindrance that occurs when the bulky oligo-tag segment 
translocates the pore. Secondly, that the tag is elongated and aligned parallel to the DNA 
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strand during translocation. Hence, when the tag is attached via a longer linker, a longer 
oligo-tag segment is formed resulting in a longer translocation event. In all cases the event 
durations were an order of magnitude longer than that of non-modified ssDNA which is 
typically 180 μs.9 The average amplitude of the translocation events was also determined. 
It was expected that within each set of oligonucleotides (O1-O3 and O4-O6) the amplitude 
of blockades would be similar. This would indicate that the blockades were due to the 
action of a single bulky oligo-tag segment acting independently from the others. However, 
this was not the case; a near linear relationship was observed between the number of tags 
and the amplitude of blockade. The results suggested that as the number of tags 
increased, so did the cross-sectional diameter of the oligonucleotides, which would 
account for the increasing amplitude. There are two plausible explanations for this 
observation. Firstly, despite the length of the linker in comparison to the distance 
between the STR units, it is possible that the tags were completely spanning the STR and 
interacting with one another. Effectively, the tags acted as an insulator or shield to 
increase the overall diameter of the oligonucleotide. Alternatively, the DNA strands were 
being compressed as they translocated the pore, hencing reducing the distances between 
the bases. Secondly, as the linkers are hydrophobic chains, they had no means of 
interacting with the oligonucleotide, which has a net negative charge. Consequently, the 
oligo-tag segment may not be compact enough to give reliable and comparable 
amplitudes of blockades. Furthermore, due to the hydrophobic nature of the linkers, they 
may have been more likely to interact with another linker rather than the oligonucleotide. 
These explanations are partially supported by the fact that the amplitudes of blockades 
were on a par with non-modified ssDNA (91.7%).9 This indicates the formed oligo-tag 
segment may not be much wider than non-modified DNA.  
 
3.5. Conclusion 
The aim of this study was to develop a nanopore-based strategy to size nucleotide repeat 
sequences, which are the basis for DNA fingerprinting. It was proposed that this could be 
achieved by incorporating a single adamantane-modified nucleotide per repeat unit. It 
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was hoped that subsequent nanopore analysis would result in electrical traces with 
distinct step-like modifications, where the number of steps corresponded to the number 
of modified nucleotides and hence the number of repeat units.  
Three adamantane-modified nucleosides, with varying linker lengths, were 
successfully synthesized using Sonogashira cross-coupling. The corresponding nucleotides 
were prepared via the Yoshikawa phosphorylation procedure. The original procedure was 
optimised with regards to reaction time, temperature and number of equivalents of POCl3. 
The optimized procedure was successfully applied to a range of nucleoside analogues 
which were then subjected to primer extension assays. It was demonstrated that the 
majority of the nucleotides were suitable substrates for both DNA and Taq pol. However, 
poor incorporation was observed for the sterically demanding peptide-tagged nucleotides 
and the amino-proparagyl derivative. Using a molecular model of the polymerase active 
site, it was proposed that the latter formed adverse electrostatic interactions within the 
enzyme. This notion was supported by experiments which aimed to minimise these 
interactions. In particular, performing the assay at elevated temperatures and acylating 
the amino-functional group resulted in increased incorporation. Despite the success of the 
optimized conditions, they could not be applied to all nucleoside analogues. 
Phosphorylation reactions of the adamantane-modified nucleoside analogues required 
careful monitoring for the formation of key intermediates, and as such, the reaction times 
were highly variable compared to other nucleoside analogues. Nonetheless, the 
nucleotides were successfully synthesised and incorporated into oligonucleotides.  
Having shown that the adamatane-modified nucleosides were suitable substrates 
for DNA pol, the sensing approach was tested using chemically synthesised 
oligonucleotides which possessed STR sequences. A single adamantane-nucleoside was 
placed within each STR. A linear relationship was observed between the number of tags 
present in the oligonucleotide and the dwell time. This suggested that as the number of 
tags increased, the resistance experienced by the oliognucleotide increased, increasing 
the translocation time. In spite of this, step-like disturbances were not observed in the 
electrical traces. The most plausible explanation for this is that the tags did not sufficiently 
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increase the diameter of the DNA. Indeed, the amplitude of blockades of the modified 
oligonucleotides was on a par with non-modified ssDNA. This observation, combined with 
the τoff data, indicated that the formed oligo-tag segments were not compact enough to 
occlude the flow of ions. As oligonucelotides possess a net negative charge, a more 
compact oligo-tag segment could be formed by employing a linker that possess some 
positive charge. 
 
3.6. Materials and Methods 
All reagents and anhydrous solvents were purchased from Sigma Aldrich unless otherwise 
stated. All organic solvents and water (HPLC grade) were purchased from Fischer 
Scientific. O-(benzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate 
(HBTU) was purchased from NovaBiochem. 5-iodo-2'-deoxyuridine was purchased from 
CarboSynth. Deep VentR® (exo
-) and Taq polymerases were purchased from New England 
Biolabs. DNA primers and templates were purchased from Integrated DNA Technologies. 
Nanopore analysis was performed as described in the Materials and Methods 
section of Chapter 1 (section 2.11). HPLC analysis was performed using reverse phase 
Varian ProStar system with a Model 210 solvent delivery mode and a Model 320 dual 
wave-length detector. The mobile phase A consisted of 0.1 M triethylammonium 
bicarbonate buffer (pH 7) and mobile phase B consisted of neat acteonitrile. The UV 
absorbance was monitored at 260 nm. Analytical HPLC analysis was performed using a 
Varian Pursuit XRS C18 column (250 x 4.6 mm). The gradient started with 2% eluent B and 
rose linearly to 25% B over 10 min with a flow rate of 1 mL min-1. Preparative purification 
was performed on the same system using a Polaris C18 column (100 x 21.2 mm, 5 mm 
beads). The gradient started with 2% eluent B and rose linearly to 25% B over 10 min with 
a flow rate of 10 mL min-1. Fractions containing the desired product were pooled, the 
solvent removed under reduced pressure to approximately 2 mL and the solution 
lyophilised overnight. Ion exchange chromatography was performed on an ÄktaPurifier 10 
FPLC system (GE Healthcare). Mobile phase A consisted of 0.1 M triethylammonium 
bicarbonate buffer (pH 7). Mobile phase B consisted of 0.8 M triethylammonium 
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bicarbonate buffer (pH 7). Analytical ion exchange was performed using a Resource Q 
column (1 mL, GE Healthcare). The gradient started with 0% B and rose linearly to 100% B 
over 10 min at 1 mL min-1. Preparative ion exchange was performed using a Resource S 
column (6 mL, GE Healthcare). The gradient started at 0% B and rose linearly to 100% B 
over 10 min at 2 mL min-1. ESI-MS analysis was performed using a Waters Aquity Ultra 
performance LC-MS system equipped with an Aquity UPLC BEH C18 column (50 x 2.1 mm, 
1.7 mm beads). 1H- and 13C-NMR spectra were recorded at 293K on a Bruker AVANCE500 
or -600 MHz spectrometer. 31P-NMR spectra were recorded a Bruker AMX300 
spectrometer. Coupling constants are reported in Hz. Reference NMR solvent signals 
CDCl3: δH = 7.26 ppm, δC = 77.0 ppm; D2O: δH = 4.79 ppm; (CD3)2SO: δH = 2.50 ppm, δC = 
39.5 ppm; CD3OD: δH = 3.31 ppm, δC = 49.0 ppm; unless otherwise stated. Multiplicities 
for 1H coupling are shown as s (singlet), d (doublet), t (triplet), m (multiplet), or a 
combination of the above. Thin Layer Chromatography (TLC) was performed on aluminium 
backed Sigma-Aldrich TLC plates with F254 fluorescent indicator. Visualisation achieved by 
absorption of UV light or with the use of potassium permanganate solution [KMnO4 (1.25 
g), Na2CO3 (6.25 g), water (250 mL)]. DMT-protecting groups were visualised by exposing 
TLC plates to fumes of HCl. Normal phase flash chromatography was carried out using 
silica gel (43 – 60 μm) supplied by Merck. Oligonucleotide synthesis was performed at the 
University of Southampton according to [190]. In brief, the oligonucleotides were 
synthesised on an Applied Biosystems Expedite synthesiser on solid support (Glen 
Research, CPG, pore size 500 Å) on a 1.0 μmol scale. The synthesis was carried out in the 
standard mode using 2-cyanoethyl-N,N-diisopropylphosphoramidites. The coupling time 
for incorporation of the modified nucleotides (0.02-0.04 M in DCM/ACN, 1:1, v/v) was 
increased from 40 s to 650 s. The coupling efficiency was monitored by UV absorption of 
the cleaved dimethoxytrityl cation. After the synthesis, the solid supports were dried and 
incubated overnight with 1 mL aqueous ammonium hydroxide at 55 °C. The deprotected 
and cleaved oligonucleotides were then lyophilised. The crude oligonucleotides were 
redissolved into 0.1 M TEAB buffer, pH 7, and partially purified by size exclusion on NAP-
25 columns (GE Healthcare). The column was equilibrated by passing through HPLC-grade 
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water (10 mL) under gravity. The DNA sample was loaded onto the column in a total 
volume of 0.5 mL. The first 1.3 mL was discarded thereby removing impurities formed 
during the deprotection step. Elution of the oligonucleotides was achieved by loading 
water (1 mL) onto the column. The collected oligonucleotides were further purified by 
preparative HPLC and subsequently characterised using MALDI-MS (performed by Julie 
Herniman, University of Southampton). The chemical characteristics of the 
oligonucleotides are summarised in Table 8. 
Table 8: Chemical characterisation of adamantane-modified oligonucleotides 
   mass [m/z] 
Oligo 
Modified 
nucleotide[a] 
Number 
of STR 
repeats 
Expected Observed[d] 
O1 4c[b] 1 8308.5 8594.4 
O2 4c 2 8524.6 8267.7 
O3 4c 3 8740.7 9135.7 
O4 4a[c] 1 8349.5 8334.4 
O5 4a 2 8592.7 8727.5 
O6 4a 3  8835.8  8822.1 
[a]Oligonucleotide sequence: 1 STR, 3'-TTT TTT TTU*TCT TTTCT TTTCT TTT TT-5'; 2 STRs, 3'-TTT TTT TTU*TCT 
TU*TCT TTTCT TTT TT-5'; 3 STRs, 3'-TTT TTT TTU*TCT TU*TCT TU*TCT TTT TT-5' 
[b]Long linker 
[c]Short linker 
[d]Due to difficulties in desalting the samples, it was not possible to get very accurate masses. 
 
3.6.1. Synthesis of propynoic acid (adamantan-1-yl methyl)-amide, 2a 
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Propiolic acid (112 μl, 1.8 mmol) was mixed with anhydrous DMF (4 mL) and the resultant 
solution cooled to 0 °C on an ice bath. To the chilled solution, EEDQ (540 mg, 2.2 mmol) 
was added followed by adamantane methylamine (321 uL, 1.8 mmol) drop-wise. The 
resultant mixture was stirred at 0 °C for 30 min then at room temperature overnight. After 
14 h, the reaction mixture was washed with 2.5 M HCl (3 x 20 mL) and dried over MgSO4. 
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The residue was absorbed onto the silica and then purified by flash chromatography (35 % 
EtOAc/Hexane, Rf = 0.50) to afford a white solid (276 mg, 71%).
1H NMR (600 MHz, MeOD) 
δppm: 1.51 (d, J=2.45 Hz, 6H, H-b), 1.66-1.69 (m, 3H, H-d), 1.72-1.79 (m, 3H, H-e), 1.97 
(br.s., 3H, H-c), 2.91 (s, 2H, H-6), 3.58 (s, 1H, H-1). 13C NMR (600 MHz, MeOD) δppm: 29.8 
(C-c), 35.5 (C-a), 37.9 (C-f), 41.3 (C-b), 52.2 (C-6), 75.9 (C-2), 78.3 (C-3), 155.1 (C-4). m/z 
(ESI) 218.1540 [M], C14H20NO requires 218.1545.  
 
3.6.2. Synthesis of pent-4-ynoic acid (adamanta-1-ylmethyl)-amide, 2b 
H
N
O
H
H
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f
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HBTU (688 mg, 1.8 mmol), 4-pentynoic acid (178 mg, 1.8 mmol), and DMAP (23 mg, 0.2 
mmol) were placed in an oven dried flask and purged with argon then suspended in 
anhydrous DMF (5 mL). To the resultant solution, Et3N (260 μL, 1.9 mmol) then 
adamantane methylamine (300 μL, 1.7 mmol) were added slowly drop wise. After 16 h 
stirring under argon, silica was added to the reaction mixture and the solvent was 
removed in vacuo. The crude material was absorbed onto the silica and purified by flash 
chromatography (35% EtOAc/Hexane, Rf = 0.51) to afford the title compound as a white 
solid (404 mg, 97%). 1H NMR (500 MHz, CDCl3) δppm: 1.49 (d, J=2.21 Hz, 6H, H-b), 1.57 - 
1.65 (m, 3H, H-d), 1.71 (d, J=12.30 Hz, 3H, H-e), 1.97 (br. s., 3H, H-c), 2.02 (t, J=2.52 Hz, 1H, 
H-1), 2.40 - 2.48 (m, 2H, H-4) 2.52 - 2.59 (m, 2H, H-5), 2.98 (d, J=6.31 Hz, 2H, H-8). 13C NMR 
(500 MHz, CDCl3) δppm: 15.27 (C-5), 28.27 (C-c), 33.74 (C-a), 35.57 (C-4), 36.98 (C-f), 40.24 
(C-b), 51.30 (C-8), 69.66 (C-2), 83.25 (C-3), 171.51 (C-6). m/z (CI) 246 [M+H]+, C16H24NO 
requires 245.35992. 
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3.6.3. Synthesis of hex-5-ynoic acid (adamantan-1-ylmethyl)-amide, 2c 
H
N
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H
H
H
d
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a
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c
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HBTU (1.2 g, 3.3 mmol) and DMAP (38 mg, 0.3 mmol) was placed in an oven dried flask, 
then purged with argon then suspended in anhydrous DMF (10 mL). To the resultant 
yellow solution, Et3N (470 μL, 3.3 mmol) was added followed by 5-hexynoic acid (370 μL, 
3.3 mmol) and adamantane methylamine (540 μL, 3.0 mmol) dropwise. After 18 h stirring 
at room temperature, the crude material was concentrated in vacuo and the resulting oil 
purified by flash chromatography (35% EtOAc/Hexane, Rf = 0.5) to afford the title 
compound as a colourless oil which solidified on standing. The solid was co-evaporated 
with MeOH (3 x 10 mL) to remove traces of triethylamine the dried under high vacuum 
(688 mg, 83%). 1H NMR (600 MHz, CDCl3) δppm: 1.48 (d, J=2.45 Hz, 6H, H-b), 1.63 (d, 
J=11.48 Hz, 3H, H-d), 1.72 (d, J=12.23 Hz, 3H, H-e), 1.85-1.91 (m, 2H, H-5), 1.97-1.99 (m, 
3H, H-c), 2.00 (t, J=2.64 Hz, 1 H, H-1), 2.28 (td, J=6.87, 2.64 Hz, 2H, H-4), 2.36 (t, J=7.43 Hz, 
2H, H-6), 2.97 (d, J=6.21 Hz, 2H, H-9).   13C NMR (600 MHz, CDCl3) δppm: 17.9 (C-4), 24.3 (C-
5), 28.3 (C-c), 33.7 (C-a), 35.3 (C-6), 37.0 (C-f), 40.3 (C-b), 51.1 (C-9), 69.4 (C-2), 83.7 (C-3), 
172.6 (C-7). m/z (CI) 260 [M+H]+, C17H25NO requires 259.19361. 
3.6.4. General procedure for Sonogashira cross-coupling 
To the adamantane methylamide (2 eq), 5-iodo-2'-deoxyuridine (1 eq), palladium tetrakis 
(0.2 eq to nucleoside) and CuI (0.1 eq to nucleoside) were added. The solids were 
thoroughly purged with argon. Anhydrous DMF (5 mL) was added via syringe followed by 
triethylamine (1.5 eq to adamantane methylamide). After stirring at room temperature 
overnight, the solvent was removed in vacuo. The resulting orange/brown oils were 
purified by flash chromatography (7% MeOH/DCM). The purified products were co-
evaporated with anhydrous MeOH and dried under high-vacuum to remove traces of 
triethylamine. 
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3.6.4.1. 5-(Propynoic acid (adamantan-1-ylmethyl)-amide)-2'-deoxyuridine, 3a 
HN
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The product was isolated as a white solid, (74 mg, 63%, Rf = 0.14) 
1H NMR (600 MHz, 
MeOD) δppm: 1.54 (br.s., 6H, H-b), 1.68 (d, J=11.11 Hz, 3H, H-d), 1.75 (d, J=11.29, 3H, H-e), 
1.97 (br.s., 3H, H-c), 2.25 (dt, J=13.32, 6,42 Hz, 2H, H-2'), 2.95 (br.s., 2H, H-11), 3.70-3.88 
(m, 2H, H-5'), 3.93-4.01 (m, 1H, H-4'), 4.36-4.46 (m, 1H, H-3'), 6.22 (t, J=6.21 Hz, 1H, H-1'), 
8.60, (s, 1H, H-6). 13C NMR (600 MHz, MeOD) δppm: 29.77 (C-c), 35.31 (C-a), 38.00 (C-f), 
41.22 (C-b), 41.99 (C-2'), 52.40 (C-11), 62.46 (C-5'), 71.89 (C-3'), 78.90 (C-8), 87.58 (C-1'), 
87.97 (C-7), 89.36 (C-4'), 97.26 (C-5), 148.67 (C-6), 150.87 (C-2), 155.71 (C-9), 164.49 (C-4). 
m/z 442.1956 [M-H]-, C23H29N3O6 requires 443.49286. 
3.6.4.2. 5-(Pentynoic acid (adamantan-1-ylmethyl)-amide)-2'-deoxyuridine, 3b 
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The product was isolated as a white solid (44 mg, 53%, Rf = 0.15) 
1H NMR (600 MHz, 
MeOD) δppm: 1.50 (d, J=2.30 Hz, 6H, H-b), 1.60 (d, J=11.29 Hz, 3H, H-d), 1.70 (d, J=12.05 Hz, 
3H, H-e), 1.90 (br.s., 3H, H-c), 2.18 (m, 1H, H-2'), 2.29 (ddd, J=13.55, 6.02, 3.39 Hz, 1H, H-
2''), 2.47 (t, J=6.96 Hz, 2H, H-9), 2.68 (t, J=6.96 Hz, 2H, H-10), 2.85-2.92 (m, 2H, H-13), 3.74 
(dd, J=11.95, 3.29 Hz, 1H, H-5'), 3.80 (dd, J=11.95, 3.11 Hz, 1H, H-5''), 3.94 (q, J=3.20 Hz, 
1H, H-4'),  4.40 (dt, J=6.21, 3.29 Hz, 1H, H-3'), 6.23 (t, J=6.59 Hz, 1H, H-1'), 8.25 (s, 1H, H-6). 
13C NMR (600 MHz, MeOD) δppm: 17.29 (C-10), 29.78 (C-c), 35.16 (C-9), 36.16 (C-a), 38.00 
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(C-f), 41.24 (C-b), 41.75 (C-2'), 52.15 (C-13), 62.66 (C-5'), 72.15 (C-3'), 73.56 (C-7), 86.94 (C-
1'), 89.14 (C-4'), 93.63 (C-8), 100.86 (C-5), 144.73 (C-6), 151.18 (C-2), 164.70 (C-4), 174.46 
(C-11). m/z (ESI) 472.2467 [M+H]+, C25H33N3O6 requires 471.5460. 
3.6.4.3. 5-(Hexynoic Acid (adamantan-1-ylmethyl)-amide)-2'-deoxyuridine, 3c 
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The product was isolated as a glassy colourless solid (83 mg, 30%, Rf
 = 0.03). 1H NMR (600 
MHz, MeOD) δppm: 1.47-1.53 (m, 6H, H-b), 1.65 (d, J=11.48 Hz, 3H, H-d), 1.73 (d, J=12.05 
Hz, 3H, H-e), 1.86 (quin, J=7.06 Hz, 2H, H-10), 1.94 (br.s., 3H, H-c), 2.21 (dt, J=13.60, 6.66 
Hz, 1H, H-2'), 2.30 (ddd, J=13.60, 6.16, 3.76 Hz, 1H, H-2''), 2.42 (m, 4H, H-9 & H-11), 2.86-
2.90 (m, 2H, H-14), 3.74 (dd, J=12.05, 3.20 Hz, 1H, H-5'), 3.82 (dd, J=12.05, 3.01 Hz, 1H, H-
5''), 3.93 (q, J=3.20 Hz, 1H, H-4'), 4.37-4.43 (m, 1H, H-3'), 6.24 (t, J=6.49 Hz, 1H, H-1'), 8,27 
(s, 1H, H-6). 13C NMR (600 MHz, MeOD) δppm: 19.66 (C9), 25.87 (C10), 29.87 (C-c), 35.25 (C-
a), 35.94 (C11), 38.15 (C-f), 41.42 (C-b), 41.84 (C-2'), 52.20 (C-14), 62.67 (C-5'), 72.07 (C-3'), 
74.01 (C-7), 86.99 (C-1'), 89.18 (C-4'), 94.27 (C-8), 101.10 (C-5), 144.46 (C-6), 151.31 (C-2), 
164.98 (C-4), 175.81 (C-12). m/z (ESI) 508.2433 [M+Na]+, C26H35N3O6 requires 485.5726. 
3.6.5. General procedure for Yoshikawa phosphorylation 
The nucleoside (0.2 mmol) and proton sponge (71 mg, 0.3 mmol) were placed in an oven-
dried flask then purged with argon before the addition of trimethyl phosphate (2.0 mL). 
Once the solids had dissolved, the resultant orange/brown clear solution was cooled to 
between -10 and -15°C on a salt ice bath and POCl3 (30 μL, 0.3 mmol) added via syringe. 
The disappearance of the nucleoside was followed by TLC (7% MeOH/DCM) or by 
analytical HPLC. Once the nucleoside was no longer detected, typically after 2-3 h, 
tributylammonium pyrophosphate solution (0.5 M, 2 mL anhydrous DMF) was added 
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followed by tributylamine (0.16 mL). After 45 min, the reaction was quenched by the 
addition of ice cold TEAB (0.1 M, 20 mL) and stirred at 0 °C for 30 min. Once warmed to 
room temperature, the aqueous solution was washed with ethylacetate (3 x 30 mL) then 
concentrated in vacuo. The crude material was purified by preparative HPLC to remove 
traces of the proton sponge. Fractions containing the phosphorylated material were 
pooled and the volume reduced to approximately 2 mL. The solution was filtered through 
using a 0.2 micron spin column the purified further by preparative ion exchange 
chromatography. Fractions containing the desired triphosphate were pooled, 
concentrated in vacuo then lyophilised overnight to give the triphosphates as 
triethylammonium salts.  
3.6.5.1. 5-(Propynoic acid adamantan-1-ylmethyl)-amide)-2'-deoxyuridine 5'-
triphosphate triethylammonium salt, 4a 
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The product was isolated as a white solid (121 mg, 13%). 1H NMR (600 MHz, D2O) δppm: 
1.26-1.31 (m, 9H, (CH3CH2)3N,  1.53 (br.s., 6H, H-b), 1.62-1.68 (m, 3H, H-d), 1.68-1.75 (m, 
3H, H-e), 1.97 (br.s., 3H, H-c), 2.39-2.51 (m, 2H, H-2'), 2.92-3.02 (m, 2H, H-11), 3.04-3.12 
(m, 2H, H-5'), 3.21 (q, J=7.34 Hz, 6H, (CH3CH2)3N), 4.25 (m, 1H, H-4'), 4.66 (m, 1H, H-3'), 
6.27 (t, J=6.59 Hz, 1H, H-1'), 8.43 (s, 1H, H-6). 13C NMR (600 MHz, D2O) δppm: 28.61 (C-c), 
34.55 (C-a), 36.96 (C-f), 39.74 (C-2'), 40.19 (C-b), 42.89 (C-5'), 52.16 (C-11), 71.12 (C-3'), 
87,07 (C-4' & C1'), 97.31 (C-5), 148.40 (C-6), 150.98 (C-2), 155.81 (C-4), 164.83 (C-9). 31P 
NMR (300 MHz, D2O) δppm: -22.00 (m, 1P, P-β), -10.45 (m, 1P, P-α), 1.26 (m, 1P, P-γ). m/z 
(ESI) 684.1129 [M+H]+, C23H32N3O15P3 requires 683.43256.  
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3.6.5.2. 5-(Pentynoic acid (adamantan-1-ylmethyl)-amide)-2'-deoxyuridine-5'-
triphosphosphate triethylammonium Salt, 4b 
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The product was isolated as a white solid (3 mg, 2%). 1H NMR (600 MHz, D2O) δppm: 1.34 (t, 
J=7.15 Hz, 9H, (CH3CH2)3N), 2.37-2.41 (m, 2H, H-2'), 2.48-2.54 (m, 1H, H-2''), 2.56-2.62 (m, 
2H, H-9), 2.71-2.76 (m, 2H, H-10), 2.80-2.87 (m, 2H, H-13), 3.19-3.25 (m, 6H, (CH3CH2)3N), 
3.68-3.72 (m, 2H, H-5'), 3.85-3.90 (m, 1H, H-4'), 4.24-4.30 (m, 1H, H-3'), 6.32 - 6.36 (m, 1H, 
H-1'), 8.21 - 8.25 (m, 1H, H-6). m/z (ESI) 712.1418 [M+H]+, C25H36N3O15P3 requires 
711.13593. 
3.6.5.3. 5-(Hexynoic Acid (adamantan-1-ylmethyl)-amide)-2'-deoxyuridine-5'-
triphosphate triethylammonium salt, 4c 
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The product was isolated as a white solid (9 mg, 5%). 1H NMR (600 MHz, D2O) δppm: 1.34 (t, 
J=7.25 Hz, 9H, (CH3CH2)3N), 1.47 (m, 6H, H-b), 1.60 (d, J=12.05 Hz, 3H, H-d), 1.70 (d, 
J=12.05 Hz, 3H, H-e), 1.8 -1.91 (m, 2H, H-10), 1.92 (br. s., 3H, H-c), 2.40 (m, 2H, H-2'), 2.47-
2.54 (m, 4H, H-9 & H-11), 3.00 (m, 2H, H-14), 3.08 (m, 2 H, H-5'), 3.54 (q, J=7.20 Hz, 6H, 
(CH3CH2)3N), 4.22 (m, 1H, H-4'), 4.65 (m, 1H, H-3'), 6.31 (t, J=6.87 Hz, 2H, H-1'),  8.12 (s, 
1H, H-6). 13C NMR (600 MHz, D2O) δppm: 18.62 (C-9), 24.09 (C-10), 28.61 (C-c), 34.12 (C-a), 
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35.11 (C-11), 36.96 (C-f), 39.27 (C-2'), 40.23 (C-b), 42.91 (C-5'), 49.39 (C-14), 71.36 (C-3'), 
72.51 (C-7), 86.24 (C-4'), 95.80 (C-8), 100.97 (C-5), 144.11 (C-6), 151.21 (C-2), 165.56 (C-4), 
176.76 (C-12). 31P NMR (300 MHz, D2O) δppm: -21.53 (br.s., 1P, P-β), -9.93 (br.s., 1P, P-α), 
1.28 (br.s., 1P, P-γ). m/z (ESI) 724.1418 [M-H]-, C26H38N3O15P3 requires 725.15158  
3.6.6. Phosphorylation via the Moffatt-Khorana approach 
3.6.6.1. Synthesis of 5-iodo-2'-deoxyuridine-5'-monophosphate, 10 
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To a chilled (-3 °C) suspension of iodouridine (250 mg, 0.7 mmol) and proton sponge (908 
mg, 4.2 mmol) in anhydrous acetonitrile (5 mL), POCl3 (260 μL, 2.6 mmol) was added. The 
resultant pale orange solution was stirred for 6 h at -3 °C at which point, TLC analysis 
indicated that the starting material had been consumed. The reaction mixture was 
quenched with 50 mL ice cold 0.1 M TEAB buffer. After stirring at room temperature for 1 
h, the solution was washed with ethylacetate (4 x 60 mL) and concentrated in vacuo.  The 
crude material was purified by preparative HPLC followed by ion exchange purification to 
yield the title compound as a colourless glassy solid (63 mg, 21%); (IPA:NH4OH:H2O, 6 : 1 : 
3; Rf starting material = 0.47; Rf product = 0.12). 
1H NMR (600 MHz, D2O) δppm: 1.29 (t, J=7.25 Hz, 
9H, (CH3CH2)3N)), 2.34-2.44 (m, 2H, H-2'), 3.21 (q, J=7.30 Hz, 6H, (CH3CH2)3N)), 4.04-4.11 
(m, 2H, H-5'), 4.19-4.22 (m, 1H, H-4'), 4.57 (dt, J=5.98, 3.13 Hz, 1H, H-3'), 6.29 (t, J=6.87 Hz, 
1H, H-1'), 8.28 (s, 1H, H-6). 13C NMR (600 MHz, D2O) δppm: 39.67 (C-2'), 65.29 (C-5'), 68.34 
(C-5), 71.68 (C-3'), 86.39-86.47 (C-1' & C-4'), 146.84 (C-6), 152.05 (C-2), 163.87 (C-4). 31P 
NMR (300 MHz, D2O) δppm: 1.76 (s, 1P, Pα). m/z (ESI) 432. 9298 [M-H]
-, C9H11IN2O8P
- 
requires 433.07102. 
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3.6.6.2. Synthesis of 5-iodo-2'-deoxyuridine-5'-phosphoromorpholidate, 11 
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10 was coevaporated with anhydrous DMSO (3 X 2 mL) then suspended in anhydrous 
DMSO (2 mL). To the solution, morpholine (30 μL, 308 μmol) was added followed by 2, 2'-
dithiopyridine (34 mg, 153 μmol) 5 min later. After a further 5 min, triphenylphosphine 
(41 mg, 153 μmol) was added causing the solution to turn from colourless to bright 
yellow. The solution was stirred at room temperature for 1 h after which TLC analysis 
suggested that the reaction has gone to completion. The title compound was precipitated 
from solution by the addition of NaI (0.1 M in acetone, 10 mL). The suspension was 
centrifuged at 4 °C, 3220 rcf for 10 min. The supernatant was discarded and replaced with 
fresh NaI solution. The pellet was resuspended into solution then recentrifuged to the 
pellet. This purification process was performed a total of three times. The pellet was 
subsequently dried under vacuum to remove traces of the solvent, giving rise to the title 
compound, a white solid, as the sodium salt. (14 mg, 70%); (IPA:NH4OH:H2O, 6 : 1 : 3; Rf 
0.41). 1H NMR (600 MHz, D2O) δppm: 2.38 (ddd, J=14.16, 8.23, 6.21 Hz, 1H, H-2'), 2.58 (ddd, 
J=14.07, 5.98, 1.98 Hz, 1H, H-2''), 3.05-3.12 (m, 4 H, H-6'), 3.73 (t, J=4.42 Hz, 4H, H-7'), 
4.00-4.09 (m, 2H, H-5'), 4.36 (m, 1H, H-4'), 4.77 - 4.83 (m, 1H, H-3'), 6.32 (t, J=8.40 Hz, 1H, 
H-1'), 8.21 (s, 1H, H-6'). 13C NMR (600 MHz, D2O) δppm: 39.34 (C-2'), 45.41 (C-6'), 65.01 (C-
5'), 67.55 (C-7') 70.44 (C-3'), 85.74-85.83 (C-1' & C-4'), 146.11 (C-6). 31P NMR (300 MHz, 
D2O) δppm: 8.43 (br.s., 1P, P-α). m/z (ESI) 501.9987 [M-H]
-, C13H18IN3O8P
- requires 
502.17610. 
3.6.7. Primer extension assay 
Samples containing 150 pmol of DNA oligonucleotide primer of sequence 5'-ATG GGA CTA 
ACT AAT CTT TGC TTA-3' and 170 pmol of template 5'-TAT TCC ATG TGA TAA GCA AAG ATT 
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AGT TAG TCC CAT-3' were added polymerase extension mix. The mix contained 1U Deep 
VentR exo
-, 1X ThermopolTM buffer (from New England Biolabs; provided with the enzyme) 
and 40 mM of natural dNTP nucleotides or dUTP derivatives in a total volume of 30 μL. 
The reaction mixtures were heated to 85 °C for 2 min to denature DNA duplexes, and 
incubated at 57 °C for 1.5 h to anneal and extend the primers, followed by immediate 
chilling on ice. The extension products were visualised by denaturing PAGE (18%) using 4–
5 μL aliquots of the mixtures denatured by addition of formamide and subsequent heating 
at 95 °C. The formamide denaturing solution was composed of: aqueous bromophenol 
blue (0.01%, 100 μL), ThermopolTM buffer (1 mL of 10X solution), formamide (8.8 mL) and 
aqueous EDTA (100 mM, 100 μL). 
 
3.6.8. Preparation of 18% polyacrylamide gels for electrophoresis 
To urea (6.3 g), 10x TBE buffer (Tris-Borate-EDTA buffer, 1.5 ml), formamide (2.75 ml) and 
bis-acrylamide (6 ml, 40%) were added. The resultant solution was heated at 37 °C and 
shaken at regular intervals over a 15 minute period. Once the urea had dissolved, 
ammonium persulfate solution (75 µL) and TEMED (N,N,N’,N’-tetramethyl 
ethylenediamine, 7.5 µL) were added to the preparation and thoroughly mixed. The gel 
solution was pipetted between glass plates and a comb added. The plates were 
maintained at 37 °C for 20 min to facilitate polymerisation. After this time they were 
allowed to cool to room temperature before being refrigerated. Primer extension 
products were visualised using ethidium bromide and recorded with a Ultra-Violet CCD 
camera. 
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3.6.9. Synthesis of 5'-(4,4'-dimethoxytrityl)-5-iodo-2'-deoxyuridine, 14 
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5-Iodo-2'-deoxyuridine (540 mg, 1.5 mmol) was co-evaporated with anhydrous pyridine (3 
x 4 mL). To the resultant residue, DMAP (9 mg, 0.07 mmol, 0.05 eq) was added and the 
solids purged with argon. The solids were dissolved in anhydrous pyridine (4 mL) then Et3N 
added (280 uL, 2.0 mmol, 1.4 eq). The mixture was allowed to stir for 10 min before the 
addition of DMT-Cl (671 mg, 2.0 mmol, 1.4 eq) in three equal portions over three hours. 
After an additional 1 h stirring, MeOH (1 mL) was added to consume any excess DMT-Cl. 
After stirring for an additional 15 min, the reaction mixture was concentrated in vacuo. 
The resultant residue was re-suspended in DCM (20 mL), washed with sat. NaHCO3 (3 x 20 
mL) and dried over MgSO4 then concentrated to give the crude material. Purification by 
flash chromatography (silica deactivated with Et3N; eluent 4% MeOH/DCM + 1% Et3N, Rf = 
0.46) afforded an off-white solid. The solid was co-evaporated with HPLC grade MeOH (2 x 
20 mL) and dried in vacuo overnight to remove any residual Et3N (629 mg, 68%). 
1H NMR 
(600 MHz, MeOD) δppm: 2.29-2.41 (m, 2H, H-2'), 3.34-3.35 (m, 2H, H-5'), 3.78 (s, 6H, OMe), 
4.04 (q, J=3.20 Hz, 1H, H-4'), 4.46 (dt, J=5.88, 2.80 Hz, 1H, H-3'), 6.22 (t, J=7.62 Hz, 1H, H-
1'), 6.86-6.89 (m, 4H, H-9'), 7.20-7.23 (m, 1H, H-15'), 7.30 (t, J=7.72 Hz, 2H, H-13'), 7.34-
7.37 (m, 4H, H-8'), 7.44-7.47 (m, 2H, H-14'), 8.19 (s, 1H, H-6). 13C NMR (600 MHz, MeOD) 
δppm: 41.61 (C-2'), 55.41 (OMe), 63.58 (C-5'), 68.74 (C-5), 72.56 (C-3'), 85.63 (C-1'), 86.52 
(C-4'), 87.17 (C-6'), 113.50 (C-9'), 127.22-130.21 (C-8', C-13', C-14' & C-15'), 135.35 (C-7' & 
C-12'), 144.40 (C-6), 149.95 (C-2), 158.78 (C-10'), 160.181 (C-4). m/z (ESI) 679.0895 
[M+Na]+, C30H29IN2O7 requires 679.4649. 
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3.6.10. Synthesis of 5'-(4,4'-dimethoxytrityl)-5-(propynoic acid-(Adamantan-1-
ylmethyl))-amide-2'-deoxyuridine, 15a 
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Prepared via the Sonogashira cross-coupling reaction described above. The crude material 
was purified twice by flash chromatography (silica-gel type-G/type-H, 15:1, w/w). The 
silica was neutralised with Et3N (1 mL per 5 g silica). Eluent 0-2.5% MeOH/DCM + 0.1% 
Et3N. The isolated product was co-evaporated with MeOH (3 x 15 mL) then dried in vacuo 
to remove the residual triethylamine. The title compound was isolated as an off-while 
solid (53 mg, 71%, (4% MeOH/DCM) Rf = 0.25). 
1H NMR (600 MHz, MeOD) δppm: 1.47 (d, 
J=2.26 Hz, 6H, H-b), 1.63 (d, J=11.48 Hz, 3H, H-d), 1.72 (d, J=12.05 Hz, 3H, H-e), 1.93 (br. s., 
3H, H-c), 2.41 (dd, J=13.65, 6.87 Hz, 1H, H-2'), 2.52 (ddd, J=13.74, 6.21, 3.01 Hz, 1H, H-2''), 
2.85-2.92 (m, 2H, H-11), 3.27 (dd, J=10.73, 3.01 Hz, 1H, H-5'), 3.38 (dd, J=10.82, 3.86 Hz, 
1H, H-5''), 3.75 (d, J=3.01 Hz, 6H, OMe), 4.10 (q, J=3.33 Hz, 1H, H-4'), 4.46 (dt, J=5.88, 2.99 
Hz, 1H, H-3'), 6.13 (t, J=6.49 Hz, 1H, H-1'), 6.83-6.89 (m, 4H, H-9' ), 7.18 (t, J=7.30 Hz, 1H, 
H-15'), 7.26-7.29 (m, 2H, H-13'), 7.30-7.34 (m, 4H, H-8'), 7.39-7.43 (m, 2H, H-14'), 8.25 (s, 
1H, H-6). 13C NMR (600 MHz, MeOD) δppm: 29.73 (C-c), 35.29 (C-a), 37.96 (C-f), 41.21 (C-b), 
42.44 (C-2'), 47.86 (C-11), 52.32 (s), 53.59 (s), 55.77-55.79 (OMe), 64.93 (C-5'), 72.94 (C-
3'), 78.35 (C-7), 88.25-88.70 (C-1', C-4', C-6', & C-8), 97.20 (C-5), 114.32 (C-9'), 127.98-
131.41 (C-8', C-13', C-14' & C-15'), 136.62-137.13 (C7' & C-12'), 146.14 (C-6), 147.68 (C-2'), 
155.30 (C-9), 160.22 (C-10'), 164.47 (C-4). m/z (ESI) 746.3385 [M+H]+, C44H47N3O8 requires 
745.85928. 
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3.6.11. Synthesis of 5'-(4,4'-dimethoxytrityl)-5-(pentynoic acid-(adamantan-1-ylmethyl))-
amide-2'-deoxyuridine, 15b 
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Prepared as 15a. The product was isolated as a white solid. (84 mg, 56% isolated yield, (4% 
MeOH/DCM) Rf = 0.28).
 1H NMR (600 MHz, MeOD) δppm: 1.43-1.48 (m, 6H, H-b), 1.56 (d, 
J=11.67 Hz, 3H, H-d), 1.66 (d, J=12.23 Hz, 3H, H-e), 1.87 (br.s., 3H, H-c), 2.25 (td, J=7.25, 
3.01 Hz, 2H, H-2'), 2.36-2.43 (m, 2H, H-13), 2.79 (m, 2H, H-9), 2.92 (m, 2H, H-10), 3.28 (dd, 
J=10.73, 2.82 Hz, 1H, H-5'), 3.33-3.37 (m, 1H, H-5''), 3.70-3.76 (s, 6H, OMe), 4.01-4.06 (m, 
1H, H-4'), 4.49-4.54 (m, 1H, H-3'), 6.21 (t, J=6.59 Hz, 1H, H-1'), 6.81-6.87 (m, 4H, H-9'), 
7.17-7.22 (m, 1H, H-15'), 7.25-7.31 (m, 2H, H-13'), 7.35 (d, J=8.47, 4H, H-8'), 7.44-7.48 (m, 
2H, H-14'), 8.09 (s, 1H, H-6). 13C NMR (600 MHz, MeOD) δppm: 29.75 (C-c), 35.16 (C-a), 
38.00 (C-f), 41.21 (C-b), 42.18 (C-2'), 52.21-53.57 (C-9, C-10, & C-13), 55.85 (OMe), 64.84 
(C-5'), 72.74 (C-3'), 73.19 (C-7), 87.23 (C-1'), 89.68 (C-4'), 94.12 (C-8), 101.64 (C-5), 114.38 
(C-9'), 127.98-131.43 (C-8', C-13', C-14' & C-15'), 136.87-137.18 (C-7' & C-12'), 143.97 (C-
6), 151.05 (C-2), 160.20 (C-10'), 164.74 (C-4), 174.19 (C-11). m/z (ESI) 796.3518 [M+Na]+, 
C46H51N3O8 requires 773.36762. 
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3.6.12. Synthesis of 5'-(4,4'-dimethoxytrityl)-5-(hexynoic Acid-(adamantan-1-ylmethyl))-
amide-2'-deoxyuridine, 15Cix 
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Prepared as 15a. (145 mg, 34% isolated yield). 1H NMR (600 MHz, CDCl3) δppm: 1.43-1.48 
(m, 6H, H-b), 1.56 (d, J=11.67 Hz, 3H, H-e), 1.66 (d, J=12.23 Hz, 3H, H-d), 1.87 (br.s., 3H, H-
c), 2.25 (td, J=7.25, 3.01 Hz, 2H, H-2'), 2.36-2.43 (m, 2H, H-13), 2.79 (dd, J=13.36, 6.59 Hz, 
2H, H-9), 2.92 (dd, J=13.36, 6.59 Hz, 2 H, H-10), 3.28 (dd, J=10.73, 2.82 Hz, 1H, H-5'), 3.33-
3.37 (m, 1H, H-5''), 3.70-3.76 (s, 6H, OMe), 4.01-4.06 (m, 1H, H-4'), 4.49-4.54 (m, 1H, H-3'), 
6.21 (t, J=6.59 Hz, 1H, H-1'), 6.81-6.87 (m, 4H, H-9'), 7.17-7.22 (m, 1H, H-15'), 7.25-7.31 (m, 
2H, H-13'), 7.35 (d, J=8.47, 4H, H-8'), 7.44-7.48 (m, 2H, H-14'), 8.09 (s, 1H, H-6). 
 
 
 
 
 
 
 
 
                                                             
ix
  Synthesised by Xiu Yao. 
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4 PHOTOCAGING OF 5-AZACYTIDINE FOR DRUG 
DELIVERY PURPOSES 
 
4.1. Summary 
This chapter is concerned with the synthesis of photocaged derivatives of azacytidine. 
Azanucleosides are a class of cytosine analogues which are used to treat cancers and 
bone-marrow disorders that arise due to aberrant methylation of particular regions of the 
genome. Hypermethylation of these regions abnormally enhances the function of some 
genes, the oncogenes, or cause others, tumour-suppressor genes, to lose function or be 
‘silenced’.45 This can enable proliferation of certain cancers and the onset of disease. 
Azanucleosides are able to reverse aberrant hypermethylation through two mechanisms. 
Firstly, by inducing a hypomethylated state through inhibition of DNA methyltransferase 
(DNMT), the enzyme which catalyses DNA methylation. Secondly, through direct 
incorporation into replicating DNA and RNA triggering cell death. To date, two drugs have 
been licensed for clinical use.191,192 However, they are associated with extreme toxicity 
and side-effects. It is envisaged that adverse effects could be mitigated with greater 
spatial and temporal control over drug release. Here, the synthesis of azacytidine 
analogues, whose biological activity is masked by photolabile protecting groups, is 
described. In cellular assays it was observed that biological activity of azacytidine was 
restored upon irradiation with UV light.   
4.2. Introduction 
4.2.1. DNA Methyltransferases and their Inhibition by Azanucleosides 
DNA methylation is one of several mechanisms through which the activity or function of a 
gene can be altered without change to its primary nucleotide sequence.193 This form of 
modification is termed epigenetic, and plays a crucial role in the development and 
function of many organisms. In humans and other mammals, DNA methylation occurs only 
on cytosines that precede a guanosine in the DNA sequence i.e. at CpG dinucleotides 
(where the ‘p’ stands for the phosphodiester bond between the cytosine and the guanine, 
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and indicates that they are next to each other in the DNA strand).45 The distribution of 
these dinucleotides is far less random than one would expect. Within the genome, they 
are typically found clustered in small stretches of DNA termed CpG islands.45,194 CpG 
islands are defined as regions of at least 500 base pairs in length with a GC content greater 
than 55%,43,195 and are often found within the promoter regions of a gene. These are 
regions where transcription begins.194 In a normal cell, CpG islands which are associated 
with a promoter region, are unmethylated which enables the DNA to be recognised by 
transcription factors and associated proteins.194,196 Conversely, CpG dinucleotides which 
are found outside of promoter regions are heavily methylated.196 It is thought that the 
methyl groups prevent the binding of proteins and cofactors necessary for transcription, 
and thus renders the DNA transcriptionally inert or ‘silent’.194 Heavy methylation of these 
regions serves as a protective measure to prevent the transcription of regions which may 
contain nucleotide repeat sequences (as described in chapter 3), inserted viral sequences, 
and transposons (DNA sequences that have moved from their usual location into a new 
region of the genome), all of which could prove lethal to a cell.45,197 Consequently, failure 
to regulate DNA methylation and the occurrence of aberrant methylation patterns, can 
lead to the over- or under-expression of particular proteins and is associated with several 
human diseases including psychiatric diseases, diseases of the immune system and the 
onset of cancer.44,198 
 The link between DNA methylation patterns and cancer was established over 20 
years ago. Seminal studies showed that the occurrence of methylated cytosine throughout 
the genome of tumour cells was significantly lower than levels observed in normal 
cells.199,200 It was soon demonstrated, and is now well accepted, that many cancers are 
characterised by hypomethylation in regions where most CpG dinucleotides should be 
methylated.199 In addition, hypermethylation of CpG islands in gene promoter regions is 
also a common trait.45,201 Loss of DNA methylation can ultimately lead to the transcription 
of normally silent regions of the genome and the expression of potentially harmful 
proteins. Conversely, methylation of CpG islands is associated with silencing of 
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transcription and the inactivation of genes, including tumour suppressor genes which 
would ordinarily counteract the proliferation of cancer cells.201  
Methylation of cytosine in a CpG context is catalysed by DNA methyltransferase 
(DNMT) enzyme. There are five DNMT isoforms: DNMT1, DNMT2, DNMT3a, DNMT3b and 
DNMTL.192 However, only DNMT1, 3a and 3b are involved in the methylation of 
DNA.44,198,192 DNMT1 is a maintenance methyltransferase, methylating newly synthesised 
DNA strands after each round of DNA replication.44,198,192 This isoform is thought to be 
responsible for maintaining abnormal promoter methylation.45 DNMT3a and DNMT3b are 
de novo methyltransferases, initiating methylation of unmethylated DNA in early 
embryonic development.44,198,192,194 The catalytic mechanism of DNMT is schematically 
represented in Figure 50A.   
 
 
 
 
 
 
 
 
 
 
DNMTs transfer a methyl group from S-adenosyl-methionine (SAM), an enzyme co-factor, 
to the C5 position of the pyrimidine ring of cytosine. The reaction proceeds via a 
nucleophilic attack on position C6 of the pyrimdine ring by a sulphur atom of a cysteine 
residue located within the active site of the enzyme. This results in an increase in the 
Figure 50: (A) Mechanism of DNA methylation by DNA methyltransferase (DNMT). (B) Mechanism of DNMT 
inhibition by azanucleosides. The additional nitrogen at C5 prevents β-elimintation and reformation of the 
C5-C6 double bond. This results in a permanent covalent bond between the nucleoside and the enzyme. 
The DNA-DNMT adduct triggers apoptosis. Abbrevations: Ado, adenosyl; Met, methionine; SAH, S-
adenosyl-L-homocysteine. Adapted from [191]. 
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electron density at position C5 and concomitant attack on the methyl group of SAM.202 
Abstraction of the proton from N3 followed by β-elimination then allows reformation of 
the C5-C6 double bond and release of the enzyme and DNA with methylated cytosine.  
Given that aberrant DNA methylation is associated with many diseases and 
cancers,203 DNMT represents a valid therapeutic target. The main difference between 
genetic mutations which involve alteration of the nucleotide sequence of the genome, 
and epigenetic processes, is that the former is irreversible whilst the latter is potentially 
reversible.43,45  Indeed several chemical agents have been shown to inhibit or reverse DNA 
methylation and effectively reactivate genes which have undergone epigenetic 
silencing.6,9,14,17 DNMT inhibitors fall into two categories; nucleoside analogues which are 
typically derivatives of cytidine and thus can be incorporated into genetic material, and 
non-nucleoside analogues which are structurally different from cytidine and elicit their 
effects through alternative mechanisms. To date, two nucleoside analogues have been 
approved for clinical use against certain bone-marrow disorders and leukaemia: 5-
azacytidine (Vidaza™, azacytidine) and 5-aza-2'-deoxycytidine (Dacogen™, decitabine). 
These compounds are nucleoside analogues in which the carbon atom at position 5 of the 
pyridimidine ring is replaced by a nitrogen atom and linked to a ribose and deoxyribose 
sugar, respectively (Figure 50B). Once administered, these analogues are transported into 
cells by the same facilitated nucleoside transport system that carries uridine and 
cytidine.205 The intracellular nucleosides undergo three successive phosphorylation 
reactions to their triphosphorylated active forms. Azacytidine is incorporated into both 
RNA and DNA (after deoxy-conversion), whilst the decitabine analogue is only 
incorporated into DNA.44 The nucleosides replace cytidine during DNA and RNA replication 
mediated by polymerase enzymes. As a result, they are only effective in cells which are 
actively dividing and have little effect on cells which are non-dividing or in the resting 
phase of their life cycle.44,205 This imparts some specificity towards cancerous cells which 
typically proliferate at a greater rate than normal cells.206 Once incorporated into DNA, the 
analogues which are located within the CpG islands are recognised by DNMT as though 
they were the natural nucleoside and react in a similar fashion to cytidine. However, due 
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to the presence of the nitrogen at C5, the β-elimination step cannot occur leaving an 
irreversible covalent bond between C6 and the catalytic cysteine of the enzyme (Figure 
50B). Sequestration of the enzyme by the DNA results in a rapid loss of activity and a 
reduction in methylation with each cycle of replication.202 This ultimately leads to a 
hypomethylated state and reactivation of silenced genes including those which were 
selected for during tumorigenesis. Furthermore, the presence of the DNMT-DNA adduct 
itself is thought to be cytotoxic and mutagenic triggering DNA repair with subsequent 
degradation of the DNMT or apoptosis.43,44 Azacytidine is also able to elicit cytotoxic 
effects through incorporation into RNA and interfering with protein and nucleic acid 
synthesis.202,205  
Although azanucleosides exhibit some specificity towards cancerous cells, they are 
associated with some severe side-effects, indicating that they adversely affect other 
cellular processes. These non-specific affects have been attributed to the incorporation of 
the nucleoside into rapidly dividing, normal cells of the body. For instance, myelotoxicity, 
the most acute side-effect, is due to the adverse affects on bone marrow and blood cell 
production. Such side effects have limited the clinical use of azanucleosides.45 
 
It is envisaged that the toxicity of azanucleosides could be mitigated by having greater 
spatial and temporal control over drug release. Essentially, by constraining drug release to 
cancerous tissue and minimising the exposure of healthy tissue, the side-effects 
associated with azanucleosides could be reduced. Such control could be achieved by 
administration of a ‘caged’ derivative of azanucleosides with subsequent release of the 
active drug being mediated by UV light. 
 
4.2.2. Principles of Photocaging 
Caged compounds are those which have been rendered biologically inert by chemical 
modification of a key functional group with a photolabile protecting group.207,208 
Restoration of the biological activity, or ‘uncaging’, is achieved by irradiation with light of a 
particular wavelength resulting in photolysis and removal of the photolabile group.207,208 
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This results in a concentration spike of the unmodified active molecule which can proceed 
to exert its biological affect. Within the biological arena, light is often considered to be the 
ideal trigger as it is orthogonal to the activity of the cell.207,209 With the exception of highly 
specialised cells such as those of the eye or specific plant cells, cells do not react to 
light.208 Consequently, uncaging of bioactive molecules can be achieved specifically. 
Furthermore, as light is able to penetrate cell membranes, cellular processes can be 
directly regulated by uncaging within intracellular compartments. Similarly, uncaging can 
also be triggered in the extracellular space.210 With the use of specialised equipment, such 
as lasers, it is possible to manipulate light very precisely.208,211 For instance, light can be 
emitted as a focused beam and used to illuminate very specific areas of the cytosol or 
tissue, or conversely, applied to entire cells and larger areas of the body. Light can also be 
modulated with respect to time and amplitude.208 It can be applied in a single burst 
resulting in rapid uncaging, or pulsated for gradual uncaging of a compound. In essence, 
using light to uncage an azanucleosides would enable one to control the location, time 
and dosage of the drug once it has entered the cell. 
The classical strategy towards the design and synthesis of caged bioactive 
compounds begins with the identification of functional groups which are crucial to their 
activity.24,212  Modification of these positions with a photolabile protecting group should 
prevent the formation of key interactions and thus render them biologically inert. 
Typically, the activity of a bioactive molecule is dependent upon an amino, hydroxyl, 
carboxylate or phosphate group.212 Therefore, the most common conjugation strategies 
exploit the nucleophilicity of these groups towards an electrophilic aliphatic centre. Such 
strategies are straightforward, have fair to excellent yields and can be applied in mild 
conditions; important factors when dealing with sensitive bioactive compounds.212 The 
solubility of the caged compound is also a factor which must be considered. In order to be 
used in an in vivo study, the caged compound must be soluble in aqueous conditions. This 
is traditionally quite difficult to achieve as photolabile protecting groups are generally 
hydrophobic chromophores.17,208,213 Thus when conjugated to a bioactive compound 
which is only moderately soluble to begin with, the resultant caged compound may only 
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be sparingly soluble.208 If the caged compound is to be used intracellularly, then its 
solubility will also dictate the ease with which it is taken up by the cell. For instance, in 
order to diffuse through the cell membrane passively, it must be sufficiently hydrophobic. 
Thus there is a fine line between the solubility required for use in physiological conditions 
and the hydrophobicity required for passive cellular uptake. This hurdle may potentially 
be overcome if the caged compound is able to exploit protein channels that exist in the 
cell membrane and be taken up by active or facilitated transport. The photochemical 
properties of the photolabel are also important. Ideally, uncaging should occur at 
wavelengths which are not too short (>300 nm) in order to prevent damage to the cell.212 
Additionally, the by-products of uncaging, which are released stoichiometrically,209 should 
be non-toxic. Several photolabile protecting groups meet these criteria. 
o-Nitrobenzyl (NB) alcohol derivatives are the most widely used photo-labile 
protecting groups for bioactive molecules.207,212 The structure of o-nitrobenzyl and some 
commonly used derivatives are is shown in Figure 51. Their popularity is attributed to 
their commercial availability and the ease with which they can be introduced into 
bioactive molecules.  
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Figure 51: Commonly used o-nitrobenzyl photolabile protecting groups. 
These are typically introduced as the chloroformate thus can be used to protect amines or 
alcohols as carbamates, carbonates and esters. Furthermore, their physical and 
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photochemical properties can be readily tuned. For instance, adding two methoxy groups 
to the aromatic ring of nitrobenzyloxycarbonyl (NBOC) gives rise to a 6-
nitroveratryloxycarbonyl (NOVC,) derivative, which absorbs at longer wavelengths thus is 
of more use in biological applications.209 Indeed, NOVC is undoubtedly the most popular 
photolabel in this class of compounds. The water solubility of NB derivatives can be 
increased by the introduction of a carboxylic acid functional group to the benzylic carbon 
giving rise to α-carboxy-3-nitrobenzyl (CNB). Although preparation of CNB is marginally 
more complex (the synthesis is achieved in four synthetic steps),214,215 it is particularly 
valuable for the caging of carboxylate functionalities, especially those of 
neurotransmitters.216,210,212 Indeed, several CNB-caged neurotransmitters are now 
commercially available. Furthermore, CNB-caged neurotransmitters have been shown to 
have accelerated rates of uncaging and higher quantum yields compared to their NB- and 
NPE-caged derivatives.212,210,208 The [2-(2-nitrophenyl)ethoxy]carbonyl (NPE) photolabel is 
the α-substituted derivative of NB. NPE caged compounds have also been shown of have 
higher rates of uncaging compared to NB caged compounds.212,217 
4.2.3. Photodynamic Therapy 
Precedence for the activation of prodrugs by UV light has been demonstrated in the field 
of photodynamic therapy (PDT). PDT is a photochemical approach in which a light-
activatable chemical, termed a photosensitizer (PS), and light of the appropriate 
wavelength are utilised to impart cytotoxicity.218 A schematic representation of how PDT 
might be used in a clinical setting is shown in Figure 52. 
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Figure 52: Schematic representation of photodynamic therapy (PDT). The photosensitizer (PS, green) is a 
photoactivatable chemical which can act as both an imaging and chemotherapeutic agent. Upon 
administration (1), the PS enters the systemic circulation and is widely distributed (2). The PS preferentially 
accumulates within the tumour tissue (3). Alternatively, the PS can be formulated for topical administration 
to enable direct application to diseased tissue. Irradiation of the tumour or a specific area results in 
fluorescence emission which enables the tumour to be clearly located. Additionally, a singlet oxygen (PS*) is 
generated which results in cytoxicity. Adapted from [218]. 
In essence, PDT involves the administration of a PS which localises to a target cell or 
tissue. Illumination of a specific anatomical region with UV light results in the activation of 
the PS and localised cytotoxicity. The putative cytotoxic agent in PDT is singlet oxygen.219 
The photochemical reaction through which the singlet oxygen is generated is 
schematically represented in Figure 53. In brief, following absorption of light of an 
appropriate wavelength, the PS is exited from its ground state to an excited singlet state 
(A). From here, the PS can either relax back down to the ground state by emitting a 
fluorescent photon (B) or enter the excited triplet state (C). Again, there is the opportunity 
for PS to relax back to the ground state by emitting a phosphorescent photon (D). 
Alternatively, the PS can transfer energy to other molecules via a radiationless transition. 
219,220 The transfer of an electron to a substrate molecule such as the cell membrane, 
results in the formation of free radicals. These  radicals can in turn react with oxygen to 
produce oxygenated byproducts (Type I PDT) (F).221 Alternatively, the energy can be 
transferred through a direct reaction with oxygen (Type II PDT) (E).221 In doing so, the spin 
of one of the outermost electrons is inverted resulting in the highly reactive singlet oxygen 
which reacts with different substrates resulting in toxicity (F).219,221 Due to the high 
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reactivity and extremely short half-life (<0.04 μs) of singlet oxygen, cytotoxicity is limited 
to cells within a reaction sphere of approximately 0.02 μm.222 Hence a photodynamic 
reaction will only occur in cells or tissues which contain photosensitizer, molecular oxygen 
and are illuminated with light of the appropriate wavelength.  
 
Figure 53: Simplified Jablonski diagram showing the mechanism of action of photodynamic therapy (PDT).  
When the PS is illuminated by light of a particular wavelength, it is excited from the ground state to the 
singlet state (A). Energy can be released in the form of fluorescence emission (B) returning it to the ground 
state. Alternatively, it can enter the excited triplet state (C). From here, energy can be released in the form 
of phosphorescence (D) or transferred to other molecules (E). The energy can be transferred to oxygen 
resulting in singlet oxygen which is highly cytotoxic (F). Adapted from [219]. 
Clinically, PDT has been used to treat a variety of conditions. These include the treatment 
of age-related macular degeneration;221 the leading cause of blindness in the elderly,223 
and a number of different dermatological conditions.224 The most notable application of 
PDT is in the treatment of malignant tumours.221 
The chemical structures of some PSs which have been legalised for the treatment 
of cancer are shown in Figure 54. The drugs are typically administered intravenously 
directly into systemic blood supply. However, some such as 5-aminolevulinic acid (Figure 
54), have been formulated to enable topical administration directly onto the skin.225 There 
is evidence that the drugs preferentially accumulate in tumour cells and are cleared from 
normal cells at a faster rate.220 The reason for this selectivity is not fully understood, but 
has been attributed to the reduced lymphatic drainage and increased vascular 
permeability of tumours.209,212 During surgical interventions, the flurorescent properties of 
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PSs can be used to help differentiate between healthy and cancerous tissue, and provide 
an additional means of achieving selectivity. 
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Figure 54: Molecular structure of some photosensitizers used in clinical photodynamic therapy. [225,226] 
On a cellular level, cytotoxicity is attributed to damage caused to a number of different 
organelles. The chemical structure of a PS dictates which organelle is targeted.220 For 
instance, lipophilic and anionic PSs typically localise to membranes (including plasma, 
mitochondrial, endoplasmisc reticulum and nuclear) where they alter membrane 
stability.220 Conversley, hydrophilic PSs preferentially target lysosomes to promote the 
release of hydrolytic enzymes into the cytosol, which are leathal to cells.220 Cationic PSs 
accumulate within the mitochondria due to the electrochemical gradient across the 
mitochondrial membrane.219,220 The net effect of these actions is the promotion of cell 
death via apoptosis or necrosis. On a broader level, tumour destruction can also be 
achieved by damaging the vascular supply of the tumour. The viability of a tumour is 
dependent on its ability to establish and mantain a blood supply which can provide it with 
nutrients.221 PDT has been shown to trigger constriction of the blood vessels which 
ultimately leads to tumour hypoxia and restricts growth.  
The efficacy of PDT is largely determined by the efficiency with which light penetrates 
the target tissue.227 This is in turn determined by the wavelength of the light. In general, 
longer wavelengths of light penetrate tissue more efficiently than shorter wavelengths.227 
A dramatic decrease in light penetration is observed at approximately 580 nm which 
corresponds to the absorbance band of haemoglobin.228 This is followed by a rapid rise in 
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light penetration between 600-680 nm to a gradual plateau between 700 and 800 nm. 
227,228 In essence, the greatest amount of light penetration is observed within the red 
region of the electromagnetic spectrum. As a result, red light is typically used for most 
PDT applications. The exact wavelength is determined by the absorption maxima of the 
PS. 
The depth with which light is able to penetrate tissue also instrumental in PDT efficacy. 
This parameter is determined by the absorption and scattering properties of the tissue.220 
As photons pass through tissue, a proportion is reflected from surface of the tissue whilst 
the remainder scattered within the tissue until they can escape or are absorbed by a 
chromophore.219 The extent of absorption or scattering is tissue dependent.229 For 
instance, liver tissue is characterised by poor light penetration due to its high haemoglobin 
content.220 Conversely, brain tissue has been shown to be more light scattering.220,228 
Wavelengths of light less than 800 nm are scattered with greater efficiency as they are 
equal to or less than the size of many macromolecules.220 Hence at longer wavelengths, 
light penetration increases due to decreased scattering. The relationship between the 
wavelength of light and penetration depth is described by the attenuation coefficient. 
Attentuation is the loss of mechanical energy of waves as they pass through a tissue.230 An 
inverse relationship exists between frequency (or wavelength) of a wave and penetration 
depth; the higher the frequency of a wavelength the greater the attenutation, that is, loss 
of mechanical energy. Hence higher frequency light has less penetration due to greater 
attenuation. As a result, high frequency light cannot be used to probe deep tissue or 
structures.230 A penetration depth of 2-4 mm is considered deep light penetration and this 
is typically achieved using wavelengths of 600-1000 nm.231 
 
4.2.4. Design of Photo-Caged Azacytidine Derivatives 
Based on the classical design strategy described above, it was hypothesised that the most 
effective way to cage azanucleosides would be to place the photolabile protecting group 
directly on the nucleobase. In terms of chemical synthesis, it was thought that the 
simplest way to achieve this would be to place the photolabile group on the exocyclic 
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amine at C4, by taking advantage of its nucleophilic character. Whilst modification in this 
manner would almost certainly render azanucleosides biologically inert, other key cellular 
process might also be affected.  
 The cytotoxicity and activity of azanucleosides is dependent upon their ability to 
translocate the plasma membrane of a cell. In human cells, the influx and efflux of 
nucleosides is mediated by nucleoside transporter channels. These can be subdivided into 
two classes depending on their mode of action: sodium-dependent (concentrative) or 
sodium-independent (equilibrative). The former, which are limited to specialised cells 
including leukemic cells, generally mediate the influx of nucleosides via an active process 
that requires ATP; hence can carry nucleosides against a concentration gradient.232,233 The 
latter, which are found in all cells, mediate both the influx and efflux of nucleosides in a 
process that is independent of ATP but dependant on a transmembrane concentration 
gradient.233,234 Azanucleosides, which are themselves nucleoside analogues, are readily 
transported by concentrative channels, and to a lesser extent, the equilibrative 
channels.235 Hence, it has been shown that the additional nitrogen in the pyrimidine ring 
has little effect on the ability of the nucleoside to act as a substrate for the channel. To the 
best of our knowledge, there have been no nucleoside transporter studies which utilise 
nucleosides with a sizeable base-modification. The majority of the research is centred on 
the transport of antiretroviral nucleoside analogues for the treatment of HIV. This class of 
drugs are characterised by the absence of the 3'-hydroxyl on the deoxyribose sugar.236 
Whilst this is only a slight modification, studies have shown that it is significant enough to 
reduce or completely preclude the transport of some analogues and thus reduce their 
efficacy. For instance, a study by Pastor-Anglada et al.,237 compared the abilities of 
cytidine, 2'-deoxycytidine and 2',3'-dideoxycytidine (ddC, Zalcitabine; antiretroviral drug), 
to interact with and translocate concentrative transporters. It was observed that the 
interaction of ddC with the transporter was reduced by two orders of magnitude 
compared to cytidine and 2'-deoxycytidine. This study and others illustrated the 
importance of the 2'-hydroxyl functionality in influencing the transportability of 
nucleoside analogues.237,238 Interestingly, the absence of the 2' and 3' hydroxyl group can 
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render some nucleoside analogues sufficiently hydrophobic to enable simple passive 
diffusion across the plasma membrane. This form of diffusion occurs without the aid of a 
protein channel or the expenditure of ATP. Simple diffusion has been observed for AZT,239 
d4T,240 and ABC241 (Figure 55). Based on the studies described above, it was hypothesised 
that photocaged derivatives of azanucleosides would be able to translocate the 
membrane via a transporter provided the sugar moieties were unaltered. Furthermore, 
the photolabile protecting group may render azanucleosides sufficiently hydrophobic to 
translocate the membrane passively. 
O
N3
HO
N
NH
O
O
O
HO
N
NH
O
O
AZT d4T ABC
N
N
HN
H2N
CH2OH
 
Figure 55: Antiretroviral drugs which are able to translocate the plasma membrane by simple passive 
diffusion. Abbreviations: AZT, Zidovudine, 3'-azido-3'-deoxythymidine; d4T, Stavudine, 2',3'-didehydro-3'-
deoxythymidine; ABC, Abacavir, [4R-(2-Amino-6-cyclopropylamino-purin-9-yl)-cyclopent-2-en-1S-yl]-
methanol. 
 
The effect of the photolabile protecting group on intracellular metabolism of the 
azanucleosides was also considered. All nucleoside analogue drugs are essentially inactive 
prodrugs which are dependent upon intracellular phosphorylation for their activity.242,243 
The nucleosides must be metabolised to the active triphosphate in order to be 
incorporated into cellular DNA or RNA by the action of polymerase enzymes. Once 
incorporated into the genetic material they can interfere with DNA replication or protein 
synthesis. Hence the efficacy of nucleoside analogue drugs is partly determined by the 
efficiency with which they are phosphorylated. Nucleoside triphosphorylation occurs in 
three sequential steps, each of which is catalysed by a different enzyme (Figure 56). 
Activation to the monophosphate, the initial rate limiting step, is mediated by nucleoside 
kinase enzymes.243 The exact nature of the enzyme is determined by whether a nucleoside 
possesses a ribose or deoxyribose sugar.244 For azacytidine, this step is catalysed by 
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uridine-cytidine kinase (UCK),245 whilst for decitabine this step is catalysed by 
deoxycytidine kinase.246  
 
 
 
UCK, which belongs to the nucleoside monophosphate kinase family of enzymes, 
exclusively catalyses the phosphorylation of pyrimidine ribonucleosides.242 It is 
responsible for the phosphorylation of uridine and cytidine to their respective 
monophosphates, however, can also phosphorylate cytotoxic ribonucleoside analogues 
that are used as chemotherapeutic agents.242  The specificity of UCK has been attributed 
to an induced fit enzyme-substrate interaction which is triggered by the binding of the 
sugar moiety to the active site. The hydrogen-bonding network of a ribose sugar and 
pyrimidine ring of cytidine bound to human UCK are shown in Figure 57. It has been 
proposed that the sugar moiety binds first resulting in several hydrogen-bonds between 
the hydroxyls and the amino acids that line the active site. It is thought that the hydrogen-
bonds between the 2'-hydroxyl and the guanidinium proton (η1) of arginine and the 
oxygen atom (δ2) of aspartic acid (Figure 57A), endow UCK with specificity for ribose 
Figure 56: Intracellular metabolism of azanucleosides. The nucleosides enter the cell through protein pores 
(shown in orange). After cellular uptake, azacytidine is monophosphorylated by uridine-cytidine kinase, 
whilst 5-aza-2'-deoxycytidine is phosphorylated by deoxycytidine kinase. The monophosphates are 
subsequently phosphorylated to the active triphosphate, which is then incorporated into either DNA or 
RNA. Abbreviations: NMP, nucleoside monophosphate kinase; NDP, nucleoside diphosphate.  
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sugars. Once these interactions have been established, a conformational change occurs 
which enables the base moiety to be recognised and bound. Any alterations at the 2'-
hydroxyl which result in a loss of hydrogen-bonding are likely to prevent the binding of the 
nucleoside as the conformational changes would not occur.  
 
Figure 57: The specificity of uridine-cytosine kinase for pyrimidine ribonucleosides. (A) Sugar recognition by 
UCK. The carbon atoms are coloured in grey, nitrogen atoms are coloured in blue and the oxygen atoms are 
coloured in red. (B) Hydrogen-bonding network of the substrate binding site of UCL and cytosine. Hydrogen-
bonding interactions are shown as dashed lines. Adapted from [
242
]. 
The cytosine base forms four hydrogen bonds in the active site (Figure 57B). Molecular 
modelling has shown that the binding pocket is deep within the active site of the enzyme 
and is too small to accommodate larger purine bases. However, in vivo studies have 
shown that cytidine analogues with bulky substituents at the N4-position, such as a 
benzoyl group, are efficiently phosphorylated.247 This would suggest that provided the 2'-
hydroxyl is unaltered and that at least one hydrogen-bonding interaction exists between 
N4 and the active site, the UCK will be able to phosphorylate the caged azanucleosides to 
their respective monophosphates.  
4.3. Aim 
The aim of this project was to synthesise a photocaged derivative of azacytidine to enable 
greater spatial and temporal control over drug release in vivo. The intention was to 
mitigate the side effects and toxicity associated with the drug. Azacytidine was used as the 
model nucleoside as it is readily and cheaply available. The effects of any structural 
changes on the biological activity of the nucleoside and any synthetic methods could also 
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be applied to deoxyazacytidine. At present, azacytidine has been licenced for the 
treatment of leukemic cancers. However, research is underway into its use for treating 
solid malignant tumours.248 Hence this work should be viewed as a proof-of-concept 
study. 
 A schematic representation of the aim is shown in Figure 58. While the scheme 
shows photocagged nucleoside is incorporated into the RNA, the desired outcome of 
tissue-specific hypomethylation could also be achieved if uncagging occurs at an earlier 
stage in the cascade of steps, that is, prior to incorporation. 
  
 
 
 
Figure 58: Schematic representation of the objectives of this project. Objective 1: attach a photolabile 
protecting group at N4 of azacytidine, 2. It is hypothesised that the modified nucleoside will be able to enter 
the cell through a protein pore or passively diffuse across the membrane, 3. Objective 2: determine whether 
the nucleoside is triphosphorylated by intracellular kinase enzymes, 4 and subsequently incorporated into 
RNA or DNA, 5. Irradiation of the cell with light of a particular wavelength should remove the protecting 
group, releasing azacytidine which can form a covalent bond to DNMT, 6. 
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The first specific objective was to place an o-nitrobenzyl-based photolabile protecting 
group on the N4 position of azacytidine and assess its photochemical properties. The 
second specific objective was to determine whether the caged nucleoside would be 
tolerated by cancerous cells. Based on previous studies, it was hypothesised that the 
caged nucleoside would be able to enter the cell and would be non-toxic. Once inside the 
cell, the caged nucleoside was expected to be phosphorylated by UCK and incorporated 
into genetic material. Uncaging with light of the correct wavelength was expected to 
release the bioactive azacytidine, which would then inhibit DNMT. 
4.4. Results and Discussion 
In this study, two different caging groups were introduced into the N4 exocyclic amine of 
azacytidine as carbamates (Figure 59, 1 and 2). A photocaged derivative of cytosine was 
also synthesised as a control to test the conjugation procedure (Figure 59, 3). Nucleosides 
1 and 3 were isolated with sufficient purity and yield to enable their photochemical 
properties to be determined. Furthermore, nucleoside 1 was used in cellular assays to 
determine its effects on cell viability once uncaged. 
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Figure 59: Caged nucleosides synthesised in this project. 
4.4.1. Synthesis of Caged Nucleosides 
The initial synthetic approach towards the synthesis of the caged azacytidine derivatives is 
shown in Figure 60.  It was envisaged that the hydroxyl groups of the sugar moiety could 
be protected as silyl ethers (Figure 60A, 5) then the caging group introduced into the 
exocyclic amine in the form of a chloroformate (Figure 60B, 7). The resultant carbamate 
could then be desilylated to afford the photocaged azacytidine (Figure 60A, 2). 
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Figure 60: (A) Initial strategy towards the synthesis of caged nucleoside, 2, NOVC-aza. Regents and 
Conditions; Method A: TBSOTf, pyridine, 0°C 20 min then 6 h at rt; Method B: TBDMS-Cl, imidazole, DMF, 
60-65 °C 8h. (B) Synthesis of photolabels. Reagents and Conditions: Phosgene, THF, 0°C for 1 h, then rt 
overnight. 
Silyl protection of azacytidine proceeded smoothly in moderate to high yields depending 
on the conditions employed. Using TBSOTf in pyridine (Figure 60B, Method A) the 
trisilylated product, 5, was isolated in 79% yield. Purification of the crude material was 
complicated by the presence of the disilylated nucleoside and other by-products, most 
likely the O2 or N4 silylated products. Under milder silylation conditions (Figure 60A, 
Method B), TBDMS-Cl with imidazole, the trisilylated product, 5, was isolated in a 
moderate 53 % yield. Although the mono- and disilylated products were also formed, the 
other by-products were not detected.  
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 It was initially sought to couple 6-nitroveratryloxycarbonyl chloride, NOVC-Cl, 7 
(Figure 60B) to the exocyclic amine. NOVC-Cl, was prepared in 97% yield by reaction with 
phosgene and 4,5-dimethoxy-2-nitrobenzyl alcohol, 6 (Figure 60B), and used without any 
further purification. Formation of the carbamate bond proved more challenging than had 
initially been anticipated. Reactions in neat anhydrous pyridine, at room temperature 
overnight, resulted in only trace amounts of the desired product. The product was 
detected by LCMS analysis, but not via TLC or NMR. Increasing the temperature steadily 
from 55 °C to 80 °C over the course of several hours did not facilitate formation of the 
product. Rather, degradation of the chloroformate was observed. Employing DIPEA and 
DBU as bases, marginally increased the yield of the product, as indicated by the peak area 
of the LC chromatogram. However, again, the product could not be detected by TLC or 
NMR. In each of these failed reactions, TLC analysis indicated that hydrolysis of the 
chloroformate occurred within 1 h of the reaction. Whilst efforts were made to work 
under strictly anhydrous conditions (all solvents and vessels were purged with argon, 
equipment dried in an oven then cooled in a dessicator), hydrolysis continued to be a 
problem. The poor yields and the failure of some reactions could have been attributed to 
a reduction in the amount of active NOVC-Cl. Consequently, alternative methods of 
activating 6 were investigated. 
 Three alternative acylating agents which possessed greater reactivity or stability 
were investigated. Their structures are shown in Figure 61. NOVC-tetrazolide, 10, was 
investigated for its increased reactivity compared to its chloroformate counterpart.249 The 
tetrazolide was generated in situ by the addition of 1H-tetrazole to NOVC-Cl. The 
trisilylated azacytidine, 5, and Et3N were subsequently added to this solution. 
Disappointingly, after 24 h, LCMS analysis showed that the reaction had not yielded a 
significant amount of the desired product. A similar result was obtained with the NOVC-
carbonylimidazolium chloride acylating agent, 11. This was synthesised in 85% yield by 
reaction of NOVC-Cl with 1-methylimidazole.250 The inability of both of these reagents to 
acylate the exocyclic amine of azacytidine was surprising as they had both been 
successfully used to acylate the exocyclic amine of adenosine.249,250 The final acylating 
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agent to be investigated was N-hydroxysuccinimidyl 4,5-dimethoxy-2-nitrobenzyl 
carbonate, 12. It was hypothesised that this reagent would display an increased stability in 
organic solvent compared to 10, 11 and the chloroformate (NOVC-Cl) counterparts. It was 
synthesised in 34% yield, in a reaction between NOVC-Cl, and N,N-disuccinimidyl 
carbonate.251,252 TLC of analysis of the conjugation reaction with azacytidine, did not show 
any traces of the 4,5-dimethoxy-2-nitrobenzyl alcohol, 6 (Figure 60B), suggesting that 12 
was indeed more stable. However, yet again, only small amounts of 2 were detected by 
LCMS analysis. 
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Figure 61: Alternative NOVC-based acylating agents. 
Acylation of azacytidine was eventually achieved using a one-pot, transient-protection 
strategy, developed by Alvarez et al.249 The synthetic route, which is outlined in Figure 62, 
was initially tested using cytidine, 13 and NOVC-Cl. The hydroxyl groups of cytidine were 
silylated using trimethylsilyl chloride in pyridine (Figure 62, Method A). Once the reaction 
was complete, as indicated by TLC analysis, NOVC-Cl was added. The reaction was allowed 
to proceed overnight, after which silyl deprotection was effected by the addition of 
methanol/water mix. Interestingly, LCMS analysis of the crude reaction mixture, prior to 
the deprotection step showed that the silyl groups were often already absent. Using this 
approach, NOVC-cytidine, 3, was obtained in 31% yield and good purity (as determined by 
1H NMR, Appendix 3). The synthesis was modified slightly to achieve acylation of 
azacytidine (Figure 62, Method B).253 The hydroxyl groups were silylated using 
hexamethyldisilazane in DMF. Acylation was affected by the addition of NOVC-Cl in 
pyridine, and subsequent silyl deprotection achieved using tris(dimethylamino) sulfonium 
difluorotrimethylsilicate (TAS-F) in DMF. Using this procedure, NOVC-azacytidine 2 and di-
NPE-azacytidine 1 were obtained in 2% and 10% yields, respectively. 
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Figure 62: One-point transient protection strategy. Photocaged derivatives of azacytidine (X = N) were 
synthesised via Method A. Reagents and conditions: a) HMDS, DMF, 2 h, rt; b) chloroformate 7 or 9, 
pyridine, rt overnight; c) TAS-F, DMF, 2 h, rt. Photocaged derivative of cytidine (X = C) was synthesised via 
Method B. Reagents and conditions: d) TMS-Cl, pyridine, 1 h, rt; e) NOVC-Cl, pyridine, overnight, rt; f) 
MeOH/H2O (1:1, v/v), 30 min, rt. 
One of the most significant differences between Methods A, B and the two-step 
procedures described previously was the stringency of the anhydrous conditions. Applying 
Method A to azacytidine resulted in only trace amounts of the desired product or no 
reaction at all. One plausible explanation for this is that the product degraded during the 
silyl deprotection step which employed a methanol/water mix. Azanucleosides are known 
to be unstable in aqueous solutions and in the presence of strong nucleophiles.254–256 The 
nucleosides have been shown to decompose into a number of different products via the 
opening and deformylation of the triazine ring (Figure 63).255  
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Figure 63: Ring opening and hydrolysis of azacytidine. I is in dynamic equilibrium with its ring-opened 
formylated derivative, III. Irreversible deformylation results in the formation of a guanylurea derivative, IV. 
In Method B, anhydrous conditions were maintained by co-evaporating the reaction 
mixture with anhydrous pyridine and toluene prior to each synthetic step. Furthermore, to 
minimise exposure of the product to water, TAS-F, an anhydrous source of fluoride ions, 
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was used to achieve silyl deprotection.257 In TAS-F the fluoride is present as a silicate, 
rather than the ‘naked’ ion, such as in the commonly used tetra-n-butylammoniun 
fluoride (TBAF).258 As result, TAS-F is considerably less basic and hygroscopic compared to 
TBAF, which is often contaminated with tetrabutlyammonium hydroxide and is extremely 
difficult to dry.258–260 Indeed, it has been reported that TBAF, ammonium fluoride, sodium 
ethoxide, p-toluenesulfonic acid and acetic acid can effectively remove the silyl groups 
from azacytidine, however, they also cause degradation of the triazine ring.253 As an 
additional precaution, aqueous work-up of the crude reaction mixture was not performed 
and the crude material was directly submitted to flash chromatography. Analogues 2 and 
3 were extremely polar; requiring up to 13% organic solvent for elution. Nucleoside 3 was 
marginally more hydrophobic than nucleoside 2 which facilitated its resolution during 
flash chromatography. This, and its greater stability, could also account for the improved 
isolated yield (31% versus 2% for nucleosides 3 and 2, respectively). The difference in the 
isolated yields of nucleosides 1 and 2 could also be attributed to the difference in 
hydrophobicity (10% versus 3% for nucleosides 1 and 2, respectively). 
4.4.2. Uncaging of Caged Cytidine and Azacytidine 
The absorbance and photochemical properties of analogues 1 and 3 were measured as 
they were isolated with sufficient purity. Specifically, analogue 1 was obtained in 71% 
yield and analogue 2 was obtained in 79% yield, as determined by analytical HPLC analysis. 
Their absorbance spectra are shown in Figure 64. Both nucleosides possessed two 
absorption maxima. Analogue 3 possessed maxima at 293 nm and 346 nm corresponding 
to the cytosine base and the NOVC-protecting group, respectively.261 Whilst nucleoside 1 
displayed maxima at 237 nm and 260 nm which corresponded to triazine base of 
azacytidine and the NPE protecting group, respectively.217,262  
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Uncaging of nucleosides was studied by irradiating the samples at 365 nm using a LED 
photoreactor. Photolysis of o-nitrobenzyl-based protecting groups typically occurs via an 
intramolecular hydrogen abstraction from the exocyclic α-position (with respect to the 
aryl group).207,263 In the case of NOVC, the resultant radical undergoes photoisomerisation 
to a cyclic acetal derivative which spontaneously collapses to o-nitrosobenzaldehyde and 
the uncaged compound. The uncaged compound undergoes a further decarboxylation 
reaction to release the free amine. The mechanism is outlined in Figure 65. 
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Figure 65: Mechanism of uncaging nucleoside analogue 3. 
Decarboxylation of the uncaged nucleoside with concomitant release of the amine 
presented a potential complication. It was possible that the released amine could have 
Figure 64: (A) Absorbance spectra of di-NPE-Aza, 1. The absorbance spectra of azacytidine, 4, and NPE-OH, 8, 
are superimposed. (B) Absorbance spectra of NOVC-cytidine, 3. The absorbance spectra of cytidine, 13, and 
NOVC-OH, 6 are superimposed. All components at 100 μM, ACN:H2O, 1:1, v/v, with 1% acetic acid. 
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formed an imine with the o-nitrosobenzaldehyde photo-byproduct.207 In order to avoid 
this, uncaging of analogue 3 was performed under slightly acidic conditions, to reduce the 
nucleophilicity of the amine and hydrolyse any imine that may have formed.264,265 Such 
precautions were not required for the uncaging of analogue 1, as the photo-by-product of 
NPE is an o-nitrostyrene (Figure 66). Akin to NOVC, photodeprotection begins with 
intramolecular hydrogen abstraction at the α-position, but is followed by β-elimination of 
the protected group with concomitant liberation of CO2 and the amine (Figure 66).
266,267 
However, in order to directly compare the photochemical properties of the analogues, all 
experiments were performed in the same reaction medium; ACN:H2O, 1:1, v/v, with 1% 
acetic acid. 
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Figure 66: Mechanism of uncaging nucleoside analogue 1. 
Photolysis of the caged nucleosides was monitored by analytical HPLC over several hours 
(Figure 67B). The HPLC traces indicated that the caged nucleosides were uncaged to the 
parent nucleoside and photo-by-products in almost quantitative yields. Representative 
traces for the photolysis of analogue 1 are shown in Figure 67A. Similar results were 
obtained for analogue 3.  
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Table 9: Chemical Properties of Caged Nucleosides. 
Nucleoside 
analogue 
λmax [nm] εmax (x 10
4)a  
t1/2     
[min] 
1 293, 346  1.03, 0.53   34 
3 237, 260  1.25, 0.96  77 
                                                 
                                                                         a Molar absorptivity (M-1 cm-1).  
                                                                         b  Quantum yields for the disappearance of the starting nucleosides 
 
The rate of photolysis for both nucleosides could be approximated to a first-order 
exponential decay curve. This suggested that undesired secondary effects such as further 
photolysis of the parent nucleoside, were not occurring.261 In agreement with literature 
reports, analogue 1 was photolyzed almost twice as fast as analogue 3. Specifically, the 
half-life (Table 9) for uncaging was 34 min and 77 min for 1 and 3, respectively.  
4.4.3. Preliminary Cellular Assays x  
Cellular assays were performed to determine the effect, if any, of analogue 1 on cell 
viability. Central to the drug delivery approach is the notion that the caged nucleoside 
must not have any toxic effects on the cell, and that toxicity must only occur once the 
                                                             
x
 These experiments were performed by Sabrina Stewart, UCL Cancer Institute.  
Figure 67: (A) HPLC traces for the photolysis of analogue 1 (measured at 260 nm). (B) Time-course for the 
photolysis of analogues 1 (filled circles) and 2 (empty circles). Samples (100 μM, ACN/H2O, 1:1, v/v, 1% acetic 
acid) were irradiated at 350 nm. Aliquots were taken at regular intervals then analysed by HPLC. 
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nucleoside is uncaged to the biologically active parent nucleoside. Based on literature 
reports, it was hypothesised that analogue 1 would be readily transported into cells via a 
nucleoside transporter or through passive diffusion across the plasma membrane. As the 
two photolabile-protecting groups eliminated the hydrogen-bonding capability of the 
exocyclic amine, it was believed that the nucleoside would not be metabolised to the 
active triphosphate or hence incorporated into RNA or DNA.242 Thus any affects of cell 
viability would solely be due to uptake of the nucleoside. 
 For this study, human osteosarcoma cells (SaOS-2) were used. The cells were 
seeded at a density of approximately 1 x 104 cells per well, in a 24-well dish. This was 
performed 24 h prior to exposing the cells to either azacytidine or analogue 1. The cells 
were treated with nucleosides at three different concentrations; 0.5, 1 and 1.5 μM. Due to 
solubility problems, analogue 1 was dissolved in ACN rather than distilled water. Cells 
were also treated with a solution of analogue 1 which had previously been irradiated at 
365 nm for 24 h. HPLC and MS analysis confirmed that the uncaged azacytidine was 
present in this solution (as discussed above). Additionally, untreated controls of 
acetonitrile and growth media alone were also performed. Analogue 1 and azacytidine 
were added every 24 h in fresh growth media over a 96-hour period. The density or 
confluence of the cells, which gives an indication of cell growth, was determined 
approximately every 2 h. The results are summarised in Figure 68. 
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In the presence of growth media alone (Figure 68A), the cells displayed a characteristic 
growth pattern.268 The cells possessed a base-line confluence of 30% and the number of 
cells increased almost 3-fold within 96 h. The cells were able to grow in the presence of 
analogue 1, albeit at a lower rate compared to the untreated control (Figure 68C and D). 
In particular at the lowest concentration, 0.5 μM, the growth pattern was similar to that of 
Figure 68: Growth curves for SaOS-2 cells under different conditions over 96 h period. Analogue 1 was 
dissolved into HPLC-grade acetonitrile. (A) Growth media alone. (B) Growth media with acetonitrile. (C) 0.5 
μM 1. (D) 1.5 μM 1. (E) 0.5 μM 1 irradiated. (F) 1.5 μM 1 irradiated. For (E) and (F) a 1 mM stock solution of 
analogue 1 was irradiated for 24 h at 365 nm. The sample was diluted to the appropriate concentration 
then applied to the cells. All treatment conditions were performed in triplicate. The mean confluence has 
been plotted per treatment condition, with the error bars representing the standard deviation. 
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the untreated control. As the concentration of the analogue 1 increased, the rate of cell 
growth decreased slightly. In the presence of 1.5 μM analogue 1, less than 95% confluence 
was observed within 96 h. At each concentration of the analogue, a slight dip in the 
confluence was observed every 24 h, that is, after the addition of fresh media (which 
contained analogue 1). This initially suggested that 1 elicited some toxic effects on cell 
growth. However, treating the cells with acetonitrile alone appeared to inhibit cell growth 
considerably (Figure 68B). The dips in confluence at each media change were larger than 
those observed during treatment with analogue 1 (Figure 68D). This suggested that 
acetonitrile may account for a significant proportion of the cell growth inhibition observed 
during the analogue 1 treatment.  As expected, treating the cells with an irradiated sample 
of analogue 1 reduced the rate of cell growth. Even at the lowest concentration, 0.5 μM, 
only 85% confluence was achieved at 96 h (Figure 68E). In the presence of 1.5 μM 
irradiated sample, only approximately 70% confluence was achieved at 96 h (Figure 68F). 
Furthermore, the rate of cell growth was 2-fold slower than in the presence of the caged 
nucleoside at the same concentration (Figure 68D).  
4.5. Conclusion 
The aim of this study was to introduce a photolabile protecting group into the exocyclic 
amine of azacytidine to gain greater spatial and temporal control over drug release in vivo. 
Two photo-labelled nucleoside analogues were synthesised. Their synthesis was 
somewhat complicated by the hydrolytic sensitivity of azacytidine. The presence of small 
amounts of water resulted in poor yields or no reaction at all. This was overcome by 
employing a one-pot, two-step protocol in which the reaction vessel was co-evaporated 
with anhydrous pyridine prior to the addition of each reagent, to remove residual water. 
Analogue 1 was isolated in sufficient yield and purity for cellular assays in which its effect 
on cell viability was determined.  
 Cell growth was measured in the presence of analogue 1 and a sample which had 
previously been irradiated at 365 nm for 24 h. HPLC and MS analysis confirmed that the 
irradiated sample contained azacytidine and photo-by products. Both treatments resulted 
in a reduction in the rate of cell growth compared to the untreated control. A significant 
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proportion of this was attributed to adverse effects of ACN. However, a greater rate of 
reduction was observed in cells treated with the irradiated sample. The results suggested 
that the released azacytidine and photo by-products were inhibiting cell growth.  
 In order to determine the exact cause and mechanism of this inhibition, further 
experiments are required. A comparison of the methylation levels in treated and 
untreated cells will give conclusive evidence of the mechanism of inhibition. A reduction in 
methylation levels compared to untreated controls, would suggest that the uncaged 
azacytidine is being incorporated into DNA and subsequently sequestering DNMT. 
However, if the methylation levels in the treated and untreated cells are the same, then 
this would suggest that inhibition is occurring through another mechanism; most likely 
involving the released photo-by products.  
In summary, these preliminary studies suggest by employing a photolabile protecting 
group, it is possible to have temporal and spatial control over drug release.  
4.6. Materials and Methods 
All reagents and anhydrous solvents were purchased from Sigma Aldrich unless otherwise 
stated. All other solvents and water were purchased from Fischer Scientific. Cytidine and 
5-azacytidine was purchased from Carbosynth Limited. HPLC analysis was performed using 
reverse phase Varian ProStar system with a Model 210 solvent delivery mode and a Model 
320 dual wave-length detector. The mobile phase A was HPLC-grade water and mobile 
phase B was neat HPLC-grade acteonitrile. The UV absorbance was monitored at 260 nm. 
Analytical analysis was performed using a Varian Pursuit XRS C18 column (250 x 4.6 mm). 
The gradient started with 5% mobile phase B and rose linearly to 50% B over 10 min with a 
flow rate of 1 mL min-1. ESI-MS analysis was performed using a Waters Aquity Ultra 
performance LC-MS system equipped with an Aquity UPLC BEH C18 column (50 x 2.1 mm, 
1.7 mm beads). CI-MS analysis was performed by Dr. Lisa Haigh, UCL Chemistry. 1H and 13C 
NMR spectra were recorded at 293K on a Bruker Avance III 600 MHz spectrometer. 
Coupling constants are reported in Hz. Reference NMR solvent signals CDCl3: δH = 7.26 
ppm, δC = 77.0 ppm; D2O: δH = 4.79 ppm; (CD3)2SO: δH = 2.50 ppm, δC = 39.5 ppm; 
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CD3OD: δH = 3.31 ppm, δC = 49.0 ppm. Multiplicities for 
1H coupling are shown as s 
(singlet), d (doublet), t (triplet), m (multiplet), or a combination of the above. FT-IR 
analysis was performed on a computer driven Shimadzu 8700, range: 7800-350 cm-1, 
resolution: up to 0.5 cm-1. Thin Layer Chromatography (TLC) was performed on aluminium 
backed Sigma-Aldrich TLC plates with F254 fluorescent indicator. Visualisation achieved by 
absorption of UV light or with the use of potassium permanganate solution [KMnO4 (1.25 
g), Na2CO3 (6.25 g), water (250 mL)]. Normal phase flash chromatography was carried out 
using silica gel (43 – 60 μm) supplied by Merck. UV analysis was performed using Varian 
Cary 300 Bio UV-vis Spectrophotometer and a quartz cuvette with a path length of 1 cm. 
Photolyses was conducted using a LED Photoreactor (University of York) at 365 nm. 
Nucleoside samples were at 100 μM, ACN/H2O (1:1, v/v) with 1% acetic acid, unless 
otherwise stated. 
 
4.6.1. Synthesis of 2', 3', 5'-tri-O-(tert-butyldimethylsilyl)-azacytosine, 5, via Method A 
N N
NH2
ON
O
OO
TBSO
1'
3'
4'
5'
6
5
4
3
2
TBS SBT2'  
Anhydrous pyridine (5 mL) was added to aza-cytidine (103 mg, 0.4 mmol) and the 
resultant suspension cooled to 0 °C. TBDMSOTf (470 μL) was added drop wise over the 
course of 15 min. The resultant mixture was stirred at 0 °C for an additional 5 min then at 
room temperature for 6 h after which TLC (5% MeOH/DCM) analysis indicated that the 
reaction was complete. The resultant colourless solution was partitioned between DCM 
(50 mL) and H2O, the organic phase washed with H2O, sat. NaHCO3, and brine (50 mL 
each); then dried over anhydrous Na2SO3. The dried solution was purified by flash 
chromatography (5% MeOH/DCM, Rf = 0.5) giving rise to the title compound as colourless 
glassy solid (195 mg, 79%). 1H NMR (600 MHz, DMSO-d6) δppm: -0.02-0.16 (m, 18H, Si-CH3), 
0.77-0.92 (m, 27H, C-CH3), 3.68-3.77 (m, 1H, H-4'), 3.91-4.00 (m, 2H, H-5'), 4.12 (t, J=4.41 
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Hz, 1H, H-3'), 4.29 (t, J=3.94 Hz, 1H, H-2'), 5.67 (d, J=4.10 Hz, 1H, H-1'), 7.55 (d, J=8.20 Hz, 
1H, NH2), 8.44 (s, 1H, H-6). 
13C NMR (600 MHz, MeOD) δppm: -4.83--3.17 (Si-CH3), 17.69-
18.18 (C-CH3), 25.69-25.96 (C-CH3), 61.45 (C-4'), 70.26 (C-3'), 75.01 (C-2'), 83.56 (C-5'), 
88.84 (C-1'), 153.09 (C-2), 155.60 (C-6), 165.73 (C-4). m/z (ESI) 586.7528 [M+H]+, 
C27H54N4O5Si3 requires 586.9873. 
4.6.2. Synthesis of 2', 3', 5'-tri-O-(tert-butyldimethylsilyl)-azacytosine, 5, via Method B 
To a solution of the azacytidine (200 mg, 0.8 mmol) in anhydrous DMF (10 mL), imidazole 
(556 mg, 8.2 mmol) and TBDMSCl (614 mg, 4 mmol) were added. The resultant mixture 
was heated at 60 °C for 3 h. TLC analysis indicated that the reaction was not yet complete. 
Consequently, the temperature was increased to 65 °C and the reaction mixture stirred 
for an additional 5 h. The reaction mixture was partitioned between DCM (50 mL) and 
H2O. The organic phase was then washed with H2O, sat. NaHCO3, and brine (3 x50 mL 
each), and dried over anhydrous Na2SO3. The dried organic phase was concentrated in 
vacuo giving rise to colourless oil and subsequently purified by flash chromatography (0-
3% MeOH/DCM, 5% MeOH/DCM Rf = 0.42). The title compound was isolated as colourless 
glassy solid (254 mg, 53%).  NMR and MS as above. 
4.6.3. General Synthesis of Photolabile-Protecting Groups, 7 and 9 
A solution of phosgene in toluene (2.3 mL, 20% w/w, 10.8 mmol) was added to a chilled 
suspension of the corresponding alcohol in THF (15 mL). The suspension was stirred at 0 
°C for 1 h, then at room temperature for 18 h. In each case, TLC (5% MeOH/DCM) analysis 
suggested complete conversion of the starting material to the chloroformate. The excess 
phosgene was removed under low vacuum and trapped with aqueous 0.1 M NaOH. Owing 
to the instability of the resultant products, they were immediately used for the 
subsequent reactions without any further purification.  
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4.6.3.1. (4,5-Dimethoxy-2-nitrophenyl)methyl Chloroformate, 7 
OMe
OMeO2N
OCl
O
4
5
6
1
2
3
7
8
 
Isolated as solid yellow foam (627 mg, 97 %). 5% MeOH/DCM, Rf starting material = 0.35, Rf 
product = 0.91. 
1H NMR (600 MHz, CDCl3) δppm: 3.90-3.92 (m, 3H, OMe), 3.95-3.97 (m, 3H, 
OMe), 4.98 (s, 2H, H-7), 7.05 (s, 1H, H-3), 7.54-7.73 (m, 1H, H-6). 13C NMR (600 MHz, 
CDCl3) δppm: 44.13 (C-7), 56.77 (OMe), 108.79 (C-6), 113.40 (C-3), 127.36 (C-1), 140.62 (C-
2), 149.35 (C-4), 153.91 (C-5), 165.56 or 133.79 (C8). IR (neat): 1764.5 cm-1 (C=O), 1514.7 
(C=C, Ar.). m/z (CI) 275.01889 [M], C10H10ClNO6 requires 275.01911. 
 
4.6.3.2. 2-Nitrobenzyl Chloroformate, 9 
2
1
3
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5
6
O2N
7
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8
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Isolated as an off-white solid (1.22 g, 88.9%). 5% MeOH/DCM, Rf starting material = 0.46, Rf 
product = 0.95. 
1H NMR (600 MHz, DMSO-d6) δppm: 3.15 (t, J=6.49 Hz, 2H, H-7), 4.53-4.67 (m, 
2H, H-8), 7.36-7.42 (m, 2H, H-4 & H-6), 7.50-7.53 (m, 1H, H-3), 7.89 (t, J=8.66 Hz, 1H, H-5). 
13C NMR (600 MHz, CDCl3) δppm: 34.97 (C-7), 75.10 (C-8), 123.16 (C-3), 130.22 (C-4), 
133.21-133.26 (C-1, C-5 & C-6), 148.55 (C-2). IR (neat): 1767.8 (C=O), 1516.4 (C=C, Ar.), 
1343.0 (NO2). m/z (CI) 229.61692 [M], C9H8ClNO4 requires 229.61712.  
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4.6.4. 3-(4,5-Dimethoxy-2-Nitro-Benzoyloxycarbonyl)-1-Methyl-Imidazolium Chloride, 
11250 
MeO
MeO NO2
O N
O
N
Cl
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6
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4
3
2
7
8
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To a stirred solution of 1-methylimidazole (90 μL, 1.1 mmol) in anhydrous DCM (15 mL), 7 
(300.5 mg, 1.1 mmol) was added giving rise to a clear yellow solution. After 2 h at room 
temperature, a thick yellow precipitate formed. The suspension was filtered and the 
precipitate washed with ice cold DCM (20 mL) to afford the title compound as a pale 
yellow solid (389 mg, 85%). 5% MeOH/DCM Rf = 0.87. 
1H NMR (600 MHz, CDCl3) δppm:  3.95 
(s, 3H, OMe), 4.06 (s, 3H, OMe), 5.61 (s, 2H, H-7), 7.04 (s, 1H, H-3), 7.34 (s, 1H, H-6), 7.70-
7.73 (m, 2H, H10 & H11), 9.47 (H-9). 13C NMR (600 MHz, CDCl3) δppm:  56.52-56.73 (OMe), 
67.03 (C-7),108.18 - 108.36 (C-10 & C-11), 120.22 (C-3), 121.76 (C-6), 132.58 (C-9), 139.80 
(C-2), 148.02 (C-8), 153.78 – 154.48 (C-4 &C-5). m/z (CI) 322.10336 [M-Cl]+, C14H16ClN3O6 
requires 357.07276. 
4.6.5. Synthesis of 4,5-Dimethoxy-2-Nitrobenzyl Succinimidyl Carbonate, 12 
MeO
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O O
O
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To a stirred suspension of 4,5-dimethoxy-2-nitrobenzyl alcohol (302 mg, 1.4 mmol) and 
N,N-disuccinimidyl carbonate (430 mg, 1.7 mmol) in anhydrous ACN (15 mL), Et3N (580 μl, 
4.2 mmol) was added. The resultant colourless solution was stirred at room temp for 3 h 
after which the solvent was removed under reduced pressure and the crude material 
purified by flash chromatography (50% EtOAc/Hexane, 5% MeOH/DCM Rf = 0.7) to yield 
the title compound as a solid yellow foam (202 mg, 34%). 1H NMR (600 MHz, DMSO-d6) 
δppm:  2.86 (s, 4H, H-10), 3.97 (s, 3H, OMe), 4.06 (s, 3H, OMe), 5.79 (s, 2H, H-7), 7.05 (s, 1H, 
H-3), 7.77 (s, 1H, H-6). 13C NMR (600 MHz, CDCl3) δppm: 25.41 (C-10), 56.00-56.34 (OMe), 
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69.14 (C-7), 108.45 (C-6), 112.21 (C-3), 123.51 (C-1), 140.05 (C-2), 146.94 (C-4), 148.65 (C-
8), 153.52 (C-5), 169. 93 (C-9). m/z (CI) 452.10063 [M], C19H20N20O11 requires 452.10616. 
4.6.6. Synthesis of 4-N-(6-Nitroveratryloxycarbonyl)-Cytidine, 3249  
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To a suspension of cytidine (299 mg, 1.2 mmol) in anhydrous pyridine (10 mL), TMS-Cl was 
added (790 μL, 6.2 mmol) was added over the course of 15 min. The solution was stirred 
at room temperature for 1 h at which point TLC analysis suggested that protection of the 
nucleoside was complete. To the resultant colourless solution, NOVC-Cl (400 mg, 1.4 
mmol) was added and the resultant solution stirred at room temperature overnight. 
Water/methanol mix (1:1, v/v, 5 mL) was added and the mixture stirred for 30 min then 
concentrated in vacuo. The residual pyridine was removed by co-evaporation with toluene 
(3 x 20 mL) and the resultant yellow opaque oil purified by flash chromatography (0-10% 
MeOH/DCM, Rf = 0.43) to afford the title compound as yellow foam (182 mg, 31%). 
1H 
NMR (600 MHz, DMSO-d6) δppm: 
1H NMR (600 MHz, DMSO-d6) d ppm 3.60 (ddd, J=12.19, 
5.03, 3.11 Hz, 1H, H-5'a), 3.74 (ddd, J=12.14, 4.99, 2.82 Hz, 1H, H-5'b), 3.88 (s, 3H, OMe), 
3.90 (dt, J=5.98, 2.94 Hz, 1H, C-4'), 3.95 (m, 4H, C-3' & OMe), 3.96 - 4.01 (m, 1H, C-2'), 5.08 
(d, J=5.83 Hz, 1H, 3'-OH), 5.18 (t, J=5.18 Hz, 1H, 5'-OH), 5.50 (s, 2H, H-7''), 5.78 (d, J=3.20 
Hz, 1H, H-1'), 7.03 - 7.07 (m, 1H, H-5), 7.41 (s, 1H, H-6''), 7.74 (s, 1H, H-3''), 8.45 (d, J=7.34 
Hz, 1H, H-6), 11.15 (s, 1H, NH). 13C NMR (600 MHz, DMSO-d6) δppm: 56.55-56.10 (OMe), 
59.97 (C-5'), 63.82 (C-7''), 68.72 (C-3'), 74.52 (C-2'), 84.23 (C-4'), 90.11 (C-1'), 94.04 (C-5), 
108.10 (C-3''), 110.30 (C-6''), 126.81 (C-1''), 138.83 (C-2''), 152.61-153.65 (C-4'' & C-5''), 
145.39 (C-6) 153.66 (C-8''), 154.52 (C-2), 162.76 (C-4). m/z (ESI) 505.1195 [M+Na]+, 
C19H22N4O11 requires 482.3982. 
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4.6.7. Synthesis of 4-N-(6-Nitroveratryloxycarbonyl)-5-Azacytidine, 2 
N N
HN
ON
O
OHOH
HO
O
O
OMe
OMeO2N
1'
2'3'
4'
5'
6
5
4
3
2
5''
4''
3''
2''
6''
1''
7''
8''
 
5-Azacytidine (246 mg, 1.0 mmol) was coevaporated with anhydrous pyridine (3 x 5mL) 
and subsequently suspended in anhydrous DMF (10 mL) before adding HMDS (730 μL, 4.5 
mmol). After stirring at room temperature for 2 h, TLC analysis indicated that protection 
of the nucleoside was complete. The solvent was removed in vacuo and the resultant 
residue co-evaporated with anhydrous toluene (3 x 5 mL) followed by anhydrous pyridine 
(3 x 5 mL). The dried residue was subsequently suspended in anhydrous pyridine (7 mL) 
and solution of NOVC-Cl in anhydrous DCM (553 mg, 2 mmol) added. The mixture stirred 
at room temperature overnight. The solvent was removed under reduced pressure and 
the residue coevaporated with toluene (3 x 10 mL) then suspended in anhydrous DMF (10 
mL). Silyl drprotection was achieved with the addition of tris(dimethylamino) sulfonium 
difluorotrimethylsilicate (TAS-F) (422 mg, 1.5 mmol). After 2 h the solvent was removed 
and the residue coveporated with anhydrous toluene (3 x 5 mL). The crude material was 
purified by flash chromatography (0-12.5 % MeOH/DCM, 10% MeOH/DCM Rf = 0.44) to 
yield the title compound as an off-white solid (11 mg, 2%).1H NMR (600 MHz, DMSO-d6) 
δppm:  3.64 - 3.68 (m, 1H, H-4'), 3.70 (d, J=5.27 Hz, 1H, H-2'), 3.82 - 3.85 (m, 1H, H-3'), 3.86 
(m, 4H, OMe & H-5'a), 3.88 (m, 4H, OMe & H-5'b), 4.94 - 5.00 (m, 1H, 5'OH), 5.09 - 5.18 
(m, 1H, H-1'), 5.32 - 5.38 (m, 1H, H-7''), 7.14 - 7.22 (m, 1H, H-3''), 7.66 - 7.71 (m, 1H, H-6''), 
8.64 - 8.75 (m, 1H, H-6). 13C NMR (600 MHz, DMSO-d6) δppm: 56.10 - 56.59 (OMe), 60.98 - 
62.91 ( C-5' & C-7''), 70.31 (C-3'), 74.18 (C-2'), 83.69 – 84.01 (C-1' & C-4'), 108.12 (C-6''), 
110.57 (C-3''), 139.47 (C-2''), 147.71 (C-4''), 153.24 (C-5''). m/z (ESI) 484.0941 [M+H]+, 
C18H21N5O11 requires 483.38624. 
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4.6.8. Synthesis of 4-N-[di-(2-Nitrophenyl)ethoxycarbonyl]-Azacytidine, 1 
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5-Azacytidine (122 mg, 0.5 mmol) was coevaporated with anhydrous pyridine (3 x 5 mL) 
and subsequently suspended in anhydrous DMF (10 mL) before adding HMDS (542.0 μL, 
2.5 mmol). After stirring stirring at room temperature for 2 h, TLC analysis indicated that 
protection of the nucleoside was complete. The solvent was removed in vacuo and the 
resultant residue co-evaporated with anhydrous toluene (3 x 5 mL) followed by anhydrous 
pyridine (3 x 5 mL). The resultant residue was subsequently suspended in anhydrous 
pyridine (30 mL) and solution of 2-NPE-Cl in anhydrous DCM (1.07 g, 5 mmol) added and 
the resultant mixture stirred at room temperature overnight. The solvent was removed 
under reduced pressure and the resultant residue coevaporated with toluene (3 x 10 mL) 
the suspended in anhydrous DMF (10 mL). Silyl deprotection was achieved with the 
addition of tris(dimethylamino) sulfonium difluorotrimethylsilicate (TAS-F) (486 mg, 2 
mmol). After 2 h the solvent was removed and the resultant residue coveporated with 
anhydrous toluene (3 x 5 mL). The crude material was purified by flash chromatography 
(0-10% EtOH/DCM, 10% EtOH/DCM Rf = 0.63) to yield the title compound as a colourless 
film (62.3 mg, 10%). 1H NMR (600 MHz, DMSO-d6) δppm: 3.13 - 3.20 (m, 4H, H-7''), 3.62-
3.67 (m, 1H, H-5'a), 3.83 - 3.88 (m, 1H, H-5'b), 3.95-4.00 (m, 1H, H-4'), 4.07-4.12 (m, 1H, H-
3'), 4.12-4.16 (m, 1H, H-2'), 4.39-4.49 (m, 4H, H-8''), 5.11 (d, J=6.78 Hz, 1H, 2'-OH), 5.35 (t, 
J=4.71 Hz, 1H, 5'-OH), 5.68 (d, J=1.51 Hz, 1H, 3'-OH), 5.74 (d, J=4.89 Hz, 1H, H-1'), 7.42-
7.54 (m, 4H, H-4'' & H-6''), 7.60-7.68 (m, 2H, H-5''), 7.89 - 7.95 (m, 2H, H-3''), 9.10 (s, 1H, 
H-6). 13C NMR (600 MHz, DMSO-d6) δppm: 30.63 (C-7''), 58.87 (C-5'), 67.67 (C-3'& C-8''), 
74.03 (C-2'), 83.98 (C-4'), 91.26 (C-1'), 118.16 (C-1''), 124.54 - 133.42 (C-3'', C-4'', C-5'' & C-
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6''), 149.15 (C-2''), 150.18 (C-2), 152.68 (C-9''), 159.05 (C-6), 163.61 (C-4). m/z (ESI) 631.09 
[M+H]+, C26H26N6O13 requires 630.51704. 
 
4.7. Cellular Assays 
A human osteosarcoma cell line, SaOS-2, was used for the cellular assays. The cells were 
grown in a humidified 37 °C incubator containing 5% CO2. A 24-well plate format was 
used; each well capable of holding a maximum volume of 0.5 mL growth medium. Cells 
were seeded at 1 X 104 cells per well 24 h prior to treatment with azacytidine. Two forms 
of the nucleoside analogue were used for the study; caged 1 and un-caged 1 (100 μM 
stock solutions). The un-caged sample had been irradiated at 365 nm for 1 h. HPLC and MS 
analysis confirmed the presence of the released azacytidine, 4. Four treatment conditions 
were investigated; cells with caged 1, cells with irradiated 1, cells with acteonitrile and 
cells in growth media alone. Three concentrations of caged-azacytidine, 1 were tested; 0.5 
μM, 1 μM and 1.5 μM. Caged azacytidine and acteonitrile were added every 24 h in fresh 
growth media over a 96 h period. The confluence of the cells was measured every 2 h over 
this period. 
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5 OUTLOOK 
The overarching aim of this project was to develop novel sensing approaches which made 
use of native αHL protein pores and thus could be readily applied to solid-state 
nanopores. Although the αHL protein pore is the mainstay of nanopore technology, it is 
associated with some inherent drawbacks which have limited its use. Most notably, 
instability of the lipid bilayer which supports the nanopore. Solid-state nanopores, which 
are typically fabricated from inorganic materials or organic polymers2 are more robust 
alternatives to biological pores. As result of their increased stability, they can be more 
readily integrated into sensing devices and thus are more amenable to commercialisation. 
However, they cannot be modified to the same atomic-scale precision as a biological pore, 
which limits their scope. Additionally, they are far less sensitive than biological pores. In 
this project, attempts were made to overcome this inherent discrepancy by developing 
sensing approaches where selectivity and sensitivity are not achieved via pore 
modification, but through modification of the analyte. 
 
Chapter 2 describes efforts to develop a nanopore-based approach to detect the 
enzymatic activity of a protease enzyme. Previously reported strategies14 have been based 
upon the detection of multiple peptide fragments generated as the enzyme acted upon a 
substrate in bulk solution, or required engineering of the pore to improve sensitivity. In 
the presented approach, multiple copies of a peptide substrate were tethered via a 
flexible linker to PEGA beads. The beads prevented the substrate from translocating the 
pore. Enzymatic cleavage of the immobilised substrate released a soluble peptide 
fragments. These were subsequently electrically detected as they traversed the nanopore. 
The release of a single substrate greatly simplified data analysis. Initial proof-of-concept 
experiments were performed with trypsin and a simple peptide substrate. Using HPLC 
analysis, it was observed that the rate of fragment release increased with reaction time. 
However, a disparity was observed between the rates of peptide release in homogenous 
(solution-phase) and heterogeneous (on-bead) reactions, with the latter occurring 35% 
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slower than the former. This difference was attributed to the enzyme having difficulty 
diffusing into the PEGA beads to digest the substrate. Although PEGA beads are 
permeable to enzymes with molecular weights up to 45 kD116 its mere presence retarded 
the action of the enzyme. In future experiments, this could be overcome by employing 
solid supports that possess higher surface-to-volume ratios or by simply placing a longer 
linker between the substrate and the resin.113 Alternatively, studies have shown that 
introducing positive charges into the PEGA resin improve its swelling properties and 
facilitate biotransformation.  
 Further experiments were performed in the using renin as a model enzyme and a 
His6-tagged analogue of its natural substrate, angiotensinogen. The experiments were 
performed in the presence of human serum proteins in order to mimic biological 
conditions. It was envisaged that placing a His6-tag at the N-terminus of the substrate 
would enable enzymatic digestion and downstream purification to be performed in a 
single reaction vessel.  In the course of the investigation it was demonstrated that the 
presence of the His6-tag did not interfere with the catalytic ability of the enzyme. 
Specifically, the His6-tagged fragment, angiotensin I-His6, was released. In the presence of 
Ni2+-NTA beads, the digested fragment could be concomitantly released, bound and 
eluted. Furthermore, the enzymatically released fragment could be isolated from His-rich 
serum proteins. However, only approximately 48% of the enzymatically released peptide 
was recovered. This would need to be vastly improved in order to develop commercially 
viable technology. Utilising a shallower imidazole elution gradient may aid this. 
Interestingly, non-specific release of the intact substrate was also observed. This was 
attributed to hydrolysis of the ester bond between the peptide and the linker. Although 
the hydrolytically released peptide only accounted for 5% of the amount released 
enzymatically, this may still be too high for commercial purposes. While removing the 
linker and directly coupling the peptide to resin via a permanent amide bond would 
resolve this issue, it would be impossible to assess the purity of the peptide during 
synthesis. Alternative synthetic protocols would be required. Attempts to synthesise the 
intact peptide prior to conjugation to the resin gave poor yields. An alternative method 
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would be to include a biotin molecule onto the C-terminus of the peptide. This would 
enable conjugation to strepdavidin coated beads. This could also potentially solve the 
problems concerning diffusion of the enzyme to the bead surface and removal of residual 
His-rich plasma proteins. The next step in this investigation would be to determine 
whether the nanopore is sensitive enough to detect biologically relevant concentrations of 
the enzyme. 
 
Chapter 3 continues in the same vein as Chapter 2, describing efforts to develop a 
nanopore-based strategy to characterise forensically important nucleotide repeat 
sequences, which are the basis of DNA fingerprinting. Nanopore analysis of ssDNA has 
been hampered by rapid translocation speeds and subsequent poor resolution of 
individual bases. It was envisaged that a nanopore-based sensing strategy could be 
realised by using DNA strands modified with nucleotides bearing bulky adamantane tags. 
It was hoped that these tags would increase the steric bulk and resistance of the DNA 
stands as they translocated the pore. The net effect would be a reduction in the 
translocation speed and improved resolution. Incorporation of one adamantane tag per 
repeat unit was expected to yield step-like blockades which could easily be counted and 
measured to determine the number and length of the repeats.  
 Three adamantane-bearing nucleosides, each possessing different linkers lengths, 
and their corresponding triphosphate derivatives were synthesised. The nucleotides were 
successfully incorporated into a model DNA template using PCR. Hence they were shown 
to be suitable substrates for DNA pol. The corresponding phosphoramidite derivatives 
were also synthesised and utilised to generate model oligonucleotides bearing STR repeat 
units. However, nanopore analysis of the DNA strands did not yield the expected results. 
The oligonucleotides gave rise to fleeting reductions in ionic conductivity rather than the 
expected step-like blockades. In spite of this, a linear correlation was observed between 
the number of tags present in the oligonucleotides and the dwell time. This suggested that 
the presence of the adamantane tags increased the resistance experienced by the 
oligonucleotides. The lack of step-like blockades suggested that the adamantane was not 
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sufficiently large to occlude the movement of ions through the pore. In the future, this 
could be overcome by utilising a larger tag or introducing a positive charge into the linker 
or tag itself. As oligonucleotides possess a net negative charge, as positively charged linker 
may faciliatate the formation of a more compact oligo-tag segement. A positive charge 
could be introduced in the form of a quaternary ammonium species after reduction of the 
amide bond. 
In the course of this project, three novel modified nucleosides, and their 
corresponding triphosphate derivatives were synthesised. Furthermore, the versatility of 
the Yoshikawa reaction was demonstrated.  
 
The motivation of the work presented in Chapter 4 deviates from that of the previous 
chapters, however it builds on the notion of employing nucleoside analogues to overcome 
challenges encountered in arena of chemical biology. The specific aim of this project was 
to synthesise photocaged derivatives of the nucleoside drug azacytidine, which is used to 
treat cancers that arise due to aberrant methylation of particular regions of the genome. 
Hypermethylation of these regions can abnormally enhance the function of some genes, 
such as the oncogenes, or cause other, such as tumour-suppressor genes, to be silenced. 
This can enable the proliferation of certain cancers and trigger the onset of some diseases. 
Azacytidine acts a potent anticancer agent by inducing a hypomethylated state through 
inhibition of DNA methyltransferase, the enzyme that catalyses DNA methylation. 
However, the drug is associated with extreme toxicity and side-effects due to its non 
specific actions. It was envisaged that a photocaged derivative of azacytidine would 
enable greater temporal and spatial controls over drug release. 
 Two photocaged derivatives of azacytidine were synthesised, di-NPE-aza and 
NOVC-aza. However, only di-NPE-aza was isolated in sufficient purity (71%) to enable 
investigation of its photochemical properties and activity in cellular assays. In accordance 
with literature reports,217,262 the nucleoside possessed two absorption maxima; one at 237 
nm and the other at 260 nm. These corresponded to the triazine base of azacytidine and 
the NPE protecting group, repectively. Uncagging of the nucleoside was effected by 
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irradiation at 365 nm using a LED photoreactor. Photolysis was monitored by analytical 
HPLC and MS analysis over several hours. The results indicated that the caged nucleoside 
was uncaged to the parent nucleoside and photo-by-products in near quantitative yields 
within 3 h.   
Celluar assays were performed to determine the effect of the nucleoside analogue 
on cell viability. Central to this drug delivery approach was the notion that the caged 
nucleoside must not impart any cytotoxicity, and that toxicity must only occur once the 
nucleoside is uncaged to the biologically active parent nucleoside. The caged nucleoside 
conformed to this notion somewhat. A reduction in the rate of cell growth was observed 
in the presence of di-NPE-aza. However, a more drastic reduction was observed in the 
presence of di-NPE-aza which had previously been irradiated at 365 nm. The results 
suggested that the released azacytidine was having a greater affect on cell viability. 
Additional control experiments also indicated that the ACN present in the nucleoside 
solution also had a significant negative impact on cell growth. ACN was added to aid 
dissolution of the nucleoside. Whilst the conditions were not physiologically relevant, the 
results can be viewed as proof-of-concept. The next logical step in this investigation would 
be to synthesise a nucleoside analogue which is water soluable. This would enable its 
photochemical properties and cytotoxicity to be determined under physiologically 
relevant conditions. This could potentially be achieved by placing a carboxylic functionality 
directly on the aromatic ring or the methylenes.269,270 Alternatively, the monophosphate 
derivative of di-NPE-aza could be a suitable candidate. The phosphate group would likely 
render the analogue water soluable. However, the negative charge could hinder cellular 
uptake by passive and active diffusion. A suitable protecting group, which could be 
removed intracellularly without causing toxicity, would be required. Akin to PDT, it would 
also be desirable to have a nucleoside analogue which was uncagged at longer 
wavelengths, preferably in the 600-700 nm range. This would facilitate uncagging deep 
within tissue. Light at 365 nm will not penetrate tissue sufficiently. 
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APPENDIX 
 
1. (A) Enzymatically released AngI-His6 released after 4 h incubation with renin (tR = 
15.36 min). (B) The enzymatically released peptide co-migrating with the 
synthesised peptide. An aliquot of the digest solution was spiked with 5 μg of the 
synthesised peptide. 
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2. NOESY Spectrum for nucleoside 3c (Chapter 3). Similar spectra were obtained for nucleosides 3a and 3b. 
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3. 1H NMR spectrum for nucleoside 3 (NOVC-cyt, Chapter 4). 
 
